var title_f26_9_26768="Right recurrent laryngeal nerve";
var content_f26_9_26768=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F87045&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F87045&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Right recurrent laryngeal nerve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 423px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lateral view of the right recurrent laryngeal nerve.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_9_26768=[""].join("\n");
var outline_f26_9_26768=null;
var title_f26_9_26769="Pneumocystis pneumonia CT II";
var content_f26_9_26769=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F55021&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F55021&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pneumocystis jirovecii pneumonia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 353px; height: 236px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pneumocystis jirovecii pneumonia&nbsp;in a patient on high doses of corticosteroids. Confluent consolidation is interspersed with ground glass opacities and thickening of the interlobular septa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_9_26769=[""].join("\n");
var outline_f26_9_26769=null;
var title_f26_9_26770="Bilateral tonic pupils";
var content_f26_9_26770=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F73497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F73497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    Bilateral tonic pupils",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 438px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The top panel shows the poor reaction to light in both eyes. The bottom panel shows the much better near reaction in both eyes, with the right pupil constricting a bit more than the left. These photos thus illustrate the characteristic light-near dissociation seen with tonic pupils.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Andrew G Lee, MD and Paul W Brazis, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_9_26770=[""].join("\n");
var outline_f26_9_26770=null;
var title_f26_9_26771="Reactive lymphocytosis";
var content_f26_9_26771=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F62209&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F62209&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Reactive lymphocytosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 241px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Blood smear showing lymphocytosis of normal appearing lymphocytes, as seen in pertussis and infectious lymphocytosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Baehner, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_9_26771=[""].join("\n");
var outline_f26_9_26771=null;
var title_f26_9_26772="Tacrolimus (topical): Pediatric drug information";
var content_f26_9_26772=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tacrolimus (topical): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?6/30/6630?source=see_link\">",
"    see \"Tacrolimus (topical): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?0/21/341?source=see_link\">",
"    see \"Tacrolimus (topical): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F9559507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9559514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Protopic&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9559515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Protopic&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10527272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/30/6630?source=see_link\">",
"      see \"Tacrolimus (topical): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Moderate to severe atopic dermatitis:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Discontinue use when symptoms have cleared. If no improvement occurs within 6 weeks, patients should be re-examined to confirm diagnosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children and Adolescents &ge;2-15 years: Apply a thin layer of 0.03% ointment to affected area twice daily; rub in gently and completely",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adolescents &ge;16 years and Adults: Apply a thin layer of 0.03% or 0.1% ointment to affected area twice daily; rub in gently and completely",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9564286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Protopic&reg;: 0.03% (30 g, 60 g, 100 g); 0.1% (30 g, 60 g, 100 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9559530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F9559513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088996.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088996.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10527273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For external use only; do not cover with occlusive dressings; apply thin layer and rub ointment in gently and completely onto clean, dry skin. Do not bathe, shower, or swim right after ointment application. Moisturizers can be applied after ointment application.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F13688023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature of 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10527264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Second-line agent for short-term and intermittent treatment of moderate to severe atopic dermatitis in nonimmunocompromised patients not responsive to conventional therapy or when conventional therapy is not appropriate (0.03% ointment: FDA approved in ages &ge;2 years and adults; 0.1% ointment: FDA approved in ages &ge;16 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9559512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Tacrolimus may be confused with everolimus, pimecrolimus, sirolimus, temsirolimus",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F9559549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fever, headache, hyperesthesia, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Acne, alopecia, contact dermatitis,  cyst, dry skin, eczema herpeticum, erythema, flushing (localized; following ethanol consumption), folliculitis, fungal dermatitis, pruritus, pustular rash, skin burning (tends to improve as lesions resolve), skin tingling, sunburn, urticaria, vesiculobullous rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dysmenorrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, dyspepsia, gastroenteritis, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, myalgia, paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Conjunctivitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Otitis media",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchitis, cough increased, pneumonia, rhinitis, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, flu-like syndrome, lymphadenopathy, varicella/herpes zoster",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Acute renal failure, anaphylaxis, anaphylactoid reaction, anemia, basal cell carcinoma, chest pain, hypercholesterolemia, malignant melanoma, osteomyelitis, photosensitivity reaction, seizure, septicemia, skin discoloration, squamous cell carcinoma",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10527265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to tacrolimus or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10527268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Minimize exposure to sunlight while on topical therapy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10527266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal. Topical calcineurin inhibitors have been associated with rare cases of malignancy (including skin and lymphoma); therefore, limit to short-term and intermittent treatment using the minimum amount necessary for the control of symptoms and only on involved areas",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Avoid use on malignant or premalignant skin conditions (eg, cutaneous T-cell lymphoma). Should not be used in immunocompromised patients. Do not apply to areas of active bacterial or viral infection; infections at the treatment site should be cleared prior to therapy. Patients with atopic dermatitis are predisposed to skin infections and tacrolimus therapy has been associated with risk of developing eczema herpeticum, varicella zoster, and herpes simplex. May be associated with development of lymphadenopathy; possible infectious causes should be investigated. Discontinue use in patients with unknown cause of lymphadenopathy or acute infectious mononucleosis. If symptoms of atopic dermatitis not improved within 6 weeks, re-evaluate to confirm diagnosis. Not recommended for use in patients with skin disease which may increase systemic absorption (eg, Netherton's syndrome or cutaneous GVHD). Safety of intermittent use for &gt;1 year has not been established. The use of Protopic&reg; in children &lt;2 years of age is not recommended [U.S. Boxed Warning]; only 0.03% ointment is indicated for children 2-15 years. Acute renal failure has been reported (rarely) with topical tacrolimus therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9564177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9564178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): Tacrolimus (Topical) may enhance the dermatologic adverse effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Serotonin Reuptake Inhibitor/Antagonist): May decrease the metabolism of Tacrolimus (Topical).",
"     <b>",
"      Exceptions:",
"     </b>",
"     TraZODone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Tacrolimus (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of Tacrolimus (Topical).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Tacrolimus (Topical) may enhance the nephrotoxic effect of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may enhance the nephrotoxic effect of Tacrolimus (Topical). CycloSPORINE (Systemic) may increase the serum concentration of Tacrolimus (Topical). Tacrolimus (Topical) may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Danazol: May increase the serum concentration of Tacrolimus (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Tacrolimus (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May decrease the metabolism of Tacrolimus (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: Tacrolimus (Topical) may enhance the adverse/toxic effect of Immunosuppressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cytarabine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May increase the serum concentration of Tacrolimus (Topical).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the metabolism of Tacrolimus (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: Tacrolimus (Topical) may enhance the adverse/toxic effect of Sirolimus. Sirolimus may enhance the adverse/toxic effect of Tacrolimus (Topical).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: Tacrolimus (Topical) may enhance the adverse/toxic effect of Temsirolimus. Temsirolimus may enhance the adverse/toxic effect of Tacrolimus (Topical).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9559534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9559535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies. Tacrolimus crosses the human placenta and is measurable in the cord blood, amniotic fluid, and newborn serum following systemic use. Refer to the Tacrolimus, Systemic monograph for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10527270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to an intracellular protein forming a complex which inhibits phosphatase activity of calcineurin resulting in the inhibition of T-cell activation",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10527271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Minimally absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: &lt;0.5%",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10527274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/21/341?source=see_link\">",
"      see \"Tacrolimus (topical): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not use with occlusive dressings. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction or skin infection occurs. Burning at the application site is most common in first few days; improves as atopic dermatitis improves. Limit application to involved areas. Continue for short periods as long as signs and symptoms persist; discontinue if resolution occurs; re-evaluate if symptoms persist &gt;6 weeks.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Schachner LA, Lamerson C, Sheehan MP, et al, \"Tacrolimus Ointment 0.03% Is Safe and Effective for the Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Patients: Results From a Randomized, Double-Blind, Vehicle-Controlled Study,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2005, 116(3):e334-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/9/26772/abstract-text/16140675/pubmed\" id=\"16140675\" target=\"_blank\">",
"        16140675",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16050 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-E0FBF310BF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_9_26772=[""].join("\n");
var outline_f26_9_26772=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559507\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559514\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559515\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10527272\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564286\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559530\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559513\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10527273\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13688023\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10527264\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559512\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559549\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10527265\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10527268\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10527266\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564177\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9564178\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559534\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559535\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10527270\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10527271\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10527274\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16050\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16050|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4778?source=related_link\">",
"      Tacrolimus (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/14/40165?source=related_link\">",
"      Tacrolimus (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/51/4921?source=related_link\">",
"      Tacrolimus (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/30/6630?source=related_link\">",
"      Tacrolimus (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/21/341?source=related_link\">",
"      Tacrolimus (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_9_26773="Trospium: Drug information";
var content_f26_9_26773=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Trospium: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?13/9/13460?source=see_link\">",
"    see \"Trospium: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F232166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Sanctura&reg;;",
"     </li>",
"     <li>",
"      Sanctura&reg; XR",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2934284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Sanctura&reg; XR;",
"     </li>",
"     <li>",
"      Trosec",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F232181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anticholinergic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F232167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Overactive bladder:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Immediate release: 20 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Extended release: 60 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F232168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Elderly &ge;75 years: Immediate release: Consider initial dose of 20 mg once daily (based on tolerability); Extended release: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F232169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Immediate release: 20 mg once daily at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Extended release: Use not recommended",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F232142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, extended release, oral, as chloride: 60 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sanctura&reg; XR: 60 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as chloride: 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sanctura&reg;: 20 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F232131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F232145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer 1 hour prior to meals or on an empty stomach. Administer extended release capsules in the morning with a full glass of water.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F232144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of overactive bladder with symptoms of urgency, incontinence, and urinary frequency",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F14188039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - varies based on comorbidity; Strength of recommendation - varies based on comorbidity)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F232179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Gastrointestinal: Xerostomia (9% to 22%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Tachycardia (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (4% to 7%), fatigue (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (&lt;2%), dry skin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation (9% to 10%), abdominal pain (1% to 3%), dyspepsia (1% to 2%), flatulence (1% to 2%), nausea (1%), abdominal distention (&lt;2%), taste abnormal, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (1% to 7%), urinary retention (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Dry eyes (1% to 2%), blurred vision (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Nasopharyngitis (3%), nasal dryness (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Influenza (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylaxis, angioedema, back pain, chest pain, delirium, dizziness, confusion, feces hard, gastritis, hallucinations, heat intolerance, hypertensive crisis, palpitation, rhabdomyolysis, somnolence, Stevens-Johnson syndrome, supraventricular tachycardia, syncope, T-wave inversion, visual abnormalities",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F232148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to trospium or any component of the formulation; urinary retention; gastric retention; uncontrolled narrow-angle glaucoma",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F232133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Angioedema: Cases of angioedema involving the face, lips, tongue, and/or larynx have been reported. Immediately discontinue if tongue, hypopharynx, or larynx are involved.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: May cause drowsiness, confusion, dizziness, hallucinations, and/or blurred vision, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Alzheimer's disease: Use with caution in patients with Alzheimer's disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bladder flow obstruction: Use with caution in patients with bladder flow obstruction; may increase the risk of urinary retention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal obstructive disorders: Use with caution in patients with gastrointestinal obstructive disorders (ie, pyloric stenosis); may increase the risk of gastric retention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Use with caution in patients with controlled (treated) narrow-angle glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with moderate or severe hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis due to decreased GI motility.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use immediate release formulation with caution in patients with renal impairment; dosage adjustment is required. Use of the extended release formulation is contraindicated in patients with severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ulcerative colitis: Use with caution in patients with ulcerative colitis due to decreased GI motility.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Medications eliminated by active tubular secretion (ATS): ATS is a route of elimination; use caution with other medications that are eliminated by ATS (eg, procainamide, pancuronium, vancomycin, morphine, metformin, and tenofovir).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly &ge;65 years of age; increased anticholinergic side effects are seen. Medication associated with potent anticholinergic properties which may be inappropriate in older adults depending on comorbidities (eg, dementia, delirium) (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extended release: Ethanol should not be ingested within 2 hours of the administration of the extended release formulation; may increase incidence of drowsiness.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F232137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the CNS depressant effect of Trospium. Alcohol (Ethyl) may increase the serum concentration of Trospium. Specifically, alcohol may increase the peak (maximum) serum concentration of trospium when consumed within 2 hours of taking extended-release trospium. Management: Avoid consuming any alcohol within 2 hours of taking a dose of trospium XR.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetFORMIN: May decrease the serum concentration of Trospium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Anticholinergic Agents may enhance the therapeutic effect of Mirabegron. This may result in acute urinary retention.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Specifically, the risk of oligohidrosis and hyperthermia may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F232162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Ethanol may enhance the sedative effects of trospium. Ethanol may increase the peak (maximum) serum concentration of trospium when consumed within 2 hours of taking extended release trospium. Management: Avoid use of ethanol. Avoid consuming any alcohol within 2 hours of taking a dose of extended release trospium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Administration with a fatty meal reduces the absorption and bioavailability of trospium. Management: Administer 1 hour prior to meals or an empty stomach. Administer extended release capsules in the morning with a full glass of water.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F232139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F232150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal studies. There are no adequate or well-controlled studies in pregnant women; use only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F232172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F17969770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if trospium is excreted in breast milk. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F232151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take1 hour prior to meals or on an empty stomach.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F232149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, 24-hour",
"     </b>",
"     (Sanctura XR Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg (30): $224.56",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, 24-hour",
"     </b>",
"     (Trospium Chloride ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg (30): $202.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Sanctura Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (60): $254.39",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Trospium Chloride Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (60): $170.26",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F232152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ceris (FR);",
"     </li>",
"     <li>",
"      Prometrium (KP);",
"     </li>",
"     <li>",
"      Regurin (GB, IE);",
"     </li>",
"     <li>",
"      Sancturos (KP);",
"     </li>",
"     <li>",
"      Spasium (TH);",
"     </li>",
"     <li>",
"      Spasmed (EE);",
"     </li>",
"     <li>",
"      Spasmex (AR, CN, IL, KP, RU, TH, TR, TW);",
"     </li>",
"     <li>",
"      Spasmo-Lyt (AE, BG, BH, CL, CY, CZ, DK, EG, FI, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Spasmo-Urgenin Neo (CH);",
"     </li>",
"     <li>",
"      Spasmolyt (AT, DE, KP, MY, SG, TH);",
"     </li>",
"     <li>",
"      Spasmoplex (PT);",
"     </li>",
"     <li>",
"      Stocpium (KP);",
"     </li>",
"     <li>",
"      Tiromax (KP);",
"     </li>",
"     <li>",
"      Tospin (TW);",
"     </li>",
"     <li>",
"      Uracare (TW);",
"     </li>",
"     <li>",
"      Uraplex (ES, GR, IT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F232132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Trospium antagonizes the effects of acetylcholine on muscarinic receptors in cholinergically innervated organs. It reduces the smooth muscle tone of the bladder.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F232147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: &lt;10%; decreased with a high-fat meal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 395 - &gt;600 L, primarily in plasma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 48% to 85%",
"     <i>",
"      in vitro",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hypothesized to be via esterase hydrolysis and conjugation; forms metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Immediate release formulation: ~10% (range: 4% to 16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Immediate release formulation: 20 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe renal insufficiency (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute): ~33 hours; extended release formulation: ~35 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: 5-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (85%); urine (~6%; mostly as unchanged drug) primarily via active tubular secretion",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/9/26773/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chancellor M and de Miguel F, &ldquo;Treatment of Overactive Bladder Selective Use of Anticholinergic Agents With Low Drug-Drug Interaction Potential,&rdquo;",
"      <i>",
"       Geriatrics",
"      </i>",
"      , 2007, 62(5):15-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/9/26773/abstract-text/17489643/pubmed\" id=\"17489643\" target=\"_blank\">",
"        17489643",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Staskin D, Sand P, Zinner N, et al, &ldquo;Once Daily Trospium Chloride is Effective and Well Tolerated for the Treatment of Overactive Bladder: Results From a Multicenter Phase III Trial,&rdquo;",
"      <i>",
"       J Urol",
"      </i>",
"      , 2007, 178(3 Pt 1): 978-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/9/26773/abstract-text/17632131/pubmed\" id=\"17632131\" target=\"_blank\">",
"        17632131",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zinner N, Gittelman M, Harris R, et al, &ldquo;Trospium Chloride Improves Overactive Bladder Symptoms: A Multicenter Phase III Trial,&rdquo;",
"      <i>",
"       J Urol,",
"      </i>",
"      2004, 171(6 Pt 1):2311-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/9/26773/abstract-text/15126811/pubmed\" id=\"15126811\" target=\"_blank\">",
"        15126811",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10320 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-08BE826B45-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_9_26773=[""].join("\n");
var outline_f26_9_26773=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232166\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2934284\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232181\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232167\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232168\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232169\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232142\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232131\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232145\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232144\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14188039\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232179\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232148\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232133\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300185\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232137\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232162\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232139\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232150\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232172\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F17969770\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232151\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232149\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232152\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232132\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232147\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10320\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10320|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/9/13460?source=related_link\">",
"      Trospium: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_9_26774="Atrial fibrillation tutorial";
var content_f26_9_26774=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F62698&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F62698&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1046px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Atrial fibrillation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 279px; height: 121px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Atrial fibrillation is an irregularly irregular rhythm without regular or organized atrial activity. Atrial activation is rapid (generally greater than 320 beats per minute) and of various amplitudes. No discrete P waves are seen on this tracing. Instead, rapid, irregular, variable and low amplitude oscillating fibrillatory waves are observed between the QRS complexes. When the arrhythmia is of long duration, the fibrillatory waves may be inapparent.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 456px\">",
"   <div class=\"ttl\">",
"    Sinus rhythm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 103px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_9_26774=[""].join("\n");
var outline_f26_9_26774=null;
var title_f26_9_26775="UVB therapy (broadband and narrowband)";
var content_f26_9_26775=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   UVB therapy (broadband and narrowband)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/9/26775/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/9/26775/contributors\">",
"     Herbert H&ouml;nigsmann, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/9/26775/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/9/26775/contributors\">",
"     Craig A Elmets, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/9/26775/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/9/26775/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/9/26775/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 16, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H10844492\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Broadband ultraviolet B (UVB) radiation (280 to 320 nm), with or without topical tar, has been used for the treatment of moderate to severe psoriasis for decades. In the early 1980s, the observation that wavelengths around 311 nm were more effective than broad-spectrum UVB in clearing psoriasis led to a major advancement in phototherapy with the development of fluorescent lamps emitting selective UVB spectra in the range of 311 to 313 nm (narrowband UVB) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26775/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Narrowband UVB has since become the type of phototherapy most frequently used for the treatment of psoriasis and a wide range of skin diseases, including atopic dermatitis, vitiligo, early stages of mycosis fungoides, and pruritic disorders (",
"    <a class=\"graphic graphic_table graphicRef87494 \" href=\"UTD.htm?5/16/5388\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26775/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will discuss the mechanism of action, treatment protocols, indications, and adverse effects of UVB therapy. PUVA therapy and the use of UVB for the treatment of specific skin conditions are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33160?source=see_link\">",
"       \"Psoralen plus ultraviolet A (PUVA) photochemotherapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40042?source=see_link&amp;anchor=H23#H23\">",
"       \"Treatment of psoriasis\", section on 'Ultraviolet light'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/26/44457?source=see_link&amp;anchor=H11#H11\">",
"       \"Management of severe refractory atopic dermatitis (eczema)\", section on 'Phototherapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/44/21193?source=see_link&amp;anchor=H13#H13\">",
"       \"Vitiligo\", section on 'Ultraviolet light'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/62/20455?source=see_link&amp;anchor=H11#H11\">",
"       \"Polymorphous light eruption\", section on 'Phototherapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17017?source=see_link&amp;anchor=H19#H19\">",
"       \"Treatment of early stage (IA to IIA) mycosis fungoides\", section on 'Phototherapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7546?source=see_link&amp;anchor=H82845666#H82845666\">",
"       \"Lymphomatoid papulosis\", section on 'Phototherapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/46/20200?source=see_link&amp;anchor=H57289244#H57289244\">",
"       \"Parapsoriasis (small plaque and large plaque parapsoriasis)\", section on 'Phototherapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6058?source=see_link&amp;anchor=H8354466#H8354466\">",
"       \"Pruritus: Overview of management\", section on 'Phototherapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/43/44727?source=see_link&amp;anchor=H9315409#H9315409\">",
"       \"Prurigo nodularis\", section on 'Phototherapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10844506\">",
"    <span class=\"h1\">",
"     PRINCIPLES AND MECHANISMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UVB radiation (280 to 320 nm) is absorbed in the epidermis and superficial dermis by molecules called chromophores which include DNA, urocanic acid (a breakdown product of histidine abundantly present in stratum corneum), keratin, and melanin. Although nuclear DNA is the main chromophore in the skin, there is evidence that UVB also targets cytoplasm and cell membrane components, including cell surface receptors, kinases, phosphatases, and transcription factors [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26775/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Photochemical reactions convert the chromophores into photoproducts that stimulate signal transduction pathways leading to the activation of transcription factors, cytokine secretion, and a variety of cellular responses, including cell cycle arrest and apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26775/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Decreased cell proliferation, immunosuppression, and T cell apoptosis may contribute to the UVB-mediated suppression of disease activity in inflammatory and lymphoproliferative skin disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26775/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3469743\">",
"    <span class=\"h2\">",
"     Effects on DNA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important chromophore in the skin is nuclear DNA. The absorption of UVB by nucleotides leads to the formation of cyclobutane pyrimidine dimers and pyrimidine (6-4)-photoproducts, which play a key role in both UVB therapeutic effect and toxicity.",
"   </p>",
"   <p>",
"    The majority of UV-induced DNA lesions are not translated into a mutation, because cells have a variety of antimutagenic mechanisms that prevent mutation formation at sites of DNA damage. The tumor suppressor gene p53 has a central role in the regulation of the cellular responses to DNA damage, which include cell cycle arrest, DNA repair, and apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26775/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    DNA lesions that are not repaired may lead to cytosine-thymine transition mutations, which represent the initial event in skin carcinogenesis, or to cell death. Severely damaged cells (&ldquo;sunburn cells&rdquo;) undergo apoptosis as the result of a &ldquo;cellular proofreading&rdquo; mechanism in which p53 erases aberrant cells through the activation of the death receptor Fas and proapoptotic effector proteins Bax (Bcl-2&ndash;associated X protein), Bak, Bid, and PUMA [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26775/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Apoptosis of UVB-damaged cells occurs not only in keratinocytes but also in T-cells infiltrating the dermis or epidermis. T-cells apoptosis is the main mechanism underlying the depletion of the neoplastic infiltrate in mycosis fungoides.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3469750\">",
"    <span class=\"h2\">",
"     Effects on the immune system",
"    </span>",
"    &nbsp;&mdash;&nbsp;UVB radiation induces the release of a variety of proinflammatory and immunosuppressive cytokines from keratinocytes and T-cells. Proinflammatory cytokines (eg, interleukin [IL]-1, IL-6, IL-8, and TNF-alpha) play an important role in local and systemic sunburn reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26775/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30136?source=see_link\">",
"     \"Sunburn\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanisms involved in UVB-induced immunosuppression are complex and only partially understood. They involve:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Downregulation of interferon (IFN)-gamma, IL-2, and IL-12 and increased secretion of IL-4 and IL-10 [",
"      <a class=\"abstract\" href=\"UTD.htm?26/9/26775/abstract/5,8,11,12\">",
"       5,8,11,12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Functional impairment of epidermal Langerhans cells and dermal dendritic cells and reduced expression of ICAM-1 and other adhesion molecules, resulting in a reduced capacity of antigen presentation to effector T cells [",
"      <a class=\"abstract\" href=\"UTD.htm?26/9/26775/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Reduced activation of effector and memory T cells [",
"      <a class=\"abstract\" href=\"UTD.htm?26/9/26775/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Induction of T cells with",
"      <span class=\"nowrap\">",
"       regulatory/suppressive",
"      </span>",
"      activity [",
"      <a class=\"abstract\" href=\"UTD.htm?26/9/26775/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Apoptosis of dermal T cells.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite its immunosuppressive effects, UVB phototherapy is not associated with an increased risk of cutaneous infections, with the exception of reactivation of Herpes simplex infection. Studies suggest that UVB radiation may induce keratinocyte-derived antimicrobial peptides that prevent skin colonization by pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26775/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3364831\">",
"    <span class=\"h1\">",
"     DEVICES FOR BROADBAND AND NARROWBAND UVB",
"    </span>",
"    &nbsp;&mdash;&nbsp;Devices for broadband UVB therapy utilize fluorescent lamps emitting a wide range of wavelengths. Approximately two-thirds of the output is in the UVB range (280 to 320 nm) and the rest is primarily in the UVA range (320 to 400 nm) (",
"    <a class=\"graphic graphic_figure graphicRef87492 \" href=\"UTD.htm?9/17/9503\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26775/abstract/16\">",
"     16",
"    </a>",
"    ]. Devices for narrowband UVB therapy use the TL-01 fluorescent lamps that emit UVB in the range of 311 to 313 nm [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26775/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Different phototherapy devices are designed to treat the whole body, localized regions, or only lesional skin. Those used for large body surface areas resemble booths that patients enter for each treatment. Smaller devices, including small handheld units, are used to treat limited areas (eg, palms, soles, scalp).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9245446\">",
"    <span class=\"h1\">",
"     CLINICAL INDICATIONS FOR UVB THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most common indications for UVB therapy, in particular for narrowband UVB, include moderate to severe psoriasis that is unresponsive to topical therapy, severe atopic dermatitis, and vitiligo [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26775/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Narrowband UVB is also indicated for the prevention of polymorphous light eruption. Additional indications for UVB phototherapy are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef87494 \" href=\"UTD.htm?5/16/5388\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The use of UVB phototherapy for the treatment of specific skin conditions is discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40042?source=see_link&amp;anchor=H23#H23\">",
"       \"Treatment of psoriasis\", section on 'Ultraviolet light'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/26/44457?source=see_link&amp;anchor=H11#H11\">",
"       \"Management of severe refractory atopic dermatitis (eczema)\", section on 'Phototherapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/44/21193?source=see_link&amp;anchor=H13#H13\">",
"       \"Vitiligo\", section on 'Ultraviolet light'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/62/20455?source=see_link&amp;anchor=H11#H11\">",
"       \"Polymorphous light eruption\", section on 'Phototherapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17017?source=see_link&amp;anchor=H19#H19\">",
"       \"Treatment of early stage (IA to IIA) mycosis fungoides\", section on 'Phototherapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7546?source=see_link&amp;anchor=H82845666#H82845666\">",
"       \"Lymphomatoid papulosis\", section on 'Phototherapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/46/20200?source=see_link&amp;anchor=H57289244#H57289244\">",
"       \"Parapsoriasis (small plaque and large plaque parapsoriasis)\", section on 'Phototherapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6058?source=see_link&amp;anchor=H8354466#H8354466\">",
"       \"Pruritus: Overview of management\", section on 'Phototherapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/43/44727?source=see_link&amp;anchor=H9315409#H9315409\">",
"       \"Prurigo nodularis\", section on 'Phototherapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10844520\">",
"    <span class=\"h1\">",
"     DOSIMETRY AND TREATMENT PROTOCOLS",
"    </span>",
"   </p>",
"   <p>",
"    <strong>",
"     Determination of the initial dose",
"    </strong>",
"    &mdash; Before initiating phototherapy, the initial irradiation dose for the individual patient must be determined. The starting dose can be established by determining the minimal erythema dose (MED) with phototesting or by using an empirical method based upon the patient&rsquo;s skin phototype (",
"    <a class=\"graphic graphic_table graphicRef60541 \" href=\"UTD.htm?15/37/15963\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The patient&rsquo;s MED is determined by exposing six small template areas (eg, circles of 1 cm diameter) of nonexposed skin (lower back, buttocks) to an incremental series of UVB irradiations. Increases are made by fixed values (eg, 10",
"    <span class=\"nowrap\">",
"     mJ/cm",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    or by a fraction (eg, 40 percent) of the previous dose. The MED is defined as the lowest dose that causes a minimally perceptible erythema reaction 24 hours after irradiation. Sunbathing or exposure to solaria must be avoided before phototesting.",
"   </p>",
"   <p>",
"    Treatment is generally started with an initial dose of UVB equal to 50 to 70 percent of the MED. It is important to document the type of lamp used for MED determination, since values obtained with broadband or narrowband sources are markedly different (",
"    <a class=\"graphic graphic_table graphicRef87493 \" href=\"UTD.htm?4/9/4251\">",
"     table 3",
"    </a>",
"    ). Narrowband UVB is approximately 10 times less erythemogenic than broadband UVB. Thus, MEDs determined by using narrowband UVB devices are considerably higher than those determined with broadband sources.",
"   </p>",
"   <p>",
"    The determination of the initial dose based upon the patient&rsquo;s skin phototype may not reflect the actual sensitivity of a particular individual. However, this method is used for practical reasons in many phototherapy centers, particularly in the United States. The initial irradiation doses of broadband and narrowband UVB for the treatment of psoriasis recommended by the American Academy of Dermatology are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef88228 \" href=\"UTD.htm?22/48/23307\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26775/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15647452\">",
"    <span class=\"h2\">",
"     Treatment initiation, frequency, and dose increments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment is generally started with an initial dose equal to 70 percent of the MED for broadband UVB and 50 percent of the MED for narrowband UVB or according to the Fitzpatrick skin type (",
"    <a class=\"graphic graphic_table graphicRef88228 \" href=\"UTD.htm?22/48/23307\">",
"     table 4",
"    </a>",
"    ). Doses are then gradually increased to the maximum tolerated dose or 2000 to 5000",
"    <span class=\"nowrap\">",
"     J/cm",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    whichever is lower [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26775/abstract/19\">",
"     19",
"    </a>",
"    ]. Treatments are given two to five times per week. The duration of each treatment ranges from several seconds (at the beginning of treatment) to several minutes, depending upon the type of irradiation unit used.",
"   </p>",
"   <p>",
"    Since UVB-induced erythema peaks at 24 hours after exposure, the radiation dose should not be increased on consecutive days for patients receiving more than three treatments per week. The dose increase is determined based upon the effects of the previous treatment (ie, presence and intensity of erythema). Dose increments usually vary between 10 and 40 percent of the last used dose.",
"   </p>",
"   <p>",
"    The goal of dose increment is to achieve a minimally perceptible erythema, which is the clinical indicator of optimal dosimetry. As an example, in a patient receiving three treatments per week, the UVB dose can be increased by 40 percent if the patient has no evidence of erythema from the previous treatment. In contrast, if a mild erythema is noticeable, the dose increase should be limited to 20 percent of the previous dose. If a mild erythema persists even with smaller dose increments, the dose should be maintained until erythema subsides.",
"   </p>",
"   <p>",
"    In a patient receiving five treatments per week, smaller dose increments should be given every other session (30 percent in the absence of erythema; 15 percent if mild erythema is noted; no increase if there is persistent erythema).",
"   </p>",
"   <p>",
"    In patients who develop intense or painful erythema, irradiation is stopped until the symptoms subside and then resumed. Treatment is continued until complete remission is achieved or no further improvement can be obtained with continued phototherapy.",
"   </p>",
"   <p>",
"    Guidelines for the use of narrowband UVB therapy for the treatment of psoriasis and other skin disorders have been published in Europe and in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26775/abstract/19-22\">",
"     19-22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15647413\">",
"    <span class=\"h2\">",
"     Maintenance therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance therapy may prolong remission. However, the optimal maintenance schedules for specific diseases have not been determined. For the treatment of cutaneous T-cell lymphoma, most therapists perform maintenance treatment for several months to a year. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17017?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of early stage (IA to IIA) mycosis fungoides\", section on 'Phototherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For the treatment of psoriasis, some centers advocate a two-month maintenance phase with twice-weekly exposures for one month and once-weekly exposures for another month. The last effective UVB dose is given throughout the maintenance phase. If relapses occur during the maintenance phase, treatment frequency and UVB dose are increased until clearing is achieved.",
"   </p>",
"   <p>",
"    In a small randomized trial, 46 patients with psoriasis who had achieved a 75 percent reduction of the psoriasis area and severity index (PASI) after 12 weeks of narrowband UVB therapy were assigned to maintenance treatment or observation for two months [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26775/abstract/23\">",
"     23",
"    </a>",
"    ]. More patients in the maintenance group than in the observation group (12 of 22 versus 8 of 24) remained in remission after two months, although the difference was not statistically significant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10844535\">",
"    <span class=\"h2\">",
"     Combination therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both topical and systemic agents can be used in conjunction with UVB phototherapy to improve its efficacy, reduce the cumulative UVB dose, and minimize long-term side effects.",
"   </p>",
"   <p>",
"    Emollients (eg, petrolatum, salicylic acid ointments) increase the transmission of UV radiation by altering the optical properties of the stratum corneum [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26775/abstract/24\">",
"     24",
"    </a>",
"    ]. Application of a thin layer of emollient such as petrolatum before UVB exposure is used in some institutions. However, the benefits of emollients before UVB exposure have not been evaluated in randomized trials. &nbsp;",
"   </p>",
"   <p>",
"    Topical dithranol, vitamin D derivatives, and retinoids in conjunction with narrowband UVB phototherapy have been reported as beneficial in a few small uncontrolled studies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26775/abstract/25-29\">",
"     25-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Systemic retinoids such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/1/39958?source=see_link\">",
"     acitretin",
"    </a>",
"    increase the efficacy of phototherapy, particularly in patients with chronic plaque psoriasis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26775/abstract/30\">",
"     30",
"    </a>",
"    ]. Retinoids hasten and enhance the response to phototherapy and reduce treatment frequency, duration, and cumulative UVB doses [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26775/abstract/19,31\">",
"     19,31",
"    </a>",
"    ]. &nbsp;However, despite its many advantages, retinoid-UVB therapy is infrequently used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40042?source=see_link&amp;anchor=H33#H33\">",
"     \"Treatment of psoriasis\", section on 'Retinoids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    may have a synergistic effect with UVB therapy for the treatment of psoriasis. In a small randomized trial, patients treated with methotrexate and narrowband UVB achieved a &gt;90 percent reduction of the baseline psoriasis area and severity index (PASI) more rapidly than patients treated with placebo plus narrowband UVB (median time 4 weeks versus &gt;24 weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26775/abstract/32\">",
"     32",
"    </a>",
"    ]. However, further studies are needed to confirm the efficacy of this combination therapy and evaluate potential short- and long-term adverse effects.",
"   </p>",
"   <p>",
"    There are a few reports of UVB phototherapy in combination with biologics for the treatment of psoriasis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26775/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13399426\">",
"    <span class=\"h1\">",
"     TARGETED PHOTOTHERAPY WITH 308 NM DEVICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lasers and lamps emitting monochromatic excimer light at 308 nm wavelength have a clinical use similar to narrowband UVB therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22360?source=see_link&amp;anchor=H1638077#H1638077\">",
"     \"Principles of laser and intense pulsed light for cutaneous lesions\", section on 'Excimer laser'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Excimer lasers emit a higher amount of radiation over a shorter period of time than conventional narrowband UVB devices and are particularly useful for the treatment resistant psoriasis plaques that are unresponsive to other treatments or located in difficult areas (eg, scalp, palms, soles, knees, and elbows) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26775/abstract/35\">",
"     35",
"    </a>",
"    ]. Excimer lamps may be used to treat large body areas, but have a lower power density than lasers.",
"   </p>",
"   <p>",
"    Targeted phototherapy may be a treatment modality for stable vitiligo, localized chronic dermatoses (eg, granuloma annulare, lichen planus, lichen simplex chronicus, alopecia areata) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26775/abstract/36-38\">",
"     36-38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3470084\">",
"    <span class=\"h1\">",
"     SAFETY MEASURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Safety measures for patients undergoing UVB phototherapy include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Wearing UV-blocking goggles to protect the eyes and prevent conjunctivitis and photokeratitis",
"     </li>",
"     <li>",
"      Protecting the face (if not involved in the disease process) either by using a sunscreen with an SPF of 50+ or a cloth barrier",
"     </li>",
"     <li>",
"      Protecting the genitalia (if not involved in the disease process) by wearing underwear",
"     </li>",
"     <li>",
"      Avoiding concurrent natural sun exposure",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10844620\">",
"    <span class=\"h1\">",
"     SHORT- AND LONG-TERM ADVERSE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short-term adverse effects of UVB phototherapy include erythema, skin dryness, pruritus, blistering, and increased frequency of recurrent herpes simplex (",
"    <a class=\"graphic graphic_table graphicRef87496 \" href=\"UTD.htm?28/30/29163\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Long-term adverse effects include photoaging and the possibility of photocarcinogenesis. The carcinogenic potential of narrowband phototherapy has not been determined. A systematic review of the carcinogenic risk associated with PUVA and narrowband UVB therapy for psoriasis suggests that narrowband UVB therapy does not increase the risk of skin cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26775/abstract/39\">",
"     39",
"    </a>",
"    ]. However, there is a need for larger studies with longer follow-up time to assess the risk of skin cancer among patients treated with narrowband UVB phototherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10844627\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Absolute contraindications for UVB phototherapy are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Xeroderma pigmentosum",
"     </li>",
"     <li>",
"      Lupus erythematosus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Relative contraindications to UVB therapy include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      History of photosensitivity diseases (eg, chronic actinic dermatitis, solar urticaria)",
"     </li>",
"     <li>",
"      History of melanoma",
"     </li>",
"     <li>",
"      History of nonmelanoma skin cancer",
"     </li>",
"     <li>",
"      History of treatment with arsenic or ionizing radiation because of the increased risk for skin cancer",
"     </li>",
"     <li>",
"      Immunosuppression for organ transplant patients",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10168650\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Narrowband UVB (311 to 313 nm) is the type of phototherapy most frequently used for the treatment of moderate to severe psoriasis and a wide range of skin diseases, including atopic dermatitis, vitiligo, early stages of mycosis fungoides, and pruritic disorders (",
"      <a class=\"graphic graphic_table graphicRef87494 \" href=\"UTD.htm?5/16/5388\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10844492\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The main cytochemical target of UVB is nuclear DNA. The UVB-induced DNA damage stimulates signal transduction pathways leading to the activation of transcription factors, cytokine secretion, immunosuppression, and a variety of cellular responses, including cell cycle arrest and apoptosis. (See",
"      <a class=\"local\" href=\"#H10844506\">",
"       'Principles and mechanisms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Devices for broadband UVB therapy utilize fluorescent lamps emitting a wide range of wavelengths, mostly in the UVB range (280 to 320 nm) and, in part, in the UVA range (",
"      <a class=\"graphic graphic_figure graphicRef87492 \" href=\"UTD.htm?9/17/9503\">",
"       figure 1",
"      </a>",
"      ). Devices for narrowband UVB therapy use the TL-01 fluorescent lamps that emit UVB in the range of 311 to 313 nm. (See",
"      <a class=\"local\" href=\"#H3364831\">",
"       'Devices for broadband and narrowband UVB'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment is generally started with an initial dose of UVB equal to 50 to 70 percent of the minimal erythema dose (MED) or at a dose determined by the patient&rsquo;s phototype (",
"      <a class=\"graphic graphic_table graphicRef88228 \" href=\"UTD.htm?22/48/23307\">",
"       table 4",
"      </a>",
"      ). It is important to document the type of lamp used for MED determination, since values obtained with broadband or narrowband sources are markedly different (",
"      <a class=\"graphic graphic_table graphicRef87493 \" href=\"UTD.htm?4/9/4251\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10844520\">",
"       'Dosimetry and treatment protocols'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The radiation dose is then gradually increased by 10 to 40 percent of the previous dose. The goal of dose increment is to achieve a minimally perceptible erythema, which is the clinical indicator of optimal dosimetry. Treatment is continued until complete remission is achieved or no further improvement can be obtained with continued phototherapy. The role for maintenance therapy is uncertain. (See",
"      <a class=\"local\" href=\"#H15647452\">",
"       'Treatment initiation, frequency, and dose increments'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common indications for UVB therapy, in particular for narrowband UVB, include moderate to severe psoriasis that is unresponsive to topical therapy, severe atopic dermatitis, and vitiligo. (See",
"      <a class=\"local\" href=\"#H9245446\">",
"       'Clinical indications for UVB therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During UVB phototherapy, the eyes must be protected with UV-blocking goggles. The face, genital area, and skin that is not involved must be protected with an SPF 50+ sunscreen or a cloth barrier. (See",
"      <a class=\"local\" href=\"#H3470084\">",
"       'Safety measures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Short-term adverse effects of UVB phototherapy include erythema, skin dryness, pruritus, blistering, and increased frequency of recurrent herpes simplex (",
"      <a class=\"graphic graphic_table graphicRef87496 \" href=\"UTD.htm?28/30/29163\">",
"       table 5",
"      </a>",
"      ). Long-term adverse effects include photoaging and photocarcinogenesis, although the carcinogenic potential of narrow band UVB is less established. (See",
"      <a class=\"local\" href=\"#H10844620\">",
"       'Short- and long-term adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26775/abstract/1\">",
"      Fisher T. UV-light treatment of psoriasis. Acta Derm Venereol 1976; 56:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26775/abstract/2\">",
"      Parrish JA, Jaenicke KF. Action spectrum for phototherapy of psoriasis. J Invest Dermatol 1981; 76:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26775/abstract/3\">",
"      van Weelden H, De La Faille HB, Young E, van der Leun JC. A new development in UVB phototherapy of psoriasis. Br J Dermatol 1988; 119:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26775/abstract/4\">",
"      Honig B, Morison WL, Karp D. Photochemotherapy beyond psoriasis. J Am Acad Dermatol 1994; 31:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26775/abstract/5\">",
"      Weichenthal M, Schwarz T. Phototherapy: how does UV work? Photodermatol Photoimmunol Photomed 2005; 21:260.",
"     </a>",
"    </li>",
"    <li>",
"     Garmyn M, Yarosh DB. The molecular and genetic effects of ultraviolet radiation exposure on skin cells. In: Photodermatology, Lim HW, Honigsmann H, Hawk JLM.  (Eds), Informa Healthcare USA Inc., New York 2007. p.41.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26775/abstract/7\">",
"      H&ouml;nigsmann H. Phototherapy for psoriasis. Clin Exp Dermatol 2001; 6:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26775/abstract/8\">",
"      Nickoloff BJ. Cracking the cytokine code in psoriasis. Nat Med 2007; 13:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26775/abstract/9\">",
"      Bhana S, Lloyd DR. The role of p53 in DNA damage-mediated cytotoxicity overrides its ability to regulate nucleotide excision repair in human fibroblasts. Mutagenesis 2008; 23:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26775/abstract/10\">",
"      Raj D, Brash DE, Grossman D. Keratinocyte apoptosis in epidermal development and disease. J Invest Dermatol 2006; 126:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26775/abstract/11\">",
"      Walters IB, Ozawa M, Cardinale I, et al. Narrowband (312-nm) UV-B suppresses interferon gamma and interleukin (IL) 12 and increases IL-4 transcripts: differential regulation of cytokines at the single-cell level. Arch Dermatol 2003; 139:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26775/abstract/12\">",
"      Berneburg M, R&ouml;cken M, Benedix F. Phototherapy with narrowband vs broadband UVB. Acta Derm Venereol 2005; 85:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26775/abstract/13\">",
"      el-Ghorr AA, Norval M. Biological effects of narrow-band (311 nm TL01) UVB irradiation: a review. J Photochem Photobiol B 1997; 38:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26775/abstract/14\">",
"      Rana S, Byrne SN, MacDonald LJ, et al. Ultraviolet B suppresses immunity by inhibiting effector and memory T cells. Am J Pathol 2008; 172:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26775/abstract/15\">",
"      Schwarz T. The dark and the sunny sides of UVR-induced immunosuppression: photoimmunology revisited. J Invest Dermatol 2010; 130:49.",
"     </a>",
"    </li>",
"    <li>",
"     Cafardi JA, Pollack BP, Elmets CA. Phototherapy. In: Fitzpatrick's Dermatology in General Medicine, 8th Edition, Goldsmith LA, Katz SI, Gilchrest BA, et al.  (Eds), 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26775/abstract/17\">",
"      Tanew A, Radakovic-Fijan S, Schemper M, H&ouml;nigsmann H. Narrowband UV-B phototherapy vs photochemotherapy in the treatment of chronic plaque-type psoriasis: a paired comparison study. Arch Dermatol 1999; 135:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26775/abstract/18\">",
"      Yones SS, Palmer RA, Garibaldinos TT, Hawk JL. Randomized double-blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen-UV-A therapy vs narrowband UV-B therapy. Arch Dermatol 2006; 142:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26775/abstract/19\">",
"      Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol 2010; 62:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26775/abstract/20\">",
"      Ibbotson SH, Bilsland D, Cox NH, et al. An update and guidance on narrowband ultraviolet B phototherapy: a British Photodermatology Group Workshop Report. Br J Dermatol 2004; 151:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26775/abstract/21\">",
"      Beani JC, Jeanmougin M. [Narrow-band UVB therapy in psoriasis vulgaris: good practice guideline and recommendations of the French Society of Photodermatology]. Ann Dermatol Venereol 2010; 137:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26775/abstract/22\">",
"      Spuls PI, Tuut MK, van Everdingen JJ, et al. [The practice guideline 'Photo(chemo)therapy and systemic therapy in severe chronic plaque-psoriasis']. Ned Tijdschr Geneeskd 2004; 148:2121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26775/abstract/23\">",
"      Boztepe G, Karaduman A, Sahin S, et al. The effect of maintenance narrow-band ultraviolet B therapy on the duration of remission for psoriasis: a prospective randomized clinical trial. Int J Dermatol 2006; 45:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26775/abstract/24\">",
"      Lebwohl M, Martinez J, Weber P, DeLuca R. Effects of topical preparations on the erythemogenicity of UVB: implications for psoriasis phototherapy. J Am Acad Dermatol 1995; 32:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26775/abstract/25\">",
"      Hofmann UB, Eggert AA, Br&ouml;cker EB, Goebeler M. Calcitriol vs. dithranol in combination with narrow-band ultraviolet B (311 nm) in psoriasis. Br J Dermatol 2003; 148:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26775/abstract/26\">",
"      Carrozza P, H&auml;usermann P, Nestle FO, et al. Clinical efficacy of narrow-band UVB (311 nm) combined with dithranol in psoriasis. An open pilot study. Dermatology 2000; 200:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26775/abstract/27\">",
"      Behrens S, Grundmann-Kollmann M, Schiener R, et al. Combination phototherapy of psoriasis with narrow-band UVB irradiation and topical tazarotene gel. J Am Acad Dermatol 2000; 42:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26775/abstract/28\">",
"      Goktas EO, Aydin F, Senturk N, et al. Combination of narrow band UVB and topical calcipotriol for the treatment of vitiligo. J Eur Acad Dermatol Venereol 2006; 20:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26775/abstract/29\">",
"      Ada S, Sahin S, Boztepe G, et al. No additional effect of topical calcipotriol on narrow-band UVB phototherapy in patients with generalized vitiligo. Photodermatol Photoimmunol Photomed 2005; 21:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26775/abstract/30\">",
"      Green C, Lakshmipathi T, Johnson BE, Ferguson J. A comparison of the efficacy and relapse rates of narrowband UVB (TL-01) monotherapy vs. etretinate (re-TL-01) vs. etretinate-PUVA (re-PUVA) in the treatment of psoriasis patients. Br J Dermatol 1992; 127:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26775/abstract/31\">",
"      Lebwohl M, Drake L, Menter A, et al. Consensus conference: acitretin in combination with UVB or PUVA in the treatment of psoriasis. J Am Acad Dermatol 2001; 45:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26775/abstract/32\">",
"      Asawanonda P, Nateetongrungsak Y. Methotrexate plus narrowband UVB phototherapy versus narrowband UVB phototherapy alone in the treatment of plaque-type psoriasis: a randomized, placebo-controlled study. J Am Acad Dermatol 2006; 54:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26775/abstract/33\">",
"      Kircik L, Bagel J, Korman N, et al. Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes. J Drugs Dermatol 2008; 7:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26775/abstract/34\">",
"      Wolf P, Hofer A, Legat FJ, et al. Treatment with 311-nm ultraviolet B accelerates and improves the clearance of psoriatic lesions in patients treated with etanercept. Br J Dermatol 2009; 160:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26775/abstract/35\">",
"      K&ouml;llner K, Wimmershoff MB, Hintz C, et al. Comparison of the 308-nm excimer laser and a 308-nm excimer lamp with 311-nm narrowband ultraviolet B in the treatment of psoriasis. Br J Dermatol 2005; 152:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26775/abstract/36\">",
"      Nicolaidou E, Antoniou C, Stratigos A, Katsambas AD. Narrowband ultraviolet B phototherapy and 308-nm excimer laser in the treatment of vitiligo: a review. J Am Acad Dermatol 2009; 60:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26775/abstract/37\">",
"      Welsh O, Herz-Ruelas ME, G&oacute;mez M, Ocampo-Candiani J. Therapeutic evaluation of UVB-targeted phototherapy in vitiligo that affects less than 10% of the body surface area. Int J Dermatol 2009; 48:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26775/abstract/38\">",
"      Aubin F, Vigan M, Puzenat E, et al. Evaluation of a novel 308-nm monochromatic excimer light delivery system in dermatology: a pilot study in different chronic localized dermatoses. Br J Dermatol 2005; 152:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26775/abstract/39\">",
"      Archier E, Devaux S, Castela E, et al. Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol 2012; 26 Suppl 3:22.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13745 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-190.92.87.115-3AD7EB5AF7-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_9_26775=[""].join("\n");
var outline_f26_9_26775=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10168650\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10844492\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10844506\">",
"      PRINCIPLES AND MECHANISMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3469743\">",
"      Effects on DNA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3469750\">",
"      Effects on the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3364831\">",
"      DEVICES FOR BROADBAND AND NARROWBAND UVB",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9245446\">",
"      CLINICAL INDICATIONS FOR UVB THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10844520\">",
"      DOSIMETRY AND TREATMENT PROTOCOLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15647452\">",
"      Treatment initiation, frequency, and dose increments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15647413\">",
"      Maintenance therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10844535\">",
"      Combination therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13399426\">",
"      TARGETED PHOTOTHERAPY WITH 308 NM DEVICES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3470084\">",
"      SAFETY MEASURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10844620\">",
"      SHORT- AND LONG-TERM ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10844627\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10168650\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/13745\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13745|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/17/9503\" title=\"figure 1\">",
"      Spectrum of broad band and narrow band UVB lamps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13745|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/16/5388\" title=\"table 1\">",
"      UVB phototherapy indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/37/15963\" title=\"table 2\">",
"      Fitzpatrick skin phototypes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/9/4251\" title=\"table 3\">",
"      Broadband or narrowband UVB MED",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/48/23307\" title=\"table 4\">",
"      UVB initial dose by phototype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/30/29163\" title=\"table 5\">",
"      UVB therapy adverse effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7546?source=related_link\">",
"      Lymphomatoid papulosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/26/44457?source=related_link\">",
"      Management of severe refractory atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/46/20200?source=related_link\">",
"      Parapsoriasis (small plaque and large plaque parapsoriasis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/62/20455?source=related_link\">",
"      Polymorphous light eruption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22360?source=related_link\">",
"      Principles of laser and intense pulsed light for cutaneous lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/43/44727?source=related_link\">",
"      Prurigo nodularis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6058?source=related_link\">",
"      Pruritus: Overview of management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33160?source=related_link\">",
"      Psoralen plus ultraviolet A (PUVA) photochemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30136?source=related_link\">",
"      Sunburn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17017?source=related_link\">",
"      Treatment of early stage (IA to IIA) mycosis fungoides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40042?source=related_link\">",
"      Treatment of psoriasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/44/21193?source=related_link\">",
"      Vitiligo",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_9_26776="Primary cutaneous marginal zone lymphoma";
var content_f26_9_26776=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Primary cutaneous marginal zone lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/9/26776/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/9/26776/contributors\">",
"     Eric Jacobsen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/9/26776/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/9/26776/contributors\">",
"     Rein Willemze, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/9/26776/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/9/26776/contributors\">",
"     Timothy M Kuzel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/9/26776/contributors\">",
"     John A Zic, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/9/26776/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/9/26776/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/9/26776/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary cutaneous B cell lymphoma (PCBCL) refers to those cases of B cell lymphoma that present in the skin when there is no evidence of extracutaneous disease after the completion of an initial staging evaluation. There are three main subtypes of PCBCL:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Primary cutaneous follicle center lymphoma (PCFCL)",
"     </li>",
"     <li>",
"      Primary cutaneous large B cell lymphoma, leg type",
"     </li>",
"     <li>",
"      Primary cutaneous marginal zone lymphoma (PCMZL), this subtype is now included in the broader category of extranodal marginal zone B cell lymphoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These three subtypes appear to be unique entities with differing clinical presentation, pathologic features, and prognosis. They also require slightly differing treatment approaches. This topic review will discuss PCMZL, which is sometimes referred to as skin-associated lymphoid tissue (SALT) lymphoma. Before the current classification system, cases of PCMZL may have been classified as primary cutaneous immunocytoma or cutaneous plasmacytoma.",
"   </p>",
"   <p>",
"    The other PCBCL subtypes and other forms of cutaneous lymphoma (ie, T cell lymphoma, mycosis fungoides) are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15464?source=see_link\">",
"     \"Primary cutaneous follicle center lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/49/26391?source=see_link\">",
"     \"Primary cutaneous large B cell lymphoma, leg type\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4618?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 25 percent of patients with non-Hodgkin lymphoma (NHL) will present at an extranodal site without systemic involvement. The skin is the second most common primary extranodal site, second in frequency only to the gastrointestinal tract [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26776/abstract/1\">",
"     1",
"    </a>",
"    ]. The overall incidence of primary cutaneous lymphoma in Western countries is estimated to be 0.5 to 1 case per 100,000 people annually, of which approximately 20 percent represent primary cutaneous B cell lymphoma (PCBCL) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26776/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. The exact incidence of primary cutaneous marginal zone lymphoma is unknown.",
"   </p>",
"   <p>",
"    PCMZL usually presents in the fifth or sixth decade of life, although cases in patients as young as 15 have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26776/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no clearly defined risk factors for the development of primary cutaneous marginal zone lymphoma (PCMZL) and there is no identifiable hereditary tendency.",
"   </p>",
"   <p>",
"    An association between PCMZL and infectious agents such as Borrelia burgdorferi and autoimmune conditions has been postulated as described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Infectious etiology",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Borrelia burgdorferi",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pathogenetic links between primary cutaneous B cell lymphoma (PCBCL) and Borrelia burgdorferi infection have been established in Europe, but North American and Asian case series have thus far failed to demonstrate a similar relationship [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26776/abstract/7-10\">",
"     7-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Investigators in Belgrade demonstrated positive Borrelia serologies in 55 percent of PCBCL patients by ELISA and Western Blot [",
"      <a class=\"abstract\" href=\"UTD.htm?26/9/26776/abstract/8\">",
"       8",
"      </a>",
"      ]. By comparison, positive serologies were found in 8 percent of patients with extranodal B cell NHL overall, none of 10 patients with cutaneous T cell NHL, and 3 percent of healthy blood donors. The predominant strain identified was Borrelia afzelii, a subtype that is a primary cause of acrodermatitis chronica atrophicans [",
"      <a class=\"abstract\" href=\"UTD.htm?26/9/26776/abstract/11\">",
"       11",
"      </a>",
"      ]. However, of the 12 patients with PCBCL and positive Borrelia serologies, only two had clinical manifestations of acrodermatitis chronica atrophicans and only one had arthritis [",
"      <a class=\"abstract\" href=\"UTD.htm?26/9/26776/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a similar series of 20 cases from Scotland, seven of the PCBCL lesions contained identifiable Borrelia DNA compared with only 1 of 40 control patients [",
"      <a class=\"abstract\" href=\"UTD.htm?26/9/26776/abstract/12\">",
"       12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=see_link&amp;anchor=H19#H19\">",
"       \"Clinical manifestations of Lyme disease in adults\", section on 'Acrodermatitis chronica atrophicans'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Borrelia infection has also been reported in sporadic cases of PCFCL and PCLBCL, leg type. A possible link between Borrelia infection and PCBCL is further substantiated by reports of response of PCBCL to antibiotic therapy. However, this has been limited to case reports and does not appear to be as effective as H pylori eradication in gastric MALT lymphoma. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Differences in B. burgdorferi strains between different endemic regions may provide some explanation; Borrelia afzelii appears to be the predominant strain in Europe, while Borrelia burgdorferi sensu stricto is more common in North America [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26776/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Viral etiologies",
"    </span>",
"    &nbsp;&mdash;&nbsp;No definitive evidence exists for a link between PCBCL and viral infection (eg, Epstein-Barr virus, HIV, and hepatitis C virus) despite several case reports that have suggested an association [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26776/abstract/14-19\">",
"     14-19",
"    </a>",
"    ]. Treating hepatitis C virus infection does not appear to induce regression of PCBCL, as has been reported in splenic marginal zone lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26776/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33416?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of splenic marginal zone lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Autoimmune disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although systemic marginal zone lymphoma has been reported in conjunction with various autoimmune disorders, no definitive association between autoimmune disease and PCMZL has been established [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26776/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19610?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of extranodal (MALT) and nodal marginal zone lymphomas\", section on 'Disease associations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with PCMZL present with red to violaceous papules, plaques, or nodules localized preferentially on the trunk or upper extremities (",
"    <a class=\"graphic graphic_picture graphicRef66125 graphicRef52551 \" href=\"UTD.htm?41/12/42180\">",
"     picture 1A-B",
"    </a>",
"    ). In contrast to PCFCL, presentation with multifocal skin lesions is frequent. Ulceration is uncommon. PCMZL have a tendency to recur in the skin, but dissemination to extracutaneous sites is exceedingly rare [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26776/abstract/9,24\">",
"     9,24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19610?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of extranodal (MALT) and nodal marginal zone lymphomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of \"B\" symptoms, abnormal blood counts, or an elevated lactate dehydrogenase (LDH) should raise suspicion of a systemic lymphoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PATHOLOGIC FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of primary cutaneous marginal zone lymphoma (PCMZL) is made based upon a pathologic evaluation of a skin biopsy in a patient who has no evidence of systemic lymphoma upon staging studies. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Staging'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Morphology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin biopsy specimens are characterized by nodular to diffuse infiltrates with sparing of the epidermis. The infiltrates are composed of small lymphocytes, marginal zone B cells (centrocyte-like cells), lymphoplasmacytoid cells, and plasma cells, admixed with small numbers of centroblast- or immunoblast-like cells and many reactive T cells. Reactive germinal centers are frequently observed. They may be surrounded by a population of small to medium-sized cells with irregular nuclei, inconspicuous nucleoli and abundant pale cytoplasm (marginal zone B cells). Monotypic plasma cells are often located at the periphery of the infiltrates and in the superficial dermis beneath the epidermis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26776/abstract/21,25\">",
"     21,25",
"    </a>",
"    ]. PAS-positive intranuclear or intracytoplasmic inclusions may be present in cases with a predominance of lymphoplasmacytoid cells. Unlike extranodal marginal zone lymphoma occurring at other sites, PCMZL rarely show colonization of follicular structures, lymphoepithelial lesions or transformation into a diffuse large B cell lymphoma, though a relative increase in large transformed cells can be seen in some cases [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26776/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19610?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of extranodal (MALT) and nodal marginal zone lymphomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Immunophenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of the biopsy material with immunohistochemical stains is a key component of the diagnostic evaluation of cutaneous lymphoma. At this time flow cytometry cannot be routinely recommended as a replacement for immunohistochemical studies. This is principally because of the difficulty associated with making a single-cell suspension with this tumor type.",
"   </p>",
"   <p>",
"    The postulated normal counterpart to primary cutaneous marginal zone lymphoma (PCMZL) is a post-germinal center B cell. The neoplastic cells express CD20, CD22, CD79a, and BCL2 and are typically negative for CD3, CD5, CD10, and BCL6. Reactive germinal centers typically express BCL6 and CD10, but not BCL2. There is cytoplasmic expression of immunoglobulin with light chain restriction on paraffin sections as well as monoclonal immunoglobulin gene rearrangements [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26776/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike other extranodal marginal zone lymphomas that demonstrate trisomy 3 or t(11;18), no reliable genetic lesion is demonstrable in PCMZL [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26776/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of primary cutaneous marginal zone lymphoma (PCMZL) requires a representative biopsy of involved skin and the exclusion of non-cutaneous disease. Excisional biopsies are preferred to punch biopsies, but if a punch biopsy is taken, the diameter should be at least 4 millimeters. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Staging'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The biopsy specimen is evaluated for morphology, growth pattern, and immunohistochemical studies. A typical biopsy of PCMZL demonstrates a B cell infiltrate comprised of small to medium sized lymphocytes, often with a plasmacytoid appearance in a reactive germinal-center-like structure. B cell lineage is confirmed by the presence of CD20 or CD79a and the absence of CD3.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Systemic lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;An estimated 6 to 10 percent of patients with systemic B cell non-Hodgkin lymphoma (NHL) will develop cutaneous disease at some point in their illness [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26776/abstract/30\">",
"     30",
"    </a>",
"    ]. It is important to distinguish between patients with secondary cutaneous involvement of a systemic lymphoma and those with primary cutaneous marginal zone lymphoma (PCMZL) because these entities have drastically different prognoses and management options.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1212257987\">",
"    <span class=\"h3\">",
"     Marginal zone lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with cutaneous involvement of systemic marginal zone lymphoma (MZL) may present with skin lesions that clinically and histologically resemble those of PCMZL. While there are some clinical and pathologic findings that favor one diagnosis over the other, a systemic evaluation for disease outside of the skin is necessary to stage PCMZL and truly rule out extracutaneous disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15464?source=see_link&amp;anchor=H18#H18\">",
"     \"Primary cutaneous follicle center lymphoma\", section on 'Staging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When compared with patients with PCMZL, patients with secondary skin involvement of MZL tend to be older, and have a distribution of lesions favoring the head and neck [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26776/abstract/6\">",
"     6",
"    </a>",
"    ]. Skin biopsies of these lesions demonstrate similar histology to other types of extranodal MZL, but rarely show colonization of follicular structures or lymphoepithelial lesions, and also differ in the expression of class-switching immunoglobulins and the composition of background inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26776/abstract/6,31\">",
"     6,31",
"    </a>",
"    ]. While most noncutaneous MZLs express IgM, cases of PCMZL typically express IgG, IgA, or IgE. In addition, the inflammatory background in PCMZL most closely resembles that of a Th2 cytokine-influenced milieu whereas other extranodal marginal zone lymphomas with secondary skin involvement have a Th1 cytokine inflammatory background. Colonization of follicular structures by neoplastic marginal zone cells, as often observed in extranodal marginal zone lymphomas arising at other sites, is rarely seen in PCMZL. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41897?source=see_link\">",
"     \"T helper subsets: Differentiation and role in disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19610?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of extranodal (MALT) and nodal marginal zone lymphomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1212258068\">",
"    <span class=\"h3\">",
"     Other systemic lymphomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCMZL may also be difficult to differentiate from mantle cell lymphoma or B cell lymphocytic lymphoma with skin involvement based upon histology alone. Staining for CD5 and cyclin D1 may be useful to differentiate PCMZL (CD5-, cyclin D1-) from mantle cell lymphoma (CD5+, cyclin D1+) and skin localizations of B cell lymphocytic leukemia (CD5+, cyclin D1-). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/29/30169?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of mantle cell lymphoma\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/28/18887?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of small lymphocytic lymphoma\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Reactive infiltrate",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to differentiate the neoplastic B cell infiltrate seen in primary cutaneous B cell lymphoma (PCBCL) from reactive B cell infiltrates. In general, PCBCLs will demonstrate monotypic light chain restriction, while reactive processes will overwhelmingly be polyclonal [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26776/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Primary cutaneous diffuse large B cell lymphoma, leg type",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lesions with a diffuse pattern or a monotonous proliferation of centroblasts and immunoblasts are classified as primary cutaneous diffuse large B cell lymphoma, leg type (PCLBCL) regardless of their anatomic location. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/49/26391?source=see_link\">",
"     \"Primary cutaneous large B cell lymphoma, leg type\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Primary cutaneous follicle center lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCMZL can be differentiated from primary cutaneous follicle center lymphoma (PCFCL) based upon differences in clinical presentation and pathologic findings on the skin biopsy. PCFCL is characterized by a diffuse infiltrate of large cleaved cells (large centrocytes) with a Bcl-6+, Bcl-2-,",
"    <span class=\"nowrap\">",
"     CD10-/+",
"    </span>",
"    phenotype. In contrast, the neoplastic cells of PCMZL have a Bcl-6-, Bcl-2+, CD10- phenotype. Moreover, monotypic Ig light chain expression by the lymphoplasmacytoid and plasma cells (typically located at the periphery of the nodular infiltrates and subepidermally) is a hallmark of PCMZL and rarely observed in PCFCL. Morphologically, differentiation between PCFCL with a (partly) follicular growth pattern and PCMZL with reactive follicular structures may sometimes be difficult. However, in such cases, the differential expression of Bcl-6, Bcl-2 and CD10 may result in the correct diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15464?source=see_link\">",
"     \"Primary cutaneous follicle center lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Cutaneous T cell lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous T cell lymphomas can be distinguished from cutaneous B cell lymphomas through their expression of T cell markers such as CD2, CD3, and CD5. In addition, cutaneous T cell lymphomas can be identified by T cell receptor (TCR) gene rearrangement studies. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4618?source=see_link&amp;anchor=H19#H19\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Intravascular lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravascular large B cell lymphoma, also known as malignant angioendotheliomatosis, is a distinctly uncommon non-Hodgkin lymphoma variant that typically presents as multiple, erythematous tender nodules, tumors, or telangiectasias in older patients. Isolated involvement of the skin does occur, but the disease more frequently affects multiple organ systems, including the central nervous system (CNS), producing a wide variety of symptoms, ranging from generalized confusion or dementia to focal motor and sensory deficits. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13511?source=see_link\">",
"     \"Intravascular large cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Extramedullary plasmacytoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extramedullary plasmacytoma, also known as extraosseous plasmacytoma, can rarely present with isolated skin lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26776/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. Differentiation between this and primary cutaneous marginal zone lymphoma (PCMZL) with prominent plasmacytic differentiation can be extremely difficult and sometimes impossible.",
"   </p>",
"   <p>",
"    Skin involvement in extramedullary plasmacytoma typically demonstrate nodular or diffuse infiltrates of CD38 positive, CD20 negative, and LCA negative mature plasma cells with monotypic cytoplasmic immunoglobulin. The plasma cells may be multinucleate [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26776/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. Coexistent clonal lymphocytes are not found [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26776/abstract/28\">",
"     28",
"    </a>",
"    ]. In contrast, CD20 expression favors the diagnosis of PCMZL. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/17/16662?source=see_link\">",
"     \"Diagnosis and management of solitary extramedullary plasmacytoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the case of extreme plasma cell differentiation, staging studies to confirm the absence of disease outside of the skin should include a bone marrow biopsy and aspirate, skeletal survey, serum immunoglobulins, serum and urine protein electrophoresis, complete blood count, calcium, and serum chemistries, including renal function and alkaline phosphatase in addition to the staging studies described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;At the time of diagnosis, patients with suspected primary cutaneous lymphoma should undergo a complete history, physical examination, and staging evaluation. This evaluation both confirms the diagnosis of primary cutaneous lymphoma by excluding involvement of other sites and provides information to guide treatment. This staging evaluation is described in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15464?source=see_link&amp;anchor=H18#H18\">",
"     \"Primary cutaneous follicle center lymphoma\", section on 'Staging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary cutaneous marginal zone lymphoma (PCMZL) is a rare disorder; accordingly, large trials are lacking. The published data regarding treatment consist entirely of retrospective reviews and anecdotal reports. The generally indolent nature of PCBCL has shifted focus to localized, low morbidity modalities such as radiotherapy.",
"   </p>",
"   <p>",
"    In general, our treatment approach depends upon the number of lesions, their location, and the presence of symptoms attributable to the lesions (eg, pruritus). Extracutaneous spread is uncommon and survival with PCMZL is excellent, with five-year survival rates of 98 to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26776/abstract/5,24,28\">",
"     5,24,28",
"    </a>",
"    ]. Our treatment approach is largely based upon observations from the largest literature review that reported outcomes of 288 patients with PCMZL treated with different modalities, as described below [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26776/abstract/39\">",
"     39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Radiation therapy &mdash; Compilation of data on 132 patients treated with 30 to 45 Gy of radiation revealed a 99 percent complete response rate. Relapses were seen in 60 patients (46 percent), most of which were limited to the skin. Three patients had extracutaneous progression. One study demonstrated responses to lower doses (4 Gy in two fractions) of radiation [",
"      <a class=\"abstract\" href=\"UTD.htm?26/9/26776/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Excision &mdash; Of 75 patients treated with complete surgical excision, all but one obtained a complete response. During an undefined period of follow-up, skin relapse was seen in approximately 43 percent.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       Rituximab",
"      </a>",
"      &mdash; A small number of patients treated with intralesional (9 patients) or systemic (3 patients) rituximab have been reported with complete response (CR) rates of 89 and 67 percent, respectively. Relapses in the skin were seen in 50 to 60 percent of patients. No extracutaneous relapses were reported. Another trial of intralesional rituximab in 35 patients with PCMZL or PCFCL confirmed these early findings, reporting a complete response (CR) in 71 percent with a median time to CR of eight weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?26/9/26776/abstract/41\">",
"       41",
"      </a>",
"      ]. Median disease-free survival was approximately two years.",
"     </li>",
"     <li>",
"      Intralesional interferon alpha &mdash; Eight cases treated with intralesional interferon alpha (IFN) have been reported in the literature with all obtaining a complete response after a median of eight weeks. Two patients relapsed with both obtaining a second complete response with repeat IFN treatment.",
"     </li>",
"     <li>",
"      Single agent or multiagent chemotherapy &mdash; Cumulative data on 14 patients treated with single agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"       chlorambucil",
"      </a>",
"      showed responses in all patients, nine of which were complete (64 percent). Of the nine patients who obtained a complete response, three relapsed. Multiagent chemotherapy, mostly CHOP-like, demonstrated complete responses in 28 of 33 patients (85 percent). Relapses were seen in a little over half.",
"     </li>",
"     <li>",
"      Antibiotics &mdash; Reports of antibiotic use in patients with coexisting PCMZL and Borrelia infection have had mixed results. Six of 14 patients reported in the literature achieved a complete response. Treatment appeared to be most successful with cephalosporin therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27498?source=see_link\">",
"       \"Treatment of Lyme disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Our general approach to treatment is based upon the observational data described above and attempts to maximize response in early stage disease where localized therapy is effective and has limited toxicities. In comparison, our approach to patients with disseminated disease attempts to limit exposure to potentially toxic agents because of the indolent nature of these tumors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with lesions that can be contained within one radiation field, we suggest initial treatment with local radiation therapy rather than observation or more aggressive therapy (eg, combination chemotherapy or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      therapy). A radiation dose of 20 to 36 Gy is typically used and the treatment area should include a margin of healthy appearing tissue. Solitary lesions in areas not amenable to radiation therapy may be excised surgically.",
"     </li>",
"     <li>",
"      For patients with multifocal disease, we suggest an initial observation period with localized treatment approaches (eg, radiation therapy, excision, or intralesional steroids) reserved for symptomatic lesions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     ASSESSING DISEASE RESPONSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;We evaluate and restage patients 8 to 12 weeks after the completion of therapy. Restaging should consist of repeating laboratory and clinical examinations used to stage the disease at presentation. We typically do not repeat a bone marrow biopsy unless there is suspicion of new bone marrow involvement such as an abnormal complete blood count. If the radiographic studies were normal at the time of diagnosis, we reserve repeat imaging for patients in whom there is a clinical concern for systemic spread based upon symptoms, laboratory results, or physical examination.",
"   </p>",
"   <p>",
"    Following the completion of therapy, restaging, and documentation of complete remission, patients are seen at periodic intervals to monitor for treatment complications and assess for possible relapse. The frequency and extent of these visits depends upon the comfort of both the patient and physician.",
"   </p>",
"   <p>",
"    For patients who are in complete remission, we re-evaluate with a physical examination every three months for the first two years following therapy. The frequency of clinic visits is then decreased thereafter. We do not use imaging studies or blood examinations in the routine follow-up of asymptomatic individuals. This is principally because recurrences are almost always detected by clinical examination. In a retrospective analysis that included 14 patients with PCMZL followed for a median of 44 months, there were 12 episodes of recurrence, all of which were identified by physical examination [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26776/abstract/42\">",
"     42",
"    </a>",
"    ]. Neither blood examinations nor imaging procedures established recurrence or progression in any patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     TREATMENT AT RELAPSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately half of patients initially treated with radiation therapy will relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26776/abstract/39\">",
"     39",
"    </a>",
"    ]. Most relapses are confined to the skin. If they appear outside of the prior radiation field, most will respond to radiation therapy. If they occur inside the radiation field, surgical excision or single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    may be used. While multiagent chemotherapy remains an option for difficult to treat disease, it is rarely necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21004249\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with PCMZL usually have an indolent clinical course. Cutaneous relapses are common, in particular in patients with multifocal skin lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26776/abstract/24,43\">",
"     24,43",
"    </a>",
"    ]. Extracutaneous dissemination is, however, uncommon. In two studies, only 6 of 71 (8.5 percent) and 9 of 144 (6.2 percent) patients with a histologically confirmed PCMZL developed extracutaneous disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26776/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. The prognosis of patients with PCMZL is excellent, with five-year survival rates of 98 to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26776/abstract/5,24,28,43-45\">",
"     5,24,28,43-45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary cutaneous B cell lymphoma (PCBCL) refers to those cases of B cell lymphoma that present in the skin when there is no evidence of extracutaneous disease at the time of diagnosis and after the completion of an initial staging evaluation. Primary cutaneous marginal zone lymphoma (PCMZL) is a PCBCL and is also included in the broader category of extranodal marginal zone B cell lymphoma. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no clearly defined risk factors for the development of PCMZL; however, an association between PCMZL and infectious agents such as Borrelia burgdorferi has been postulated. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients typically present with asymptomatic, localized, deep red to brown infiltrated plaques or grouped nodules surrounded by an area of diffuse erythema. Lesions are generally localized to one body region, often the extremities or trunk. Disseminated lesions are rare. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of PCMZL requires a representative biopsy of involved skin and the exclusion of non-cutaneous disease in the appropriate clinical setting. A typical biopsy of PCMZL demonstrates a B cell infiltrate comprised of small to medium sized lymphocytes, often with a plasmacytoid appearance in a reactive germinal-center-like structure. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Pathologic features'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The staging evaluation both confirms the diagnosis by excluding involvement of other sites and provides information to guide treatment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15464?source=see_link&amp;anchor=H18#H18\">",
"       \"Primary cutaneous follicle center lymphoma\", section on 'Staging'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      PCMZL is a rare disorder; accordingly, large trials are lacking. The published data regarding treatment consist entirely of retrospective reviews and anecdotal reports. In general, our treatment approach depends upon the number of lesions, their location, and the presence of symptoms attributable to the lesions (eg, pruritus):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with focal disease (a solitary lesion or lesions that can be contained within one radiation field), we suggest treatment with radiation therapy rather than chemotherapy, surgical excision, or observation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). A radiation dose of 20 to 36 Gy is typically used and the treatment area should include a margin of healthy appearing tissue. Surgical excision of observation is an acceptable alternative for lesions that are not amenable to radiation therapy (eg, in a location at which radiation toxicity is increased). (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with asymptomatic multifocal disease, we suggest observation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with symptomatic multifocal disease, we suggest that treatment be directed at the symptomatic lesion with either radiation therapy or excision rather than chemotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The choice between radiation therapy and excision may be made based upon predicted toxicities for the affected site. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately half of patients initially treated with radiation therapy will relapse. Most relapses are confined to the skin and are treated with the same modalities as initial therapy. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Treatment at relapse'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26776/abstract/1\">",
"      Burg G, Kerl H, Przybilla B, Braun-Falco O. Some statistical data, diagnosis, and staging of cutaneous B-cell lymphomas. J Dermatol Surg Oncol 1984; 10:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26776/abstract/2\">",
"      Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105:3768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26776/abstract/3\">",
"      Dores GM, Anderson WF, Devesa SS. Cutaneous lymphomas reported to the National Cancer Institute's surveillance, epidemiology, and end results program: applying the new WHO-European Organisation for Research and Treatment of Cancer classification system. J Clin Oncol 2005; 23:7246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26776/abstract/4\">",
"      Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood 2009; 113:5064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26776/abstract/5\">",
"      Fink-Puches R, Zenahlik P, B&auml;ck B, et al. Primary cutaneous lymphomas: applicability of current classification schemes (European Organization for Research and Treatment of Cancer, World Health Organization) based on clinicopathologic features observed in a large group of patients. Blood 2002; 99:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26776/abstract/6\">",
"      Gerami P, Wickless SC, Querfeld C, et al. Cutaneous involvement with marginal zone lymphoma. J Am Acad Dermatol 2010; 63:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26776/abstract/7\">",
"      Anthonissen FM, De Kesel M, Hoet PP, Bigaignon GH. Evidence for the involvement of different genospecies of Borrelia in the clinical outcome of Lyme disease in Belgium. Res Microbiol 1994; 145:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26776/abstract/8\">",
"      Jeli S, Filipovi-Ljeskovi I. Positive serology for Lyme disease borrelias in primary cutaneous B-cell lymphoma: a study in 22 patients; is it a fortuitous finding? Hematol Oncol 1999; 17:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26776/abstract/9\">",
"      Li C, Inagaki H, Kuo TT, et al. Primary cutaneous marginal zone B-cell lymphoma: a molecular and clinicopathologic study of 24 asian cases. Am J Surg Pathol 2003; 27:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26776/abstract/10\">",
"      Wood GS, Kamath NV, Guitart J, et al. Absence of Borrelia burgdorferi DNA in cutaneous B-cell lymphomas from the United States. J Cutan Pathol 2001; 28:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26776/abstract/11\">",
"      Balmelli T, Piffaretti JC. Association between different clinical manifestations of Lyme disease and different species of Borrelia burgdorferi sensu lato. Res Microbiol 1995; 146:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26776/abstract/12\">",
"      Goodlad JR, Davidson MM, Hollowood K, et al. Primary cutaneous B-cell lymphoma and Borrelia burgdorferi infection in patients from the Highlands of Scotland. Am J Surg Pathol 2000; 24:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26776/abstract/13\">",
"      Slater DN. Borrelia burgdorferi-associated primary cutaneous B-cell lymphoma. Histopathology 2001; 38:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26776/abstract/14\">",
"      Beylot-Barry M, Vergier B, Masquelier B, et al. The Spectrum of Cutaneous Lymphomas in HIV infection: a study of 21 cases. Am J Surg Pathol 1999; 23:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26776/abstract/15\">",
"      McGregor JM, Yu CC, Lu QL, et al. Posttransplant cutaneous lymphoma. J Am Acad Dermatol 1993; 29:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26776/abstract/16\">",
"      Watabe H, Kawakami T, Soma Y, et al. Primary cutaneous T-cell-rich B-cell lymphoma in a zosteriform distribution associated with Epstein-Barr virus infection. J Dermatol 2002; 29:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26776/abstract/17\">",
"      Nagore E, Ledesma E, Collado C, et al. Detection of Epstein-Barr virus and human herpesvirus 7 and 8 genomes in primary cutaneous T- and B-cell lymphomas. Br J Dermatol 2000; 143:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26776/abstract/18\">",
"      Peris K, Niedermeyer H, Cerroni L, et al. Detection of Epstein-Barr virus genome in primary cutaneous T and B cell lymphomas and pseudolymphomas. Arch Dermatol Res 1994; 286:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26776/abstract/19\">",
"      Viguier M, Rivet J, Agbalika F, et al. B-cell lymphomas involving the skin associated with hepatitis C virus infection. Int J Dermatol 2002; 41:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26776/abstract/20\">",
"      Hermine O, Lefr&egrave;re F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002; 347:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26776/abstract/21\">",
"      Rijlaarsdam JU, van der Putte SC, Berti E, et al. Cutaneous immunocytomas: a clinicopathologic study of 26 cases. Histopathology 1993; 23:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26776/abstract/22\">",
"      Cunningham-Rundles C, Cooper DL, Duffy TP, Strauchen J. Lymphomas of mucosal-associated lymphoid tissue in common variable immunodeficiency. Am J Hematol 2002; 69:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26776/abstract/23\">",
"      Pereira FO, Graf H, Nomura LM, et al. Concomitant presentation of Hashimoto's thyroiditis and maltoma of the thyroid in a twenty-year-old man with a rapidly growing mass in the neck. Thyroid 2000; 10:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26776/abstract/24\">",
"      Hoefnagel JJ, Vermeer MH, Jansen PM, et al. Primary cutaneous marginal zone B-cell lymphoma: clinical and therapeutic features in 50 cases. Arch Dermatol 2005; 141:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26776/abstract/25\">",
"      Cerroni L, Signoretti S, H&ouml;fler G, et al. Primary cutaneous marginal zone B-cell lymphoma: a recently described entity of low-grade malignant cutaneous B-cell lymphoma. Am J Surg Pathol 1997; 21:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26776/abstract/26\">",
"      Connors JM, Hsi ED, Foss FM. Lymphoma of the skin. Hematology Am Soc Hematol Educ Program 2002; :263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26776/abstract/27\">",
"      Rijlaarsdam U, Bakels V, van Oostveen JW, et al. Demonstration of clonal immunoglobulin gene rearrangements in cutaneous B-cell lymphomas and pseudo-B-cell lymphomas: differential diagnostic and pathogenetic aspects. J Invest Dermatol 1992; 99:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26776/abstract/28\">",
"      Willemze R, Kerl H, Sterry W, et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 1997; 90:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26776/abstract/29\">",
"      Zinzani PL, Magagnoli M, Galieni P, et al. Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients. J Clin Oncol 1999; 17:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26776/abstract/30\">",
"      Sterry W, Kr&uuml;ger GR, Steigleder GK. Skin involvement of malignant B-cell lymphomas. J Dermatol Surg Oncol 1984; 10:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26776/abstract/31\">",
"      van Maldegem F, van Dijk R, Wormhoudt TA, et al. The majority of cutaneous marginal zone B-cell lymphomas expresses class-switched immunoglobulins and develops in a T-helper type 2 inflammatory environment. Blood 2008; 112:3355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26776/abstract/32\">",
"      Magro C, Crowson AN, Porcu P, Nuovo GJ. Automated kappa and lambda light chain mRNA expression for the assessment of B-cell clonality in cutaneous B-cell infiltrates: its utility and diagnostic application. J Cutan Pathol 2003; 30:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26776/abstract/33\">",
"      Kazakov DV, Belousova IE, M&uuml;ller B, et al. Primary cutaneous plasmacytoma: a clinicopathological study of two cases with a long-term follow-up and review of the literature. J Cutan Pathol 2002; 29:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26776/abstract/34\">",
"      Green T, Grant J, Pye R, Marcus R. Multiple primary cutaneous plasmacytomas. Arch Dermatol 1992; 128:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26776/abstract/35\">",
"      Burg G, Kempf W, Haeffner AC, et al. Cutaneous lymphomas. Curr Probl Dermatol 1997; 9:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26776/abstract/36\">",
"      Torne R, Su WP, Winkelmann RK, et al. Clinicopathologic study of cutaneous plasmacytoma. Int J Dermatol 1990; 29:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26776/abstract/37\">",
"      Walker E, Robertson AG, Boorman JG, McNicol AM. Primary cutaneous plasmacytoma: the use of in situ hybridization to detect monoclonal immunoglobulin light-chain mRNA. Histopathology 1992; 20:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26776/abstract/38\">",
"      Chang YT, Wong CK. Primary cutaneous plasmacytomas. Clin Exp Dermatol 1994; 19:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26776/abstract/39\">",
"      Senff NJ, Noordijk EM, Kim YH, et al. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood 2008; 112:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26776/abstract/40\">",
"      Neelis KJ, Schimmel EC, Vermeer MH, et al. Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas. Int J Radiat Oncol Biol Phys 2009; 74:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26776/abstract/41\">",
"      Pe&ntilde;ate Y, Hern&aacute;ndez-Mach&iacute;n B, P&eacute;rez-M&eacute;ndez LI, et al. Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: an epidemiological observational multicentre study. The Spanish Working Group on Cutaneous Lymphoma. Br J Dermatol 2012; 167:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26776/abstract/42\">",
"      Terhorst D, Mestel DS, Humme D, et al. Evaluation of different methods in the follow-up of patients with indolent types of primary cutaneous lymphomas. Br J Dermatol 2012; 166:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26776/abstract/43\">",
"      Gerami P, Wickless SC, Rosen S, et al. Applying the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and S&eacute;zary syndrome in primary cutaneous marginal zone lymphoma. J Am Acad Dermatol 2008; 59:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26776/abstract/44\">",
"      Senff NJ, Hoefnagel JJ, Jansen PM, et al. Reclassification of 300 primary cutaneous B-Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers. J Clin Oncol 2007; 25:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26776/abstract/45\">",
"      Zinzani PL, Quaglino P, Pimpinelli N, et al. Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas. J Clin Oncol 2006; 24:1376.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4739 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-3548BCC041-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_9_26776=[""].join("\n");
var outline_f26_9_26776=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Infectious etiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Borrelia burgdorferi",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Viral etiologies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Autoimmune disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PATHOLOGIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Morphology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Immunophenotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Systemic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1212257987\">",
"      - Marginal zone lymphoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1212258068\">",
"      - Other systemic lymphomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Reactive infiltrate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Primary cutaneous diffuse large B cell lymphoma, leg type",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Primary cutaneous follicle center lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Cutaneous T cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Intravascular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Extramedullary plasmacytoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      STAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      ASSESSING DISEASE RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      TREATMENT AT RELAPSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21004249\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4739\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4739|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/2/27695\" title=\"picture 1A\">",
"      PCMZL solitary tumor on lower leg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/54/43872\" title=\"picture 1B\">",
"      PCMZL multifocal skin lesions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=related_link\">",
"      Clinical manifestations of Lyme disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19610?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of extranodal (MALT) and nodal marginal zone lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/29/30169?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of mantle cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4618?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/28/18887?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of small lymphocytic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33416?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of splenic marginal zone lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/17/16662?source=related_link\">",
"      Diagnosis and management of solitary extramedullary plasmacytoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13511?source=related_link\">",
"      Intravascular large cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15464?source=related_link\">",
"      Primary cutaneous follicle center lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/49/26391?source=related_link\">",
"      Primary cutaneous large B cell lymphoma, leg type",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41897?source=related_link\">",
"      T helper subsets: Differentiation and role in disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27498?source=related_link\">",
"      Treatment of Lyme disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_9_26777="Exercise-induced anaphylaxis: Clinical manifestations, epidemiology, pathogenesis, and diagnosis";
var content_f26_9_26777=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Exercise-induced anaphylaxis: Clinical manifestations, epidemiology, pathogenesis, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/9/26777/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/9/26777/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/9/26777/contributors\">",
"     Albert L Sheffer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/9/26777/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/9/26777/contributors\">",
"     F Estelle R Simons, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/9/26777/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/9/26777/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/9/26777/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise-induced anaphylaxis (EIAn) is a disorder in which anaphylaxis occurs in association with physical exertion. There is a related condition called food-dependent, exercise-induced anaphylaxis (FDEIAn), in which symptoms develop only if exercise takes place within a few hours of eating, and in most cases, only if a specific food is eaten in the pre-exercise period.",
"   </p>",
"   <p>",
"    The clinical manifestations, theories of pathogenesis, evaluation, and diagnosis of EIAn and FDEIAn will be reviewed here. The management and prognosis of EIAn and FDEIAn, anaphylaxis caused solely by foods, and the diagnosis and management of anaphylaxis from any cause are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/45/42709?source=see_link\">",
"     \"Exercise-induced anaphylaxis: Management and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/0/38920?source=see_link\">",
"     \"Food-induced anaphylaxis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Signs and symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise-induced anaphylaxis (EIAn) is characterized by signs and symptoms of anaphylaxis in the setting of physical exertion. Symptoms may begin at any stage of exercise, and occasionally occur just after exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/1\">",
"     1",
"    </a>",
"    ]. Early signs and symptoms typically include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diffuse warmth",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      flushing",
"     </li>",
"     <li>",
"      Pruritus",
"     </li>",
"     <li>",
"      Urticaria (hives are usually 10 to 15 mm in diameter or larger, rather than \"punctate\")",
"     </li>",
"     <li>",
"      Sudden fatigue",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If exercise continues, there is a progression to more severe symptoms, including one or more of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Angioedema of the face",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      extremities (often the hands)",
"     </li>",
"     <li>",
"      Gastrointestinal symptoms, including nausea, abdominal cramping, and diarrhea",
"     </li>",
"     <li>",
"      Laryngeal edema",
"     </li>",
"     <li>",
"      Hypotension",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      collapse",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Bronchospasm is reported in some patients, although it may be less common in EIAn than in anaphylaxis from other causes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/3\">",
"     3",
"    </a>",
"    ]. Some patients experience headache that can persist for hours to days after the attack [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The diagnostic criteria for anaphylaxis (from any cause) are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cessation of exercise usually results in immediate improvement or resolution of symptoms. Perhaps for this reason, reports of fatality are limited to a few cases [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. However, it is possible that fatal episodes may be underdiagnosed or mistaken for other causes of sudden death during exercise.",
"   </p>",
"   <p>",
"    Although stopping activity usually prevents progression of the attack, patients often do not instinctively stop exertion when they first experience symptoms. Instead, many try to run for help, which typically precipitates a dramatic worsening of symptoms. Patients should be educated about the importance of immediate cessation of activity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/45/42709?source=see_link\">",
"     \"Exercise-induced anaphylaxis: Management and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Frequency of attacks",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency and predictability with which symptoms occur vary among patients with EIAn and FDEIAn. Most patients exercise regularly, but experience attacks only occasionally. A minority of individuals experience symptoms with most attempts at exercise. Still other patients have one or two attacks over a span of several years, although such infrequent attacks should prompt a careful evaluation for undetected co-triggers and co-factors. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Other co-triggers and co-factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Triggering activities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vigorous forms of exercise, such as jogging, racquet sports, dancing, and aerobics are most often implicated, although lower levels of exertion (eg, brisk walking or yard work) are capable of triggering attacks in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     The role of food",
"    </span>",
"    &nbsp;&mdash;&nbsp;In FDEIAn symptoms occur only when the person exercises within minutes to a few hours after eating. In rare cases, symptoms occur when the food is eaten shortly after exercise. Only the combination of the food and exercise precipitates attacks. Affected patients can eat the food in question without symptoms if there is no associated exercise, and they can exercise without symptoms if they have not eaten the culprit food.",
"   </p>",
"   <p>",
"    Most patients develop symptoms only after eating a specific food, although a few have attacks if any food (usually solids rather than liquids) has been ingested [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/9\">",
"     9",
"    </a>",
"    ]. Rare patients have been described in whom symptoms only occurred if two foods were eaten together before exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The foods most commonly implicated in FDEIAn are wheat, other grains, and nuts in Western populations, and wheat and shellfish in Asian populations; however, an array of culprit foods has been reported, including fruits, vegetables, seeds, legumes, and less often, various meats, cow's milk, and egg [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/1,11-18\">",
"     1,11-18",
"    </a>",
"    ]. The amount of food ingested is important in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The processing of the food may be critical in some cases. In one report, a patient developed FDEIAn with tofu, but could tolerate soy milk [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/20\">",
"     20",
"    </a>",
"    ]. Immunoblotting identified beta-conglycinin as the main allergen. Pepsin digestion readily degraded the beta-conglycinin in soy milk, but the same allergen in tofu was resistant to pepsin digestion, suggesting that this difference in allergen stability was fundamental to the patient's presentation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other co-triggers and co-factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients develop symptoms more readily in the presence of one or more additional co-triggers and co-factors, although exercise remains the immediate inciting factor. These include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nonsteroidal antiinflammatory drugs (NSAIDs) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/21-25\">",
"       21-25",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Alcoholic beverages [",
"      <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Premenstrual or ovulatory phases of the menstrual cycle in women [",
"      <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/15,21\">",
"       15,21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Extremes of temperature (either high heat and humidity or cold exposure) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Seasonal pollen exposure in pollen-sensitized patients [",
"      <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Temporal association between co-triggers, co-factors, and exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposure to the co-trigger or co-factor typically occurs first, and then exercise precipitates symptoms.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In most cases of FDEIAn, symptoms occur when the food is ingested within minutes to two hours before exercise [",
"      <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/26\">",
"       26",
"      </a>",
"      ]. However, there are rare cases of FDEIAn in which the food was ingested shortly AFTER exercise [",
"      <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/2,4,9,27\">",
"       2,4,9,27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The temporal association between ingestion of alcoholic beverages is poorly reported, although the critical time period before exertion seems to be minutes to a few hours, similar to that of food.",
"     </li>",
"     <li>",
"      Ingestion of NSAIDs may precede exercise by hours to a day.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both EIAn and FDEIAn have been reported around the world [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/1,13,28-30\">",
"     1,13,28-30",
"    </a>",
"    ]. The female to male ratio is approximately 2 to 2.5 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adolescents and young adults account for most reported cases. Both EIAn and FDEIAn have occasionally been described in pre-adolescent children and older adults [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/29,31,32\">",
"     29,31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    EIAn and FDEIAn appear to be rare, but there have been few attempts to systematically establish prevalence. The best study surveyed all school nurses in Yokohama, Japan, to identify possible cases of EIAn or FDEIAn among Japanese adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/28\">",
"     28",
"    </a>",
"    ]. Each case was investigated and confirmed. In this population, the prevalences of EIAn and FDEIAn were 0.03 and 0.017 percent, respectively. There was no apparent gender predilection in EIAn, whereas FDEIAn was more often identified in boys, contrary to the gender ratio noted above.",
"   </p>",
"   <p>",
"    EIAn and FDEIAn are usually sporadic, although familial cases have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     THEORIES OF PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of EIAn and FDEIAn has not been determined. Theories of pathogenesis are reviewed in the following paragraphs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Exercise-induced anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous mast cell degranulation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/35\">",
"     35",
"    </a>",
"    ] and transient elevations in plasma histamine [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/36,37\">",
"     36,37",
"    </a>",
"    ] and serum tryptase [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/38,39\">",
"     38,39",
"    </a>",
"    ] have been documented in patients with EIAn. Thus, mast cell activation and release of vasoactive mediators is believed to be responsible for the associated clinical manifestations, as in other forms of anaphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The specific physiologic changes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cellular events that occur during exercise to trigger mast cell activation are not known. Several mast cell secretagogues are released during exercise, including endogenous endorphins and gastrin [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18778?source=see_link\">",
"     \"Pathophysiology of anaphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Food-dependent forms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with FDEIAn tolerate ingestion of the culprit food in the absence of exercise. Thus, it seems that this disorder involves temporary loss of tolerance, as a result of some physiologic change induced by exercise. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Temporal association between co-triggers, co-factors, and exercise'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Several theories have been proposed to explain FDEIAn:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One line of research has focused on FDEIAn caused by wheat. Omega-5 gliadin was identified as an important allergen in this disorder as well as in other anaphylactic forms of wheat allergy [",
"      <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/44,45\">",
"       44,45",
"      </a>",
"      ]. The intestinal enzyme tissue transglutaminase is activated during exercise and is capable of binding and aggregating gliadin moieties to form large immunogenic complexes that demonstrate increased IgE binding [",
"      <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/46\">",
"       46",
"      </a>",
"      ]. This model suggests that exercise may induce changes in the processing of specific allergens, leading to increased allergenicity.",
"      <br/>",
"      <br/>",
"      Another subset of patients with wheat-dependant EIAn may be sensitized through exposure to hydrolyzed wheat protein in personal products (eg, facial soap) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/47\">",
"       47",
"      </a>",
"      ]. Omega-5 gliadin is not the main allergen in this syndrome.",
"     </li>",
"     <li>",
"      Gastric permeability can increase during exercise, which may permit increased entry of intact or incompletely digested allergens into the circulation during exercise but not during rest [",
"      <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/23,48\">",
"       23,48",
"      </a>",
"      ]. NSAIDs, which can be a co-trigger, can increase gastric permeability [",
"      <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/49,50\">",
"       49,50",
"      </a>",
"      ]. Premedication with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      increases the chances that a",
"      <span class=\"nowrap\">",
"       food/exercise",
"      </span>",
"      challenge will elicit symptoms, and is sometimes used in diagnosis. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Exercise challenge testing'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Another theory is that exercise mobilizes and activates immune cells from gut-associated depots, stimulating proinflammatory responses that are normally countered by antiinflammatory responses [",
"      <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/51\">",
"       51",
"      </a>",
"      ]. Dysregulation of this process in patients with food-sensitized leukocytes could be involved in exercise-induced reactions. Alternatively, cells from these depots could be exposed to allergens as a result of increased gastric permeability.",
"     </li>",
"     <li>",
"      During exercise, blood flow is redistributed away from the viscera to the skin and musculature. This redirection of blood may carry food allergens to tissues containing mast cells that are not tolerant to those allergens, resulting in an allergic reaction during exercise, but tolerance at rest [",
"      <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Exercise may result in changes in serum osmolality within mucosal tissues, a mechanism that has been implicated in exercise-induced asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/53,54\">",
"       53,54",
"      </a>",
"      ]. Hyperosmolality increases basophil histamine release in response to allergens and radiocontrast media [",
"      <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/26,55,56\">",
"       26,55,56",
"      </a>",
"      ]. A case report demonstrated increased basophil histamine release in response to hyperosmolal medium in a patient with FDEIAn compared with cells from normal controls and individuals with food allergy [",
"      <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Dysregulation of the autonomic nervous system has been suggested in a few reports [",
"      <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/57,58\">",
"       57,58",
"      </a>",
"      ]. In one, tests of autonomic function were performed in four adolescents with FDEIAn and four normal controls, before and after exercise challenge (without the culprit food for safety). Even though challenge without food failed to induce symptoms, there was evidence of increased parasympathetic activity and decreased sympathetic activity compared with controls.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of EIAn or FDEIAn is made clinically in the majority of cases, based largely upon a meticulous history of the events surrounding the episodes and exclusion of other disorders that could present similarly. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Questions of particular importance to the evaluation of EIAn and FDEIAn will be addressed here. The evaluation of patients with anaphylaxis from any cause is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9401?source=see_link&amp;anchor=H4433858#H4433858\">",
"     \"Anaphylaxis: Confirming the diagnosis and determining the trigger(s)\", section on 'Testing for allergen trigger(s)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Diagnosis of EIAn",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of EIAn is appropriate in a patient with the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Signs and symptoms consistent with anaphylaxis that occurred during (or occasionally shortly after) exercise",
"     </li>",
"     <li>",
"      No other diagnosis that explains the clinical presentation (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Clinical history'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H22\">",
"       'Differential diagnosis'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Skin testing for specific IgE to environmental",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    food allergens should be performed if indicated by the clinical history. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Skin testing or in vitro testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A positive exercise challenge confirms the diagnosis, but a negative challenge does not reliably exclude the diagnosis. Thus, until a validated protocol for exercise challenge is established, challenge is not required for diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Diagnosis of food-dependent EIAn",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of FDEIAn is appropriate in a patient with the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Signs and symptoms consistent with anaphylaxis that occurred during (or shortly after) exercise, but only when exercise was preceded (typically by no more than two to three hours) by food ingestion (see",
"      <a class=\"local\" href=\"#H17\">",
"       'Questions about food'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      No other diagnosis that explains the clinical presentation (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Clinical history'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H22\">",
"       'Differential diagnosis'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If a specific food is implicated, then there should also be:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evidence of specific IgE to the implicated food, either by skin testing or food-specific IgE immunoassays (see",
"      <a class=\"local\" href=\"#H20\">",
"       'Skin testing or in vitro testing'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      No symptoms upon ingestion of that food in the absence of exertion, and no symptoms if exercise occurs without ingestion of that food (see",
"      <a class=\"local\" href=\"#H17\">",
"       'Questions about food'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A positive",
"    <span class=\"nowrap\">",
"     food/exercise",
"    </span>",
"    challenge confirms the diagnosis, but a negative challenge does not reliably exclude the diagnosis. Thus, until a validated protocol for exercise challenge is established, challenge is NOT required for diagnosis. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Exercise challenge testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    If testing for food sensitization is negative but the history is strongly suggestive of FDEIAn, we suggest repeat testing in six months to one year. We have encountered patients in whom sensitization was not demonstrable at presentation, but became so within a period of months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Clinical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should carefully review the details of each episode and attempt to discern the following information:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Was exercise or some type of exertion associated with each of the attacks? If not, then the patient with food-associated symptoms may have a primary food allergy with symptoms that are exacerbated by exercise.",
"     </li>",
"     <li>",
"      Does it seem that a certain level of exertion must be reached before symptoms appear, or can attacks occur at different levels of exertion? This information is useful in determining which activities the patient can safely resume in the future.",
"     </li>",
"     <li>",
"      Do symptoms begin to subside when the patient stops all physical activity? This is an important clinical feature of both EIAn and FDEIAn.",
"     </li>",
"     <li>",
"      Do other activities that involve passively heating the body induce symptoms, such as hot baths or showers, saunas? Symptoms triggered by changes in core body temperature are suggestive of cholinergic urticaria. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Differential diagnosis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Were any medications (over the counter or prescription) or alcohol ingested in the 24 hours preceding the attack? Certain medications and alcohol can amplify symptoms of anaphylaxis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Other co-triggers and co-factors'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9401?source=see_link&amp;anchor=H4433837#H4433837\">",
"       \"Anaphylaxis: Confirming the diagnosis and determining the trigger(s)\", section on 'Concurrent medications and other substances'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Do symptoms occur in specific environments (eg, indoors or outdoors)? Were there any common ambient outdoor conditions on days of attacks (eg, high humidity, peak pollen season)? Is there any seasonal variation? (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Other co-triggers and co-factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Does the patient have a history of other allergic diseases, such as allergic rhinitis (consider pollens as a possible co-factor), or chronic urticaria (could the patient have a physical urticaria with systemic symptoms)? (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Differential diagnosis'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Questions about food",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients suspected of having FDEIAn, additional questions should be directed at determining if a primary food allergy is present and if the reaction could have represented a primary food allergy that was exacerbated by exercise. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Since the last attack, has the patient ingested portion-sized amounts of the food in question in the absence of exercise, and if so, did any symptoms result? In FDEIAn, the food only causes symptoms if there is associated exercise.",
"     </li>",
"     <li>",
"      Does the patient have symptoms of oral allergy syndrome? If so, were any pollen-related foods ingested before the attack? (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11082?source=see_link\">",
"       \"Clinical manifestations and diagnosis of oral allergy syndrome (pollen-food allergy syndrome)\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Does the patient ingest any health drinks, protein bars, or other supplements? These commonly contain grains, fruits, nuts, soy, and other potential food allergens (eg, gelling agents), and are routinely overlooked by patients, who may forget to report snacks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no physical findings that are unique to patients with EIAn or FDEIAn. There may be signs of allergic diseases, such as eczematous skin changes, or allergic \"shiners,\" a transverse nasal crease (suggesting frequent nose rubbing),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pale boggy mucosa on nasal speculum examination suggesting allergic rhinitis.",
"   </p>",
"   <p>",
"    A careful skin examination should be performed to evaluate for dermographism and to ensure that urticaria pigmentosa, the characteristic skin finding in mastocytosis, is not present. Mastocytosis can present with anaphylaxis upon exertion, as well as in response to a variety of other triggers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24666?source=see_link\">",
"     \"Physical urticarias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6170?source=see_link\">",
"     \"Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cardiac examination should be performed to exclude abnormal heart sounds or rhythms, as exercise-induced cardiac conditions are in the differential diagnosis. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A baseline serum tryptase level should be measured in all patients. The blood sample should be obtained a few days or more after resolution of an episode. Serum tryptase is normal at baseline in both EIAn and FDEIAn. Elevated values at baseline are suggestive of mastocytosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6170?source=see_link\">",
"     \"Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As with anaphylaxis from other causes, laboratory abnormalities, such as elevations in serum tryptase or serum or plasma histamine, can support the clinical impression, but are not necessary for making the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/59\">",
"     59",
"    </a>",
"    ]. There are very limited data about how often elevations in these mediators are present after episodes of EIAn and FDEIAn. A negative test does not rule out anaphylaxis. These tests are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/54/40809?source=see_link\">",
"     \"Laboratory tests to support the clinical diagnosis of anaphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Skin testing or in vitro testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with food-dependant EIAn (FDEIAn), skin testing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    in vitro testing for food-specific IgE is essential to the evaluation, because sensitization to the precipitating food(s) is usually demonstrable.",
"   </p>",
"   <p>",
"    If skin testing with a commercial extract yields negative results, skin testing with fresh food (such as wheat flour) should be performed. In a study of 17 patients with wheat-dependent FDEIAn, 29 percent were skin test positive when a commercial wheat extract was used, while 80 percent tested positive to a paste of wheat flour [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Diagnosis of food-dependent EIAn'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In the evaluation of wheat-dependent exercise-induced anaphylaxis, the sensitivity of the ImmunoCAP (Phadia, Uppsala, Sweden) commercial assay for IgE to recombinant omega-5-gliadin was found to be 80 percent in a study of 50 Japanese patients with positive",
"    <span class=\"nowrap\">",
"     food/exercise",
"    </span>",
"    challenges, making this immunoassay more clinically useful than those for wheat, gluten, or other allergens [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/61\">",
"     61",
"    </a>",
"    ]. IgE to omega-5-gliadin may be positive even when IgE to wheat is negative [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/62\">",
"     62",
"    </a>",
"    ]. In the study of 17 German patients with wheat-dependent FDEIAn mentioned previously, 82 percent had IgE to omega-5-gliadin, although other gliadins (alpha, beta, and gamma) were also important, as demonstrated with experimental ImmunoCAP assays [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/60\">",
"     60",
"    </a>",
"    ]. The extent to which different populations of patients with wheat-dependent EIAn are sensitized to different wheat allergens has not been systematically evaluated.",
"   </p>",
"   <p>",
"    Skin testing or in vitro testing for IgE-sensitization to environmental allergens is useful in the evaluation of EIAn if specific co-factors are suspected, such as high pollen counts in a patient with concomitant allergic respiratory disease. However, it is not a routine component of the evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Exercise challenge testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no established protocol for exercise challenge, with or without food, to evaluate patients for EIAn or FDEIAn. A validated exercise challenge protocol would be useful in confirming the diagnosis of EIAn. It would also exclude EIAn in a patient whose reactions are believed to be dependent upon food (FDEIAn), thereby allowing them to resume exercise safely in the fasting state.",
"   </p>",
"   <p>",
"    Most studies have reported variable rates of success in eliciting symptoms with exercise challenge (with or without food) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/1,19,25,28,37,63\">",
"     1,19,25,28,37,63",
"    </a>",
"    ]. The Standard Bruce protocol for stress testing, which includes spirometry before and periodically during the procedure, has been used by several groups [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/25,28\">",
"     25,28",
"    </a>",
"    ]. In a literature review of 234 cases of FDEIAn,",
"    <span class=\"nowrap\">",
"     food/exercise",
"    </span>",
"    challenges were performed in 81 and failed to reproduce symptoms in 29 (36 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/19\">",
"     19",
"    </a>",
"    ]. Thus, a negative test does not exclude FDEIAn. The amount of food, the interval between food ingestion and exercise, and the intensity of the exercise may all be important factors [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/1,19,59\">",
"     1,19,59",
"    </a>",
"    ]. In some patients with negative",
"    <span class=\"nowrap\">",
"     food/exercise",
"    </span>",
"    challenges, premedication with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (500 mg orally before food ingestion) increased the likelihood that symptoms were elicited with repeat challenge [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Clinical manifestations'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35945?source=see_link&amp;anchor=H16#H16\">",
"     \"Performance of exercise ECG testing\", section on 'Exercise test procedure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If pursued, exercise challenge procedures should be performed by allergy specialists with the expertise, staff, and equipment available to treat anaphylaxis. Informed consent should be obtained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of EIAn includes cholinergic urticaria, mastocytosis, cardiovascular events, exercise-induced asthma and exercise-associated gastroesophageal reflux. In addition, the differential diagnosis of FDEIAn includes primary food allergy exacerbated by exercise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Cholinergic urticaria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholinergic urticaria is a form of physical urticaria characterized by small punctate wheals (1 to 3 mm in diameter) with surrounding erythema of the affected skin (",
"    <a class=\"graphic graphic_picture graphicRef53590 \" href=\"UTD.htm?41/58/42912\">",
"     picture 1",
"    </a>",
"    ). Urticaria is elicited by raising the core body temperature. Patients may experience symptoms with exercise, but also upon exposure to factors that passively increase body temperature, such as hot showers or saunas, very strong emotion, or very spicy food. Symptoms of cholinergic urticaria are usually limited to the skin, although generalized symptoms can occur if cutaneous mast cell mediators are released in sufficient amounts and diffuse into the systemic circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24666?source=see_link&amp;anchor=H20#H20\">",
"     \"Physical urticarias\", section on 'Cholinergic urticaria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cholinergic urticaria can be reproduced with passive warming. In contrast, exercise is necessary to elicit the symptoms of EIAn [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The wheals of exercise-induced anaphylaxis are usually large (10 to 15 mm in diameter), whereas those of cholinergic urticaria are typically small and punctate. This distinction is not true in all cases, and the punctate wheals of cholinergic urticaria may enlarge and coalesce as symptoms progress.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Cold-induced urticaria/anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cold-induced urticaria can cause sufficient systemic mediator release to precipitate anaphylaxis. Patients with this disorder who experience symptoms from exercising in cold weather may be mistakenly diagnosed with EIAn. However, cold ambient conditions may be a co-factor in some patients with EIAn [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/4,66,67\">",
"     4,66,67",
"    </a>",
"    ]. Questioning about passive cold exposure should reveal other circumstances in which the patient has experienced symptoms separate from exercise. An ice cube challenge is useful in diagnosing some cold-induced urticarial syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Mastocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mastocytosis describes a group of disorders of pathologic mast cell accumulation in tissues. These diseases can be limited to the skin (cutaneous mastocytosis) or involve extracutaneous tissues (systemic mastocytosis). Patients with either form are susceptible to anaphylaxis from a variety of triggers, including exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26777/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with systemic mastocytosis often have persistent elevations in serum mature tryptase, whereas patients with anaphylaxis (from various other causes) may demonstrate elevations of serum tryptase during and immediately after an episode of anaphylaxis, but the serum tryptase level returns to normal once the symptoms have fully resolved. Patients with cutaneous mastocytosis have characteristic skin findings, which are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6170?source=see_link\">",
"     \"Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Cardiovascular events",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arrhythmias and other cardiovascular events can cause sudden fatigue, dyspnea, and collapse during exercise, but do not cause pruritus, urticaria, angioedema, or laryngeal edema. Cardiovascular disorders that may be precipitated by exercise are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23192?source=see_link\">",
"     \"Arrhythmia in athletes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13898?source=see_link\">",
"     \"Risk of sudden cardiac death in athletes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Exercise-induced bronchoconstriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise-induced bronchoconstriction presents with symptoms that are limited to the airways and often occurs in patients with known asthma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1513?source=see_link\">",
"     \"Exercise-induced bronchoconstriction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Exercise-associated reflux",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laryngopharyngeal reflux during exercise can mimic mild symptoms of EIAn, including flushing, throat discomfort, and chest",
"    <span class=\"nowrap\">",
"     tightness/cough.",
"    </span>",
"    However, pruritus, urticaria, and angioedema are not observed, and the symptoms do not escalate as they can in EIAn. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/10/33960?source=see_link\">",
"     \"Laryngopharyngeal reflux\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Primary food allergy exacerbated by exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with food allergy may have reactions that are more severe because of concomitant exertion. Thus, it must be determined that a patient with suspected FDEIAn does indeed tolerate the food in the absence of exercise. A formal food challenge should be performed to determine tolerance if the patient cannot report tolerating portion-sized amounts of the food in question in the absence of exercise SINCE the last episode of anaphylaxis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/59/20409?source=see_link\">",
"     \"Oral food challenges for diagnosis and management of food allergies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exercise-induced anaphylaxis (EIAn) is a disorder in which anaphylaxis occurs in response to physical exertion. A subset of patients has a food-dependent form (FDEIAn), in which symptoms occur only if exercise takes place within a few hours of eating, and in most cases, only if a specific food is eaten. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Typical symptoms include extreme fatigue, warmth, flushing, pruritus, and urticaria, progressing to angioedema, wheezing, upper airway obstruction, and collapse. Symptoms usually begin to improve immediately upon cessation of exercise. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some patients experience symptoms only if co-triggers or co-factors are present in association with exercise. These may include specific foods, ingestion of any food, nonsteroidal antiinflammatory drugs, alcoholic beverages, high pollen levels, extremes of heat and humidity, and menstrual status in some women. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'The role of food'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Other co-triggers and co-factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of",
"      <span class=\"nowrap\">",
"       EIAn/FDEIAn",
"      </span>",
"      is usually based upon the clinical history and exclusion of other disorders. Exercise challenge is not required for the diagnosis, but a positive challenge can be useful in confirming the diagnosis. A negative challenge does not reliably exclude the diagnosis. Testing for allergen-specific IgE should be performed if indicated by the clinical history (eg, testing for foods in patients with suspected FDEIAn). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of EIAn includes cholinergic urticaria, systemic mastocytosis, cardiovascular events, exercise-induced asthma, and exercise-associated laryngopharyngeal reflux. The differential diagnosis of FDEIAn includes primary food allergy exacerbated by exercise. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/1\">",
"      Romano A, Di Fonso M, Giuffreda F, et al. Food-dependent exercise-induced anaphylaxis: clinical and laboratory findings in 54 subjects. Int Arch Allergy Immunol 2001; 125:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/2\">",
"      Maulitz RM, Pratt DS, Schocket AL. Exercise-induced anaphylactic reaction to shellfish. J Allergy Clin Immunol 1979; 63:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/3\">",
"      Sheffer AL, Austen KF. Exercise-induced anaphylaxis. J Allergy Clin Immunol 1980; 66:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/4\">",
"      Shadick NA, Liang MH, Partridge AJ, et al. The natural history of exercise-induced anaphylaxis: survey results from a 10-year follow-up study. J Allergy Clin Immunol 1999; 104:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/5\">",
"      Ausdenmoore RW. Fatality in a teenager secondary to exercise-induced anaphylaxis. Pediatr Asthma Allergy Immunol 1991; 5:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/6\">",
"      Noma T, Yoshizawa I, Ogawa N, et al. Fatal buckwheat dependent exercised-induced anaphylaxis. Asian Pac J Allergy Immunol 2001; 19:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/7\">",
"      Drouet M, Sabbah A, Le Sellin J, et al. [Fatal anaphylaxis after eating wild boar meat in a patient with pork-cat syndrome]. Allerg Immunol (Paris) 2001; 33:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/8\">",
"      Flannagan LM, Wolf BC. Sudden death associated with food and exercise. J Forensic Sci 2004; 49:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/9\">",
"      Kidd JM 3rd, Cohen SH, Sosman AJ, Fink JN. Food-dependent exercise-induced anaphylaxis. J Allergy Clin Immunol 1983; 71:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/10\">",
"      Aihara Y, Kotoyori T, Takahashi Y, et al. The necessity for dual food intake to provoke food-dependent exercise-induced anaphylaxis (FEIAn): a case report of FEIAn with simultaneous intake of wheat and umeboshi. J Allergy Clin Immunol 2001; 107:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/11\">",
"      Dohi M, Suko M, Sugiyama H, et al. Food-dependent, exercise-induced anaphylaxis: a study on 11 Japanese cases. J Allergy Clin Immunol 1991; 87:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/12\">",
"      Kano H, Juji F, Shibuya N, et al. [Clinical courses of 18 cases with food-dependent exercise-induced anaphylaxis]. Arerugi 2000; 49:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/13\">",
"      Orhan F, Karakas T. Food-dependent exercise-induced anaphylaxis to lentil and anaphylaxis to chickpea in a 17-year-old boy. J Investig Allergol Clin Immunol 2008; 18:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/14\">",
"      S&aacute;nchez-Borges M, Iraola V, Fern&aacute;ndez-Caldas E, et al. Dust mite ingestion-associated, exercise-induced anaphylaxis. J Allergy Clin Immunol 2007; 120:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/15\">",
"      Bito T, Kanda E, Tanaka M, et al. Cows milk-dependent exercise-induced anaphylaxis under the condition of a premenstrual or ovulatory phase following skin sensitization. Allergol Int 2008; 57:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/16\">",
"      Beaudouin E, Renaudin JM, Morisset M, et al. Food-dependent exercise-induced anaphylaxis--update and current data. Eur Ann Allergy Clin Immunol 2006; 38:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/17\">",
"      Asero R, Mistrello G, Roncarolo D, et al. Exercise-induced egg anaphylaxis. Allergy 1997; 52:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/18\">",
"      Romano A, Scala E, Rumi G, et al. Lipid transfer proteins: the most frequent sensitizer in Italian subjects with food-dependent exercise-induced anaphylaxis. Clin Exp Allergy 2012; 42:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/19\">",
"      Hanakawa Y, Tohyama M, Shirakata Y, et al. Food-dependent exercise-induced anaphylaxis: a case related to the amount of food allergen ingested. Br J Dermatol 1998; 138:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/20\">",
"      Adachi A, Horikawa T, Shimizu H, et al. Soybean beta-conglycinin as the main allergen in a patient with food-dependent exercise-induced anaphylaxis by tofu: food processing alters pepsin resistance. Clin Exp Allergy 2009; 39:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/21\">",
"      Wade JP, Liang MH, Sheffer AL. Exercise-induced anaphylaxis: epidemiologic observations. Prog Clin Biol Res 1989; 297:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/22\">",
"      Harada S, Horikawa T, Ashida M, et al. Aspirin enhances the induction of type I allergic symptoms when combined with food and exercise in patients with food-dependent exercise-induced anaphylaxis. Br J Dermatol 2001; 145:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/23\">",
"      Matsuo H, Morimoto K, Akaki T, et al. Exercise and aspirin increase levels of circulating gliadin peptides in patients with wheat-dependent exercise-induced anaphylaxis. Clin Exp Allergy 2005; 35:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/24\">",
"      Fujii H, Kambe N, Fujisawa A, et al. Food-dependent exercise-induced anaphylaxis induced by low dose aspirin therapy. Allergol Int 2008; 57:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/25\">",
"      Aihara M, Miyazawa M, Osuna H, et al. Food-dependent exercise-induced anaphylaxis: influence of concurrent aspirin administration on skin testing and provocation. Br J Dermatol 2002; 146:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/26\">",
"      Eggleston PA, Kagey-Sobotka A, Proud D, et al. Disassociation of the release of histamine and arachidonic acid metabolites from osmotically activated basophils and human lung mast cells. Am Rev Respir Dis 1990; 141:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/27\">",
"      Wolaczyk-Medrala A, Barg W, Radliska A, et al. Food-dependent exercise-induced anaphylaxis-sequence of causative factors might be reversed. Ann Agric Environ Med 2010; 17:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/28\">",
"      Aihara Y, Takahashi Y, Kotoyori T, et al. Frequency of food-dependent, exercise-induced anaphylaxis in Japanese junior-high-school students. J Allergy Clin Immunol 2001; 108:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/29\">",
"      Du Toit G. Food-dependent exercise-induced anaphylaxis in childhood. Pediatr Allergy Immunol 2007; 18:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/30\">",
"      Barg W, Wolanczyk-Medrala A, Obojski A, et al. Food-dependent exercise-induced anaphylaxis: possible impact of increased basophil histamine releasability in hyperosmolar conditions. J Investig Allergol Clin Immunol 2008; 18:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/31\">",
"      Caminiti L, Passalacqua G, Vita D, et al. Food-exercise-induced anaphylaxis in a boy successfully desensitized to cow milk. Allergy 2007; 62:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/32\">",
"      Pourpak Z, Ghojezadeh L, Mansouri M, et al. Wheat anaphylaxis in children. Immunol Invest 2007; 36:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/33\">",
"      Longley S, Panush RS. Familial exercise-induced anaphylaxis. Ann Allergy 1987; 58:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/34\">",
"      Grant JA, Farnam J, Lord RA, et al. Familial exercise-induced anaphylaxis. Ann Allergy 1985; 54:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/35\">",
"      Sheffer AL, Tong AK, Murphy GF, et al. Exercise-induced anaphylaxis: a serious form of physical allergy associated with mast cell degranulation. J Allergy Clin Immunol 1985; 75:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/36\">",
"      Lewis J, Lieberman P, Treadwell G, Erffmeyer J. Exercise-induced urticaria, angioedema, and anaphylactoid episodes. J Allergy Clin Immunol 1981; 68:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/37\">",
"      Sheffer AL, Soter NA, McFadden ER Jr, Austen KF. Exercise-induced anaphylaxis: a distinct form of physical allergy. J Allergy Clin Immunol 1983; 71:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/38\">",
"      Oyefara BI, Bahna SL. Delayed food-dependent, exercise-induced anaphylaxis. Allergy Asthma Proc 2007; 28:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/39\">",
"      Schwartz HJ. Elevated serum tryptase in exercise-induced anaphylaxis. J Allergy Clin Immunol 1995; 95:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/40\">",
"      Sheffer AL, Austen KF. Exercise-induced anaphylaxis. J Allergy Clin Immunol 1984; 73:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/41\">",
"      Casale TB, Bowman S, Kaliner M. Induction of human cutaneous mast cell degranulation by opiates and endogenous opioid peptides: evidence for opiate and nonopiate receptor participation. J Allergy Clin Immunol 1984; 73:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/42\">",
"      Lin RY, Barnard M. Skin testing with food, codeine, and histamine in exercise-induced anaphylaxis. Ann Allergy 1993; 70:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/43\">",
"      Tharp MD, Thirlby R, Sullivan TJ. Gastrin induces histamine release from human cutaneous mast cells. J Allergy Clin Immunol 1984; 74:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/44\">",
"      Palosuo K, Alenius H, Varjonen E, et al. A novel wheat gliadin as a cause of exercise-induced anaphylaxis. J Allergy Clin Immunol 1999; 103:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/45\">",
"      Daengsuwan T, Palosuo K, Phankingthongkum S, et al. IgE antibodies to omega-5 gliadin in children with wheat-induced anaphylaxis. Allergy 2005; 60:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/46\">",
"      Palosuo K, Varjonen E, Nurkkala J, et al. Transglutaminase-mediated cross-linking of a peptic fraction of omega-5 gliadin enhances IgE reactivity in wheat-dependent, exercise-induced anaphylaxis. J Allergy Clin Immunol 2003; 111:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/47\">",
"      Fukutomi Y, Itagaki Y, Taniguchi M, et al. Rhinoconjunctival sensitization to hydrolyzed wheat protein in facial soap can induce wheat-dependent exercise-induced anaphylaxis. J Allergy Clin Immunol 2011; 127:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/48\">",
"      Yano H, Kato Y, Matsuda T. Acute exercise induces gastrointestinal leakage of allergen in lysozyme-sensitized mice. Eur J Appl Physiol 2002; 87:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/49\">",
"      Oshima T, Miwa H, Joh T. Aspirin induces gastric epithelial barrier dysfunction by activating p38 MAPK via claudin-7. Am J Physiol Cell Physiol 2008; 295:C800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/50\">",
"      Lichtenberger LM, Zhou Y, Dial EJ, Raphael RM. NSAID injury to the gastrointestinal tract: evidence that NSAIDs interact with phospholipids to weaken the hydrophobic surface barrier and induce the formation of unstable pores in membranes. J Pharm Pharmacol 2006; 58:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/51\">",
"      Cooper DM, Radom-Aizik S, Schwindt C, Zaldivar F Jr. Dangerous exercise: lessons learned from dysregulated inflammatory responses to physical activity. J Appl Physiol 2007; 103:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/52\">",
"      Robson-Ansley P, Toit GD. Pathophysiology, diagnosis and management of exercise-induced anaphylaxis. Curr Opin Allergy Clin Immunol 2010; 10:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/53\">",
"      Anderson SD, Daviskas E. The mechanism of exercise-induced asthma is ... J Allergy Clin Immunol 2000; 106:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/54\">",
"      Eggleston PA, Kagey-Sobotka A, Schleimer RP, Lichtenstein LM. Interaction between hyperosmolar and IgE-mediated histamine release from basophils and mast cells. Am Rev Respir Dis 1984; 130:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/55\">",
"      Nielsen BW, Bjerke T, Damsgaard TM, et al. Hyperosmolarity selectively enhances IgE-receptor-mediated histamine release from human basophils. Agents Actions 1992; 35:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/56\">",
"      Stellato C, de Crescenzo G, Patella V, et al. Human basophil/mast cell releasability. XI. Heterogeneity of the effects of contrast media on mediator release. J Allergy Clin Immunol 1996; 97:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/57\">",
"      Fukutomi O, Kondo N, Agata H, et al. Abnormal responses of the autonomic nervous system in food-dependent exercise-induced anaphylaxis. Ann Allergy 1992; 68:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/58\">",
"      Kato Y, Nagai A, Saito M, et al. Food-dependent exercise-induced anaphylaxis with a high level of plasma noradrenaline. J Dermatol 2007; 34:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/59\">",
"      Loibl M, Schwarz S, Ring J, et al. Definition of an exercise intensity threshold in a challenge test to diagnose food-dependent exercise-induced anaphylaxis. Allergy 2009; 64:1560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/60\">",
"      Hofmann SC, Fischer J, Eriksson C, et al. IgE detection to &alpha;/&beta;/&gamma;-gliadin and its clinical relevance in wheat-dependent exercise-induced anaphylaxis. Allergy 2012; 67:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/61\">",
"      Matsuo H, Dahlstr&ouml;m J, Tanaka A, et al. Sensitivity and specificity of recombinant omega-5 gliadin-specific IgE measurement for the diagnosis of wheat-dependent exercise-induced anaphylaxis. Allergy 2008; 63:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/62\">",
"      Park HJ, Kim JH, Kim JE, et al. Diagnostic value of the serum-specific IgE ratio of &omega;-5 gliadin to wheat in adult patients with wheat-induced anaphylaxis. Int Arch Allergy Immunol 2012; 157:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/63\">",
"      Romano A, Di Fonso M, Giuffreda F, et al. Diagnostic work-up for food-dependent, exercise-induced anaphylaxis. Allergy 1995; 50:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/64\">",
"      Kaplan AP, Natbony SF, Tawil AP, et al. Exercise-induced anaphylaxis as a manifestation of cholinergic urticaria. J Allergy Clin Immunol 1981; 68:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/65\">",
"      Casale TB, Keahey TM, Kaliner M. Exercise-induced anaphylactic syndromes. Insights into diagnostic and pathophysiologic features. JAMA 1986; 255:2049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/66\">",
"      Morimoto K, Sanada S, Hara T, Hide M. [Two cases of food-dependent exercise-induced anaphylaxis difficult to evoke symptoms by provocation test]. Arerugi 2006; 55:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/67\">",
"      Ii M, Sayama K, Tohyama M, Hashimoto K. A case of cold-dependent exercise-induced anaphylaxis. Br J Dermatol 2002; 147:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/68\">",
"      Wanderer AA, Hoffman HM. The spectrum of acquired and familial cold-induced urticaria/urticaria-like syndromes. Immunol Allergy Clin North Am 2004; 24:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26777/abstract/69\">",
"      Brockow K, Jofer C, Behrendt H, Ring J. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy 2008; 63:226.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 384 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-C9EBEEE8B0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_9_26777=[""].join("\n");
var outline_f26_9_26777=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Signs and symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Frequency of attacks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Triggering activities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      The role of food",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other co-triggers and co-factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Temporal association between co-triggers, co-factors, and exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      THEORIES OF PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Exercise-induced anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Food-dependent forms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Diagnosis of EIAn",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Diagnosis of food-dependent EIAn",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Clinical history",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Questions about food",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Skin testing or in vitro testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Exercise challenge testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Cholinergic urticaria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Cold-induced urticaria/anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Mastocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Cardiovascular events",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Exercise-induced bronchoconstriction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Exercise-associated reflux",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Primary food allergy exacerbated by exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/384\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/384|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/58/42912\" title=\"picture 1\">",
"      Cholinergic urticaria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9401?source=related_link\">",
"      Anaphylaxis: Confirming the diagnosis and determining the trigger(s)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23192?source=related_link\">",
"      Arrhythmia in athletes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11082?source=related_link\">",
"      Clinical manifestations and diagnosis of oral allergy syndrome (pollen-food allergy syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6170?source=related_link\">",
"      Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/45/42709?source=related_link\">",
"      Exercise-induced anaphylaxis: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1513?source=related_link\">",
"      Exercise-induced bronchoconstriction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/0/38920?source=related_link\">",
"      Food-induced anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/54/40809?source=related_link\">",
"      Laboratory tests to support the clinical diagnosis of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/10/33960?source=related_link\">",
"      Laryngopharyngeal reflux",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/59/20409?source=related_link\">",
"      Oral food challenges for diagnosis and management of food allergies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18778?source=related_link\">",
"      Pathophysiology of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35945?source=related_link\">",
"      Performance of exercise ECG testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24666?source=related_link\">",
"      Physical urticarias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13898?source=related_link\">",
"      Risk of sudden cardiac death in athletes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_9_26778="Management of the short bowel syndrome in children";
var content_f26_9_26778=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of the short bowel syndrome in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/9/26778/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/9/26778/contributors\">",
"     Jon A Vanderhoof, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/9/26778/contributors\">",
"     Rosemary J Pauley-Hunter, NP-C, MS, RN",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/9/26778/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/9/26778/contributors\">",
"     Craig Jensen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/9/26778/contributors\">",
"     Kathleen J Motil, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/9/26778/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/9/26778/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/9/26778/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short bowel syndrome (SBS) is a malabsorptive state that is caused by massive resection of the small intestine, or occasionally by a congenital defect or disease-associated loss of absorption. It is a functional definition, implying a significant amount of malabsorption of both macronutrients and micronutrients and is not necessarily dependent on the loss of bowel or a particular length of bowel. SBS is the most common cause of intestinal failure, a term which refers to the state when an individual&rsquo;s gastrointestinal function is inadequate to maintain his or her nutrient and hydration status without intravenous or enteral supplementation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The type and severity of clinical manifestations of SBS vary. Depending on the patient&rsquo;s age and the quantity and location of affected bowel, patients with SBS may have any combination of the following problems:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Excessive fluid and electrolyte losses",
"     </li>",
"     <li>",
"      Inability to absorb adequate energy and protein",
"     </li>",
"     <li>",
"      Inability to absorb necessary vitamins and minerals",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In many cases, the process of intestinal adaptation ultimately may permit transition to oral feeding. During the past two decades, advances in care of patients with SBS resulted in shorter duration of parenteral nutrition (PN), and significantly higher mean weight-for-age for infants with SBS as compared with previous cohorts [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An overview of the management of pediatric patients with SBS is provided here. The pathogenesis of this disorder and the chronic complications that may occur (eg, liver disease, gallstones, bacterial overgrowth, and hyperoxaluria) are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/56/30601?source=see_link\">",
"     \"Pathophysiology of the short bowel syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/45/29400?source=see_link\">",
"     \"Chronic complications of the short bowel syndrome in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18730?source=see_link\">",
"     \"Parenteral nutrition-associated liver disease in infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1885633\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of short bowel syndrome (SBS) is approximately 0.02 to 0.1 percent among all live births [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/3,4\">",
"     3,4",
"    </a>",
"    ], 0.5 to 2.0 percent among neonatal intensive care unit admissions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/3,4\">",
"     3,4",
"    </a>",
"    ], and 0.7 percent among very low birthweight infants [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/5\">",
"     5",
"    </a>",
"    ]. Approximately 80 percent of SBS in pediatric patients develops during the neonatal period.",
"   </p>",
"   <p>",
"    In the neonatal age group, the most common causes of SBS are necrotizing enterocolitis (NEC) (35 percent), complicated meconium ileus (20 percent), abdominal wall defects (12.5 percent), intestinal atresia (10 percent), and volvulus (10 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/3\">",
"     3",
"    </a>",
"    ]. Later in childhood, the primary causes of SBS are trauma, volvulus, and Crohn's disease. Less common causes include long-segment Hirschsprung disease and intestinal hypomotility syndromes such as Berdon syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/56/30601?source=see_link\">",
"     \"Pathophysiology of the short bowel syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Estimated mortality rates for infants and children with SBS vary substantially, depending on the definitions and causes of SBS in the sampled populations. Most estimates of mortality are between 20 and 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/3,6-8\">",
"     3,6-8",
"    </a>",
"    ], with 60 percent of deaths attributed to hepatic failure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/3\">",
"     3",
"    </a>",
"    ]. In a report from the Pediatric Intestinal Failure Consortium, 27 percent died, 26 percent underwent intestinal transplantation, and 47 percent were eventually weaned from parenteral nutrition (PN) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/9\">",
"     9",
"    </a>",
"    ]. PN is the most important risk factor for liver disease in infants with SBS. Therefore, optimal management of SBS to reduce the need for PN is essential. The pathogenesis and management of parenteral nutrition-associated liver disease in infants is discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18730?source=see_link\">",
"     \"Parenteral nutrition-associated liver disease in infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     LIKELIHOOD OF RESUMING AN ORAL DIET",
"    </span>",
"    &nbsp;&mdash;&nbsp;The likelihood of successful transition to enteral feeding in short bowel syndrome (SBS) depends upon several factors [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The length of remaining small bowel",
"     </li>",
"     <li>",
"      Which segment(s) of small bowel remains, and the presence of the ileocecal valve and colon",
"     </li>",
"     <li>",
"      Intestinal adaptation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The basal metabolic rate of children with SBS may be another factor in successful weaning from parenteral nutrition. We have reported two teenagers with extreme SBS who had achieved maximal intestinal adaptation but also down regulated their resting energy expenditure to the point that their bowel absorptive capacity was able to maintain adequate growth and nutritional status without parenteral nutrition (PN) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/13\">",
"     13",
"    </a>",
"    ]. However, the basal metabolic rate also varies depending on whether the patient is malnourished or experiencing catch-up growth. Energy requirements also vary depending on the proportion of enteral feeds versus parenteral intake, since enteral nutrition is often malabsorbed in a patient with SBS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Length of remaining small intestine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intestinal length measured immediately after resection is a moderately good predictor of whether the child will become independent of the need for parenteral nutrition. However, there is considerable individual variation, in part because it is difficult to accurately estimate the intestinal length at the time of surgery, and because other factors also affect the clinical course. Therefore, intestinal length should not be used as the sole predictor of whether the child will be able to feed enterally.",
"   </p>",
"   <p>",
"    In normal infants, the length of the small intestine is approximately 125 cm at the start of the third trimester of gestation and 250 cm at term [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/14\">",
"     14",
"    </a>",
"    ]. In one series of infants with SBS due to surgical resection during the neonatal period, the likelihood of achieving independence from parenteral nutrition was more than 60 percent for infants with residual intestinal length &gt;38 cm, as compared with 7 percent in those with residual intestinal length &lt;15 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/6\">",
"     6",
"    </a>",
"    ]. Similarly, intestinal length influences the duration of dependence on parenteral nutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/10\">",
"     10",
"    </a>",
"    ]. Nonetheless, some infants with less than 20 cm of small intestine remaining eventually are able to transition from parenteral nutrition to full enteral feedings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Segments of remaining intestine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The segment of remaining intestine is important for determining the metabolic consequences of the SBS. In general, patients with an ileal remnant have better outcomes than those with a jejunal remnant. Although the proximal small intestine is primarily responsible for the absorption of proteins, carbohydrates, and fats (",
"    <a class=\"graphic graphic_figure graphicRef83401 \" href=\"UTD.htm?33/61/34775\">",
"     figure 1",
"    </a>",
"    ), the ileum is able to compensate for absorption of these nutrients after loss of the jejunum. In contrast, resection of the ileum is particularly problematic because the jejunum is unable compensate for the specialized absorptive functions of the ileum. In addition, the ileum has unique effects on gastric emptying and a greater capacity for intestinal adaptation, which are advantageous to the patient with SBS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/56/30601?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathophysiology of the short bowel syndrome\", section on 'Implications of the site of intestinal resection'",
"    </a>",
"    .) &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Loss of the ileocecal valve is associated with reduced likelihood of weaning from PN and greater complications including small bowel bacterial overgrowth and malabsorption. However, it is unclear whether these associations are independently attributable to the loss of the ileocecal valve, or whether they are mediated by the closely related factors of intestinal length and absence of the ileum. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/56/30601?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathophysiology of the short bowel syndrome\", section on 'Loss of the ileocecal valve'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although loss of the colon in adults with SBS clearly reduces the likelihood of weaning from PN, the predictive value of this factor is less clear in children. Studies in infants and children have reached inconsistent conclusions about whether or not the presence of the colon is an important predictor of weaning from PN [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/11,12,15\">",
"     11,12,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/56/30601?source=see_link&amp;anchor=H6#H6\">",
"     \"Pathophysiology of the short bowel syndrome\", section on 'Loss of the colon'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Intestinal adaptation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical course of SBS depends upon the process of intestinal adaptation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/16\">",
"     16",
"    </a>",
"    ]. Adaptation is characterized by lengthening of the intestinal villi, which is associated with an increase in their absorptive capacity, rather than upregulation of specific transporters [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/17\">",
"     17",
"    </a>",
"    ]. In addition, the small bowel typically dilates, which further increases the overall absorptive surface area.",
"   </p>",
"   <p>",
"    Factors that enhance intestinal adaptation include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Enteral feeding",
"     </li>",
"     <li>",
"      Trophic gastrointestinal hormones including GLP-2, a stimulus that is mediated primarily by the presence of fat in the intestinal lumen.",
"     </li>",
"     <li>",
"      Possible direct effects of specific nutrients such as glutamine",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of specific growth factors in animal models of SBS and in small studies on humans is an area of active research [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/18\">",
"     18",
"    </a>",
"    ] (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Pharmacologic therapy'",
"    </a>",
"    below). The mechanisms and potential mediators of intestinal adaptation are discussed in detail in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/56/30601?source=see_link&amp;anchor=H7#H7\">",
"     \"Pathophysiology of the short bowel syndrome\", section on 'Ileal adaptation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     EARLY MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the early period after intestinal resection, the predominant goals are maintenance of good nutritional status through administration of parenteral nutrition (PN) and prevention of fluid and electrolyte abnormalities (",
"    <a class=\"graphic graphic_table graphicRef72657 \" href=\"UTD.htm?9/58/10157\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/19\">",
"     19",
"    </a>",
"    ]. Enteral nutrition is initiated promptly, but in this early phase, the major portion of energy is delivered through PN [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/20-22\">",
"     20-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Large-volume fluid losses from gastric or proximal small bowel secretions are common in the early phase. As a result, fluid replacement protocols with sodium, potassium, chloride, and magnesium are important. Fluid and electrolyte losses through an ostomy or in the feces should be measured and replaced every two hours. This should be done with a solution separate from the parenteral nutrition solution, to allow timely and accurate replacement of the losses.",
"   </p>",
"   <p>",
"    Patients with short bowel syndrome (SBS) may develop hypersecretion of gastric acid and fluids, which may reduce pH below the optimal level needed for fat absorption (by inactivating pancreatic lipase and deconjugating bile salts), alter enteral drug absorption, and increase intestinal fluid losses [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/23\">",
"     23",
"    </a>",
"    ]. This phenomenon was demonstrated in a case report of a patient with SBS whose diarrhea improved after vagotomy and pyloroplasty for peptic bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/56/30601?source=see_link&amp;anchor=H8#H8\">",
"     \"Pathophysiology of the short bowel syndrome\", section on 'Gut hormones'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Initially, a histamine 2 receptor antagonist (H2 blocker) should be given intravenously to suppress gastric hypersecretion, and this may improve nutrient absorption and reduce fluid losses [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/25\">",
"     25",
"    </a>",
"    ]. If the medication appears to be effective in reducing fluid losses or improving absorption, acid suppression should be continued for several months. Studies in adults suggest that an oral proton pump inhibitor also may be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/26,27\">",
"     26,27",
"    </a>",
"    ], but this approach is not as well studied. The gastric hypersecretion typically resolves during the first few months after surgery and weaning of the acid suppressing medications should be attempted a few months after the intestinal resection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/45/29400?source=see_link&amp;anchor=H8#H8\">",
"     \"Chronic complications of the short bowel syndrome in children\", section on 'Esophagitis/Peptic ulcer disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32888166\">",
"    <span class=\"h1\">",
"     GROWTH GOALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The resting energy expenditure in infants with short bowel syndrome (SBS) is similar to those of healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/28\">",
"     28",
"    </a>",
"    ]. However, because of malabsorption, the amount of energy needed enterally generally will be 30 to 70 percent greater than that needed parenterally to achieve similar weight gain [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/29\">",
"     29",
"    </a>",
"    ]. In general, growth is monitored by assessing proportionality (ie, whether increases in weight are proportional to linear growth). However, other factors, such as genetics, should also be factored into expectations for growth. Moreover, proportional growth does not necessarily avoid stunting, which appears to be common among children with SBS. One series examined growth outcomes in 40 children with SBS beginning in infancy. In long-term follow-up (mean age 14 years), affected individuals had slightly shorter stature than was expected from calculated target height, and the bone mineral content was lower than reference values [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/30\">",
"     30",
"    </a>",
"    ]. However, the children had normal body fat percentage and normal weight-for-height ratios.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ENTERAL FEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enteral feeding is a critical goal in management of a patient with short bowel syndrome (SBS). Enteral feeds should be introduced early and advanced carefully but persistently, as rapidly as tolerated by the patient. Enteral feeds enhance the process of intestinal adaptation. Furthermore, maximizing enteral feeds minimizes the risk of the complications of parenteral nutrition (PN), including parenteral nutrition-associated liver disease (PNALD) and catheter-related bloodstream infections. Other aspects of preventing and managing PNALD include modification of PN lipid dose",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    type, and prevention of small intestine bacterial overgrowth, as discussed in separate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18730?source=see_link\">",
"     \"Parenteral nutrition-associated liver disease in infants\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/45/29400?source=see_link\">",
"     \"Chronic complications of the short bowel syndrome in children\"",
"    </a>",
"    .) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Once the infant&rsquo;s condition stabilizes, enteral feeds are slowly introduced. Commercially available electrolyte solutions for enteral use (eg, Pedialyte) may be useful adjuncts, especially in children with feeding tubes and high output fluid losses. &nbsp;",
"   </p>",
"   <p>",
"    Enteral feeding is important for several reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Enteral feeding is essential to promote intestinal adaptation, and appears to be more effective if initiated early [",
"      <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/31\">",
"       31",
"      </a>",
"      ]. This effect occurs even when only small amounts of feeds are given (sometimes termed &ldquo;trophic feeds&rdquo;). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/56/30601?source=see_link&amp;anchor=H27027264#H27027264\">",
"       \"Pathophysiology of the short bowel syndrome\", section on 'Nutrient effects'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      As enteral feeds are increased, parenteral nutrition (PN) can be decreased, and this reduces the risk for PN-associated liver disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18730?source=see_link\">",
"       \"Parenteral nutrition-associated liver disease in infants\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Some oral feeding is important in infants, to avoid feeding aversion. (See",
"      <a class=\"local\" href=\"#H11453706\">",
"       'Oral feeding'",
"      </a>",
"      below.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Composition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Considerations relevant to formula selection for infants and children with SBS are discussed below. An overview of enteral nutrition in infants and children is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/16/11529?source=see_link\">",
"     \"Enteral nutrition in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18643821\">",
"    <span class=\"h3\">",
"     Protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of formulas for enteral feeding is available commercially, and can be selected based on individual patient characteristics. For infants, we suggest initiating feeds with either breast milk or a semi-elemental formula (eg, hydrolysate formulas such as Pregestimil, Alimentum, or Nutramigen), rather than a standard formula based on cow&rsquo;s milk or soy milk. This is because infants with SBS are at increased risk for protein allergy or intolerance as compared with healthy infants [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. The primary benefit of these formulas is their hypoallergenicity rather than any absorptive advantage [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Breast milk also offers the theoretical advantage of supplying epithelial growth factors (particularly in colostrum) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/31,36\">",
"     31,36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=see_link\">",
"     \"Food protein-induced proctitis/colitis and enteropathy of infancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Elemental formulas (which contain free amino acids) are an acceptable alternative if they also contain at least 40 percent of the calories of fat. Infants and some children may be intolerant of high concentrations of free amino acids or carbohydrates and do much better on a protein hydrolysate formula, which generally has a lower osmotic load and higher fat content. However, there is limited data regarding the relative advantages and disadvantages of elemental versus hydrolyzed formulas, and it is appropriate to select formulas on a case-by-case basis, guided by the infant&rsquo;s clinical symptoms and response.",
"   </p>",
"   <p>",
"    Older children and adolescents with SBS generally do not require a protein hydrolysate or elemental formula because protein intolerance is uncommon in this age group. Moreover, complex nutrients are required for stimulating intestinal adaptation, so a diet with intact proteins should be used if possible. Thus, blenderized or other polymeric formula (eg, Compleat&reg;, Boost&reg;, or PediaSure&reg;) are appropriate choices for most children requiring tube feeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18643835\">",
"    <span class=\"h3\">",
"     Fats",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants and young children with SBS generally benefit from a diet that is relatively high in fat, ideally comprising 40 percent or more of the patient's energy intake. Fats have the benefits of a relatively low osmotic load and high energy content, and they also have the unique beneficial effects of reducing motility and promoting intestinal adaptation. Dietary fish oil, which is rich in omega-3 fatty acids, appears to be beneficial in inducing adaptation in the small intestine and colon in an animal model of SBS, thus reducing diarrhea and fecal fat excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/56/30601?source=see_link&amp;anchor=H27027264#H27027264\">",
"     \"Pathophysiology of the short bowel syndrome\", section on 'Nutrient effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Long-chain triglycerides (LCTs) are generally more beneficial than medium-chain triglycerides (MCTs) in the management of SBS. MCTs are sometimes considered because they are more water soluble than LCTs and better absorbed in the presence of bile acid or pancreatic insufficiency. However, because patients with SBS typically have normal pancreatic and biliary function, the rationale for this approach is questionable. Moreover, MCTs have a slightly lower energy density and exert a greater osmotic load in the small intestine as compared with LCTs. In addition, there is some evidence that MCTs are less effective than LCTs in promoting intestinal adaptation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/56/30601?source=see_link&amp;anchor=H27027264#H27027264\">",
"     \"Pathophysiology of the short bowel syndrome\", section on 'Nutrient effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In some cases, extensive resection of the distal ileum causes malabsorption of bile salts. Severe bile salt malabsorption can cause diarrhea due to fat malabsorption (steatorrhea) because there are insufficient bile salts for fat digestion. In addition, the unabsorbed bile acids can travel into the colon and result in bile-acid induced diarrhea. Lesser degrees of bile salt malabsorption can cause a secretory diarrhea, which tends to be watery. (See",
"    <a class=\"local\" href=\"#H11453814\">",
"     'Loss of the distal ileum'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18643842\">",
"    <span class=\"h3\">",
"     Carbohydrates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most infants with SBS, especially those without a colon, do not tolerate high concentrations of carbohydrates. This is because carbohydrates tend to have increased osmotic load as compared to fats and intact proteins. Complex carbohydrates have a lower osmotic load than simple carbohydrates (sugars), and tend to be somewhat better tolerated.",
"   </p>",
"   <p>",
"    On the other hand, adolescent and adult SBS patients with a colon may benefit from a higher carbohydrate diet, with 50 to 60 percent of calories in the form of complex carbohydrates [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/38\">",
"     38",
"    </a>",
"    ]. These patients can tolerate a higher osmotic load and gain additional benefit from colonic absorption of energy from fermented carbohydrates. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/56/30601?source=see_link&amp;anchor=H6#H6\">",
"     \"Pathophysiology of the short bowel syndrome\", section on 'Loss of the colon'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lactose restriction is not usually required for children with SBS. Most patients tolerate lactose since it is absorbed in the proximal small bowel. Furthermore, dairy products are good sources of fat, energy, and calcium. Thus, restriction of lactose containing foods should be limited to cases in which intolerance is documented through hydrogen breath testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H841098\">",
"    <span class=\"h3\">",
"     Fiber",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fiber supplementation (eg, formulas designed with added fiber, or a high-fiber diet by mouth) may enhance intestinal adaptation by promoting short-chain fatty acid production and providing an additional energy source in patients with retained colon. In addition, fiber may decrease the watery nature of the stools by absorbing stool water, which can be helpful if frequent stooling causes perineal skin breakdown. On the other hand, fiber also may exacerbate small bowel bacterial overgrowth, which is common can be problematic in some patients with SBS. Because the adverse effects of fiber are most common in infants and small children, it should probably be avoided in this age group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17780577\">",
"    <span class=\"h3\">",
"     Oxalate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because calcium has a strong affinity for fatty acids, malabsorption of fat often leads to excess oxalate absorption and subsequent development of hyperoxaluria and kidney stones. To avoid this complication, these patients should restrict their intake of oxalate. Foods high in oxalate include rhubarb, spinach, beets, potatoes and cocoa [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/45/29400?source=see_link&amp;anchor=H14#H14\">",
"     \"Chronic complications of the short bowel syndrome in children\", section on 'Hyperoxaluria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Frequency of feeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous enteral feeding via a nasogastric or gastrostomy feeding tube initially is advantageous for patients of all ages. This approach maximizes feeding tolerance in the setting of limited gut functional capacity [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/40\">",
"     40",
"    </a>",
"    ]. This also permits constant saturation of carrier transport proteins, taking full advantage of the absorptive surface area available and enhancing adaptation, which is greatest in the first few months after resection. For the same reason, after patients transition to bolus feeds or oral feeds, small frequent feedings are preferable to infrequent large feedings.",
"   </p>",
"   <p>",
"    Regardless of the length of small intestine, some oral feeding, if only a few mL per day, should be given to help prevent feeding aversion. (See",
"    <a class=\"local\" href=\"#H11453706\">",
"     'Oral feeding'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Tapering of parenteral nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enteral feedings should be advanced slowly, and parenteral calories concomitantly decreased to maintain nutritional status and compensate for fluid losses, while awaiting gut adaptation. Because of malabsorption, the amount of energy needed enterally generally will be greater than that needed parenterally to achieve similar weight gain. The most successful approach is to make frequent small increases in enteral feeds as tolerated, rather than sudden large advances in feed volume.",
"   </p>",
"   <p>",
"    One approach is to initiate enteral feedings by providing approximately 5 percent of the patient's total daily energy intake and making slow incremental advances every three to five days as tolerated beyond this point. The rate at which feeds can be advanced depends upon the amount of remaining intestine, the patient's size and age, and the patient's total absorptive capacity. Advancement as slow as 1",
"    <span class=\"nowrap\">",
"     mL/hr",
"    </span>",
"    per week may be required in some cases. &nbsp;",
"   </p>",
"   <p>",
"    Tolerance of enteral feeding can be assessed by measuring of enteral fluid loss, which reflects the degree of carbohydrate malabsorption. Fat malabsorption does not result in osmotic diarrhea, and the protein content in formulas for enteral feeding usually is insufficient to produce a significant osmotic load. If enteral losses suddenly increase during advancement of enteral feedings, intestinal absorption probably has reached its maximum and feedings should not be increased until further adaptation occurs. Carbohydrate malabsorption can be estimated directly by testing the stool or ostomy fluid for reducing substances (eg, with a Clinitest tablet) or indirectly from stool pH. Direct measurement of stool carbohydrate usually is unnecessary because marked increases in fluid losses almost always indicate significant carbohydrate malabsorption.",
"   </p>",
"   <p>",
"    Carbohydrate intolerance is the most likely cause of diarrhea in these patients, especially in the early phase, and this is best managed by the dietary measures discussed above (slow advancement and relatively high fat content of feeds). There also may be a component of gastric hypersecretion, which can be treated with acid suppressing medication (see",
"    <a class=\"local\" href=\"#H1887329\">",
"     'Antisecretory agents'",
"    </a>",
"    below). Other causes of chronic diarrhea and approaches to management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/45/29400?source=see_link&amp;anchor=H2#H2\">",
"     \"Chronic complications of the short bowel syndrome in children\", section on 'Watery diarrhea'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Indications for continued parenteral nutrition (PN) include poor weight gain or loss of maintenance weight and stomal fluid and electrolyte losses that are too extensive to be replaced orally. In some patients, feeding tolerance may continue to improve gradually for several years as intestinal adaptation progresses, ultimately allowing conversion to enteral intake [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/41\">",
"     41",
"    </a>",
"    ]. Some patients with borderline enteral function are able to maintain health with the overnight infusion of PN two or three times a week. Many children may require significant increases in parenteral nutrition during puberty to support this phase of rapid growth. The amount of supplemental PN provided must be individualized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11453706\">",
"    <span class=\"h2\">",
"     Oral feeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prompt and persistent administration of feeds through the oral route is important to help prevent the development of feeding aversion. Feeding aversion is common if oral feeds are not provided at the developmentally appropriate times, and can become a chronic problem. Thus, infants should be fed breast milk or formula by mouth, and transitioned to solids at an age-appropriate time; even if only small amounts of feeds can be given by this route because of the short bowel.",
"   </p>",
"   <p>",
"    Recommendations for most infants, based on expert opinion and experience, are as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Small oral feeds of breast milk (or formula, when necessary) are introduced during the neonatal period, or as soon as enteral feeds are tolerated. An initial approach would be 5 to 10 mL three to four times a day, concurrent with drip feedings. If the infant becomes intolerant of the oral feeds as volumes are advanced, it may be helpful to withhold continuous enteral feeds for one hour, and offer the same volume of feed that would be administered during that hour by mouth [",
"      <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/42\">",
"       42",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      Solid foods are introduced at an appropriate age (eg, between four and six months corrected gestational age), provided that there is no evidence of aspiration [",
"      <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/42\">",
"       42",
"      </a>",
"      ]. At our center, we generally begin with one tablespoon of pureed meats or vegetables once or twice a day. We avoid fruits and cereals because these have a higher osmotic load. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As enteral nutrition is gradually increased, the duration of infusion of PN can be reduced, giving patients greater freedom. Subsequently the child can transition gradually from tube feeding to oral feedings and a regular diet. Patients tend to tolerate complex carbohydrates much better than simple ones; fatty foods usually are not a problem. Patients with SBS often consume more food than would be expected for a child their age and incorrect choices may exacerbate malabsorption and increase PN requirements [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The important elements of chronic enteral nutrition are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Small frequent feedings (every two to three hours)",
"     </li>",
"     <li>",
"      A reasonable mixture of protein, carbohydrates, and fats; ideally, a minimum of 40 percent of the patient's energy intake should be provided in the form of fat",
"     </li>",
"     <li>",
"      Avoidance of hypertonic beverages (eg, sodas and fruit juices)",
"     </li>",
"     <li>",
"      Avoidance of high carbohydrate foods, especially those with simple carbohydrates, which often result in sudden osmotic fluid losses and dehydration. All forms of carbohydrate increase bacterial proliferation",
"     </li>",
"     <li>",
"      Monitoring and replacement therapy for micronutrient deficiencies. (See",
"      <a class=\"local\" href=\"#H11453713\">",
"       'Malabsorption of fat and vitamins'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once on an oral diet, children may have fat malabsorption, which usually is not problematic because the energy density of fat is twice that of protein; thus, dietary fat provides significant energy even if some is malabsorbed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11453713\">",
"    <span class=\"h2\">",
"     Malabsorption of fat and vitamins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with SBS are at risk for nutritional deficiencies, particularly while PN is being tapered and after it is discontinued. The type of nutritional deficiency depends on the extent and location of the intestinal resection. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H841297\">",
"    <span class=\"h3\">",
"     Extensive small bowel resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with extensive small bowel resection are at risk for nutrient, mineral, and vitamin deficiencies because of the loss of absorptive surface, and the deficiency risk depends on which part of the bowel was resected (",
"    <a class=\"graphic graphic_figure graphicRef83401 \" href=\"UTD.htm?33/61/34775\">",
"     figure 1",
"    </a>",
"    ). Micronutrient deficiencies may occur even if the total energy absorption and somatic growth are adequate [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Intestinal malabsorption of bile acids and cholesterol results in decreased serum cholesterol levels despite upregulation of cholesterol synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/47\">",
"     47",
"    </a>",
"    ]. The risk of nutrient deficiency is greatest after discontinuation of PN because the degree of intestinal adaptation and the absorption of nutrients are unpredictable. Regular use of a multivitamin supplement and the presence of an intact ileocecal valve have been found to be protective against the development of vitamin deficiencies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11453814\">",
"    <span class=\"h3\">",
"     Loss of the distal ileum",
"    </span>",
"    &nbsp;&mdash;&nbsp;The response to enteral feedings is in large part a function of the amount of functioning bowel. Patients with limited ileal resection (&lt;100 cm) can resume intake of most solid foods more quickly. However, resection of the terminal ileum puts these patients at risk for malabsorption of vitamin B12, bile salts, fat, and fat-soluble vitamins. Each of these problems requires specific therapy.",
"   </p>",
"   <p>",
"    Resection of the distal ileum interferes with reabsorption of bile salts. This can cause diarrhea via one of two mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A secretory diarrhea (choleretic enteropathy), due to direct effects of the malabsorbed bile salts in the colon. The diarrhea tends to be watery. In adults, this type of diarrhea is more likely if less than 100 cm of bowel including the distal ileum has been resected. It generally responds to",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/27/1462?source=see_link\">",
"       cholestyramine",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      A diarrhea caused by fat malabsorption (steatorrhea), due to insufficient bile salts for fat digestion. This diarrhea tends to be greasy. In adults, this type of diarrhea is more likely if more than 100 cm of bowel including the distal ileum has been resected. This type may worsen with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/27/1462?source=see_link\">",
"       cholestyramine",
"      </a>",
"      treatment, and tends to improve with ursodeoxycholic acid, which replenishes the bile acid supply if the patient has a portion of the terminal ileum remaining. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These two types of diarrhea may coexist in an individual patient. In infants and children, measurements of bowel length are less useful in predicting which of these mechanisms contributes to diarrhea, and these types of diarrhea may be difficult to distinguish clinically. A judicious trial of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/27/1462?source=see_link\">",
"     cholestyramine",
"    </a>",
"    can help to distinguish between the two types of diarrhea (see",
"    <a class=\"local\" href=\"#H1887329\">",
"     'Antisecretory agents'",
"    </a>",
"    below). The evaluation and management of watery diarrhea in children with SBS is discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/45/29400?source=see_link&amp;anchor=H2#H2\">",
"     \"Chronic complications of the short bowel syndrome in children\", section on 'Watery diarrhea'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19815126\">",
"    <span class=\"h2\">",
"     Laboratory monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following suggestions reflect common practice in centers with experience in managing short bowel syndrome in children, based on expert opinion and clinical experience [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/43\">",
"     43",
"    </a>",
"    ]. Additional detail on nutrient deficiencies is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/45/29400?source=see_link&amp;anchor=H12#H12\">",
"     \"Chronic complications of the short bowel syndrome in children\", section on 'Nutrient deficiencies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients on PN should be monitored with a PN profile (electrolytes, BUN, creatinine, phosphorus, magnesium, albumin, triglycerides, bile acid, and glucose) when PN is initiated, weekly until stable, and with subsequent change in PN formulation or volume. Total and direct bilirubin and aminotransferases (AST and ALT) also should be measured regularly to monitor for PNALD.",
"     </li>",
"     <li>",
"      Urine electrolytes may be measured in infants with high ostomy or stool output. One group recommends supplementing enteral feeds with sodium to maintain a urinary sodium above 20",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/43\">",
"       43",
"      </a>",
"      ] to detect reduced levels of total body electrolytes.",
"     </li>",
"     <li>",
"      Serum levels of calcium, magnesium, zinc,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"       selenium",
"      </a>",
"      , the fat-soluble vitamins (A, D, E, and K), and iron studies (iron, total iron binding capacity [TIBC] and ferritin) should be monitored every three to six months, with particular care after discontinuation of PN. Vitamin D is measured as 25-hydroxyvitamin D.",
"     </li>",
"     <li>",
"      Vitamin B12 should be monitored in patients who have had the distal ileum resected and are on partial or full enteral feeds. This is because these patients may become deficient in vitamin B12 despite adequate energy and protein absorption, and vitamin B12 supplementation may be required.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1887329\">",
"    <span class=\"h2\">",
"     Antisecretory agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous pharmacologic agents have been used to reduce stomal and fecal secretory losses in patients with short bowel syndrome (SBS):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Histamine 2 receptor antagonist (H2 blockers) and proton pump inhibitors (PPIs) inhibit excessive gastric or pancreatic secretion. These are typically useful during the early phase of SBS after intestinal resection, when gastric hypersecretion is most common. H2 blockers or PPIs may be indicated for six months or longer after the initial resection. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Early management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/27/1462?source=see_link\">",
"       Cholestyramine",
"      </a>",
"      often improves diarrhea associated with bile salt malabsorption; a trial of this agent is appropriate in patients with extensive resection of the terminal ileum. However, cholestyramine must be used judiciously since some patients may have bile acid deficiency; in these patients, cholestyramine may bind the few remaining bile salts that are necessary for fat absorption. If the diarrhea does not respond to cholestyramine treatment, bile salt malabsorption probably is not the principal cause of diarrhea. (See",
"      <a class=\"local\" href=\"#H11453814\">",
"       'Loss of the distal ileum'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/45/29400?source=see_link&amp;anchor=H2#H2\">",
"       \"Chronic complications of the short bowel syndrome in children\", section on 'Watery diarrhea'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17779220\">",
"    <span class=\"h2\">",
"     Antimotility agents",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/31/8692?source=see_link\">",
"       Loperamide",
"      </a>",
"      or other anti-motility agents can be useful in managing chronic diarrhea in older infants and children. However, it can also predispose to bacterial overgrowth, which can exacerbate malabsorption. Therefore, we suggest that these agents be used judiciously, and avoided in patients with clinical symptoms of bacterial overgrowth and in younger infants. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/45/29400?source=see_link&amp;anchor=H10#H10\">",
"       \"Chronic complications of the short bowel syndrome in children\", section on 'Bacterial overgrowth'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/6/37991?source=see_link\">",
"       Octreotide",
"      </a>",
"      increases small bowel transit time, but becomes less effective over time as tachyphylaxis develops. In addition, octreotide interferes with the process of adaptation, and predisposes patients to the development of gallstones for which they are already at high risk [",
"      <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/49,50\">",
"       49,50",
"      </a>",
"      ]. Thus, it should be used with caution and only in late stages of therapy (ie, two or more years after onset of SBS, when intestinal adaption has been achieved). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/56/30601?source=see_link&amp;anchor=H8#H8\">",
"       \"Pathophysiology of the short bowel syndrome\", section on 'Gut hormones'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1887170\">",
"    <span class=\"h2\">",
"     Growth factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth factors have been used in an attempt to hasten intestinal adaptation and to enhance mucosal growth beyond the normal limits of adaptation. Some reports have suggested that the combination of glutamine, growth hormone, and a diet high in complex carbohydrates and fiber enhance the adaptation process and facilitate the transition to enteral nutrition in adult patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/51-55\">",
"     51-55",
"    </a>",
"    ]. However, other trials are inconclusive, and most suggest that the effect does not continue beyond the end of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. Accordingly, European guidelines state that there is insufficient data to recommend the routine use of these agents in patients with SBS [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/6/44136?source=see_link&amp;anchor=H18#H18\">",
"     \"Management of the short bowel syndrome in adults\", section on 'Growth factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Glutamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glutamine is a \"conditionally essential\" amino acid that is an important source of energy for rapidly dividing cells, such as enterocytes. In animal models of enterocolitis or intestinal resection, supplemental glutamine promotes recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/59\">",
"     59",
"    </a>",
"    ]. As an example, a study using a rat model of SBS demonstrated that both enteral glutamine and oral antibiotics improved gut barrier function and decreased bacterial translocation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In spite of the sound rationale, clinical studies have not demonstrated clinical benefit from providing supplemental glutamine to promote intestinal adaptation in children with SBS. In a randomized trial, enteral glutamine supplementation did not reduce the time taken to establish full enteral feeds, improve growth, or reduce nosocomial infection rates [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/61\">",
"     61",
"    </a>",
"    ]. In separate randomized trials, parenteral glutamine supplementation did not alter intestinal permeability, the occurrence of sepsis, or clinical outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. A meta-analysis including both of these studies concluded that there was insufficient data to determine if glutamine supplementation alone affects clinical outcomes in infants with severe gastrointestinal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Growth hormone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case reports of growth hormone therapy in children with SBS suggest that there may be some benefit in those with low or limited growth hormone responsiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/53,65\">",
"     53,65",
"    </a>",
"    ]. However, the beneficial effect of this regimen is controversial due to wide variance in patient populations and lack of adequate placebo control groups [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/66\">",
"     66",
"    </a>",
"    ]. In general, growth hormone is not used in routine management of pediatric SBS.",
"   </p>",
"   <p>",
"    Clinical experience with growth hormone in patients with SBS is illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In randomized controlled crossover studies in humans given glutamine and growth hormone with various dietary maneuvers, there was modest improvement in electrolyte absorption, but no effect on small bowel morphology, stool losses, or macronutrient absorption [",
"      <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/56,67\">",
"       56,67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A systematic review of studies in adults concluded that growth hormone has a transient effect in promoting weight gain and energy absorption [",
"      <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A small observational study suggested that growth hormone may improve enteral absorption and reduce the need for parenteral nutrition (PN), but this effect was not sustained after cessation of therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/69\">",
"       69",
"      </a>",
"      ]. In the absence of a control group, it is possible that some other aspect of SBS care was responsible for the improvement observed during the study.",
"     </li>",
"     <li>",
"      A randomized open label clinical trial of growth hormone in pediatric patients with SBS failed to demonstrate any improvement in weaning from parenteral nutrition (PN) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another series demonstrated that multiple treatment approaches (growth hormone combined with glutamine and enteral nutrition at an early stage) significantly improved intestinal adaptation, and the positive effect appeared to be sustained even after growth hormone was discontinued [",
"      <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Glucagon-like peptide-2 (GLP-2)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous animal studies have demonstrated that glucagon-like peptide 2 (GLP-2), an enteroendocrine peptide released in response to luminal nutrients, initiates and maintains the small bowel adaptive response to resection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/71\">",
"     71",
"    </a>",
"    ]. In a randomized trial in adults, administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/33/10772?source=see_link\">",
"     teduglutide",
"    </a>",
"    , a GLP-2 analog, was associated with a modest improvement in intestinal absorption and nitrogen balance, but not in parenteral fluid requirement [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/72\">",
"     72",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/6/44136?source=see_link&amp;anchor=H18#H18\">",
"     \"Management of the short bowel syndrome in adults\", section on 'Growth factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10774151\">",
"    <span class=\"h3\">",
"     Other growth factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other growth factors have been evaluated in experimental models of massive small bowel resection. Hepatocyte growth factor significantly enhances intestinal epithelial cell function and mucosal mass beyond the normal adaptive response [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/73\">",
"     73",
"    </a>",
"    ]. Interleukin-11, epidermal growth factor, and basic fibroblast growth factor also have trophic effects [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/74-77\">",
"     74-77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H841534\">",
"    <span class=\"h1\">",
"     BOWEL TAILORING AND LENGTHENING PROCEDURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intestinal rehabilitation programs have improved the care of children with SBS. These are multidisciplinary teams that use medical protocols to maximize enteral feeding, often in conjunction with surgical procedures designed to improve bowel function by tapering",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lengthening and relieving obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/78-81\">",
"     78-81",
"    </a>",
"    ]. The relative contributions of the medical as compared to the surgical interventions in these programs have not been well established, nor have the indications for surgical intervention been standardized.",
"   </p>",
"   <p>",
"    In patients with dilated bowel, who are not making significant progress towards weaning from PN, two procedures are used to increase bowel length and absorptive area:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Bianchi procedure (",
"      <a class=\"graphic graphic_figure graphicRef74007 \" href=\"UTD.htm?21/3/21557\">",
"       figure 2",
"      </a>",
"      ) was the first surgical approach to lengthen the intestine [",
"      <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/82\">",
"       82",
"      </a>",
"      ]. This procedure was generally successful in improving absorption and nutritional status in most patients, but had a high rate of complications including ischemia, leaks, and recurrent dilatation. Only one Bianchi procedure can performed on a patient.",
"     </li>",
"     <li>",
"      The serial transverse enteroplasty (STEP) procedure (",
"      <a class=\"graphic graphic_figure graphicRef69242 \" href=\"UTD.htm?3/18/3363\">",
"       figure 3",
"      </a>",
"      ) was subsequently developed, and is now used preferentially in many centers because the technique is somewhat simpler and more flexible. The STEP procedure increases intestinal length, improves intestinal absorptive capacity, and may decrease the risk of D-lactic acidosis due to bacterial overgrowth [",
"      <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/83-86\">",
"       83-86",
"      </a>",
"      ]. It can be performed alone or after a prior Bianchi procedure. In one report, infants with refractory SBS who were treated with the STEP procedure had decreased dependence on parenteral feeds one year after surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/87\">",
"       87",
"      </a>",
"      ]. A STEP data registry was created to allow analysis of outcomes from a larger number of patients. The first report describes outcomes for 38 patients undergoing the STEP procedure in 19 centers, with a median follow-up of 12.6 months [",
"      <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/88\">",
"       88",
"      </a>",
"      ]. Among 29 subjects with SBS, enteral tolerance increased from 31 to 67 percent of calories. In a case series of 16 patients undergoing the STEP procedure and followed for a mean of two years, nutritional status improved, and 38 percent transitioned off of PN [",
"      <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/89\">",
"       89",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The STEP procedure can be repeated to further increase intestinal length [",
"      <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/90\">",
"       90",
"      </a>",
"      ]. Patients whose bowel re-dilates after a lengthening procedure have been found to have worse overall outcomes than those who do not [",
"      <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/91\">",
"       91",
"      </a>",
"      ]. This can be treated by serial tapering enteroplasties.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other non-transplant surgical procedures are designed to slow intestinal transit in patients with SBS [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/92\">",
"     92",
"    </a>",
"    ]. These procedures have been used successfully in some adult patients, but are contraindicated in small children and patients with small bowel bacterial overgrowth [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15788461\">",
"    <span class=\"h1\">",
"     INTESTINAL REHABILITATION PROGRAMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous reports have supported the value of managing short bowel syndrome (SBS) with a multidisciplinary team of experts in a center specializing in SBS, often termed &ldquo;intestinal rehabilitation&rdquo; programs. These centers focus on optimizing enteral feeding and weaning from parenteral nutrition (PN), with judicious use of pharmacotherapy and surgical interventions. This approach is associated with improved survival and achievement of independence from PN [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/80,81,94\">",
"     80,81,94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SMALL BOWEL TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although intestinal rehabilitation programs and non-transplant surgical procedures have improved the outcomes of children with SBS as described above, certain patients will require transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated intestinal transplantation is indicated for patients with SBS and intractable symptoms necessitating recurrent hospitalization, or those with recurrent catheter sepsis who no longer have adequate central venous access to support long-term parenteral nutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/95\">",
"     95",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/29/1497?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of intestinal and multivisceral transplantation\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Combined",
"    <span class=\"nowrap\">",
"     liver/small",
"    </span>",
"    intestine transplantation is indicated for a patient with SBS and irreversible parenteral nutrition-associated liver disease if the patient is considered likely to die in the subsequent two years without transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/95\">",
"     95",
"    </a>",
"    ]. Many patients are not considered for intestine transplant until irreversible liver disease associated with parenteral nutrition has occurred [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/96\">",
"     96",
"    </a>",
"    ]. In some cases, this is unavoidable because it can be difficult to predict the course of the liver and bowel disease. To anticipate a possible need for combined",
"    <span class=\"nowrap\">",
"     liver/small",
"    </span>",
"    intestine transplantation, we suggest that a child with an elevated direct bilirubin concentration and evidence of impaired liver synthetic function (eg, abnormal international normalized ratio [INR] that does not respond to vitamin K administration) be referred for evaluation for possible transplant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/29/1497?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of intestinal and multivisceral transplantation\", section on 'Liver-intestinal transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Progressive improvements in intestinal transplant outcomes may prompt earlier transplant procedures in the future and avoid the need for combined organ transplant. Meanwhile, improvements in prevention and management of parenteral nutrition-associated liver disease may also avoid this predicament. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/45/29400?source=see_link&amp;anchor=H5#H5\">",
"     \"Chronic complications of the short bowel syndrome in children\", section on 'Liver disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18730?source=see_link\">",
"     \"Parenteral nutrition-associated liver disease in infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H859556\">",
"    <span class=\"h2\">",
"     Donors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lack of suitable donors is an important problem in small bowel transplantation. Patients with SBS have a loss of peritoneal domain that requires donors who are significantly smaller in size. Educational efforts are needed to identify and convert potential donors to actual organ donors. Patients on the waiting list for combined",
"    <span class=\"nowrap\">",
"     liver/small",
"    </span>",
"    bowel transplantation have more difficulty because they compete with those awaiting isolated liver transplantation.",
"   </p>",
"   <p>",
"    Living-related isolated intestinal transplantation has been successfully performed [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/97\">",
"     97",
"    </a>",
"    ]. Concerns about donor safety have been raised, including risks of malabsorption and obstruction. Some authors have suggested preoperative imaging of donor vasculature and other steps to improve donor safety, but clinical experience with this technique remains limited [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/98,99\">",
"     98,99",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/29/1497?source=see_link&amp;anchor=H15#H15\">",
"     \"Overview of intestinal and multivisceral transplantation\", section on 'Living related transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survival rates for intestinal transplantation are approaching the level of other abdominal solid organ transplantation procedures. Experienced centers demonstrate one-year patient survival rates of 91 to 93 percent, and five-year patient survival rates of 75 to 78 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/100-102\">",
"     100-102",
"    </a>",
"    ]. Graft loss due to chronic rejection or renal dysfunction is diminishing with increasing experience [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/101,102\">",
"     101,102",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/29/1497?source=see_link&amp;anchor=H33#H33\">",
"     \"Overview of intestinal and multivisceral transplantation\", section on 'Graft and patient survival'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one series, one year after successful small bowel transplantation, the quality of life reported by 29 children 5 to 18 years of age was similar to published norms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/103\">",
"     103",
"    </a>",
"    ]. However, parents of the transplant recipients perceived decreased general health and physical functioning in their children compared to published norms. In another study, pre-transplantation growth-velocity was maintained after transplantation, but catch-up growth did not occur [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/104,105\">",
"     104,105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The greatest complications after small bowel transplantation are rejection of the graft and sepsis. Sepsis is the leading cause of death, and can be triggered by rejection (leading to intestinal permeability and bacterial translocation), or by the immunosuppression itself. Therefore, optimizing immunosuppression to avoid both of these complications can be challenging [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/106\">",
"     106",
"    </a>",
"    ]. Other complications after small bowel transplantation include cytomegalovirus infection and lymphoproliferative disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/107,108\">",
"     107,108",
"    </a>",
"    ]. The diagnosis of rejection can be difficult, and surveillance ileoscopies and endoscopies with biopsy are essential [",
"    <a class=\"abstract\" href=\"UTD.htm?26/9/26778/abstract/109\">",
"     109",
"    </a>",
"    ]. The typical histologic picture of rejection is cryptitis with apoptosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/29/1497?source=see_link&amp;anchor=H19#H19\">",
"     \"Overview of intestinal and multivisceral transplantation\", section on 'Postoperative complications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/29/1497?source=see_link&amp;anchor=H24#H24\">",
"     \"Overview of intestinal and multivisceral transplantation\", section on 'Acute rejection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Management of short bowel syndrome (SBS) requires a stepwise approach to maintain good nutrition and minimize complications due to malabsorption and parenteral nutrition-associated liver disease. The main considerations are summarized in the table (",
"      <a class=\"graphic graphic_table graphicRef72657 \" href=\"UTD.htm?9/58/10157\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The primary factors that influence the likelihood that a patient with SBS will ultimately be able to resume an oral diet are the length of remaining small bowel, which segments of the bowel remain, and the process of intestinal adaptation. Intestinal adaptation occurs gradually, and depends in large part on exposure of the intestine to enteral feeds. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Likelihood of resuming an oral diet'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early management of SBS primarily involves close monitoring of stool output, and replacement of these fluid and electrolyte losses. Parenteral nutrition (PN) is used for nutritional support. Enteral feeding should begin promptly once the patient stabilizes. For patients with excessive enteral fluid losses during the first few months after small bowel resection, we suggest a trial of acid suppressing medications (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Early management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Continuous enteral feeding or small frequent feedings are preferred initially. The absorptive state and feeding tolerance are reassessed frequently as adaptation progresses, mostly based on changes in stool output, and the composition and rate of enteral feeds is adjusted accordingly. The overall goal is to maximize the proportion of nutrition given via the enteral route, as tolerated. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Enteral feeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For enteral feedings of infants and children, hypoallergenic protein hydrolysate formulas or breast milk are usually best tolerated. Use of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/55/14195?source=see_link\">",
"       medium chain triglycerides",
"      </a>",
"      or amino-acid based formulas may be counterproductive because of increased osmolarity. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Composition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several pharmacological approaches have been tested in an effort to enhance intestinal adaptation and improve feeding tolerance. None of these approaches are proven to be consistently beneficial, but studies are ongoing. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Pharmacologic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with dilated bowel, who are not making significant progress towards weaning from PN, an intestinal tailoring",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lengthening procedure may be helpful. The two operations used for this purpose are the Bianchi procedure (",
"      <a class=\"graphic graphic_figure graphicRef74007 \" href=\"UTD.htm?21/3/21557\">",
"       figure 2",
"      </a>",
"      ) and the serial transverse enteroplasty (STEP) procedure (",
"      <a class=\"graphic graphic_figure graphicRef69242 \" href=\"UTD.htm?3/18/3363\">",
"       figure 3",
"      </a>",
"      ). These procedures have been used successfully in specialized centers, in the context of a multidisciplinary approach to intestinal rehabilitation. (See",
"      <a class=\"local\" href=\"#H841534\">",
"       'Bowel tailoring and lengthening procedures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A transplantation procedure is appropriate for some individuals with SBS. Isolated intestinal transplantation is indicated for those with intractable symptoms necessitating recurrent hospitalization, or those with recurrent catheter sepsis who no longer have adequate central venous access to support long-term parenteral nutrition. Combined",
"      <span class=\"nowrap\">",
"       liver/small",
"      </span>",
"      intestine transplantation is indicated for patients with SBS and irreversible parenteral nutrition-associated liver disease if they are considered likely to die in the subsequent two years without transplantation. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Small bowel transplantation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/1\">",
"      O'Keefe SJ, Buchman AL, Fishbein TM, et al. Short bowel syndrome and intestinal failure: consensus definitions and overview. Clin Gastroenterol Hepatol 2006; 4:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/2\">",
"      Olieman JF, Tibboel D, Penning C. Growth and nutritional aspects of infantile short bowel syndrome for the past 2 decades. J Pediatr Surg 2008; 43:2061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/3\">",
"      Wales PW, de Silva N, Kim J, et al. Neonatal short bowel syndrome: population-based estimates of incidence and mortality rates. J Pediatr Surg 2004; 39:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/4\">",
"      Salvia G, Guarino A, Terrin G, et al. Neonatal onset intestinal failure: an Italian Multicenter Study. J Pediatr 2008; 153:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/5\">",
"      Cole CR, Hansen NI, Higgins RD, et al. Very low birth weight preterm infants with surgical short bowel syndrome: incidence, morbidity and mortality, and growth outcomes at 18 to 22 months. Pediatrics 2008; 122:e573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/6\">",
"      Quir&oacute;s-Tejeira RE, Ament ME, Reyen L, et al. Long-term parenteral nutritional support and intestinal adaptation in children with short bowel syndrome: a 25-year experience. J Pediatr 2004; 145:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/7\">",
"      Wales PW, de Silva N, Kim JH, et al. Neonatal short bowel syndrome: a cohort study. J Pediatr Surg 2005; 40:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/8\">",
"      Grosfeld JL, Rescorla FJ, West KW. Short bowel syndrome in infancy and childhood. Analysis of survival in 60 patients. Am J Surg 1986; 151:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/9\">",
"      Squires RH, Duggan C, Teitelbaum DH, et al. Natural history of pediatric intestinal failure: initial report from the Pediatric Intestinal Failure Consortium. J Pediatr 2012; 161:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/10\">",
"      Sondheimer JM, Cadnapaphornchai M, Sontag M, Zerbe GO. Predicting the duration of dependence on parenteral nutrition after neonatal intestinal resection. J Pediatr 1998; 132:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/11\">",
"      Kaufman SS, Loseke CA, Lupo JV, et al. Influence of bacterial overgrowth and intestinal inflammation on duration of parenteral nutrition in children with short bowel syndrome. J Pediatr 1997; 131:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/12\">",
"      Spencer AU, Neaga A, West B, et al. Pediatric short bowel syndrome: redefining predictors of success. Ann Surg 2005; 242:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/13\">",
"      Vanderhoof J, Berg K, Young R. Weaning from parenteral nutrition in short bowel syndrome: All adaptation is not intestinal (abstract). J Pediatr Gastroenterol Nutr 2004; 39 Suppl 1:S348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/14\">",
"      Touloukian RJ, Smith GJ. Normal intestinal length in preterm infants. J Pediatr Surg 1983; 18:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/15\">",
"      Diamond IR, Struijs MC, de Silva NT, Wales PW. Does the colon play a role in intestinal adaptation in infants with short bowel syndrome? A multiple variable analysis. J Pediatr Surg 2010; 45:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/16\">",
"      Dowling RH, Booth CC. Functional compensation after small-bowel resection in man. Demonstration by direct measurement. Lancet 1966; 2:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/17\">",
"      Iqbal CW, Qandeel HG, Zheng Y, et al. Mechanisms of ileal adaptation for glucose absorption after proximal-based small bowel resection. J Gastrointest Surg 2008; 12:1854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/18\">",
"      Weale AR, Edwards AG, Bailey M, Lear PA. Intestinal adaptation after massive intestinal resection. Postgrad Med J 2005; 81:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/19\">",
"      Ekema G, Milianti S, Boroni G. Total parenteral nutrition in patients with short bowel syndrome. Minerva Pediatr 2009; 61:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/20\">",
"      Moukarzel AA, Haddad I, Ament ME, et al. 230 patient years of experience with home long-term parenteral nutrition in childhood: natural history and life of central venous catheters. J Pediatr Surg 1994; 29:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/21\">",
"      Colomb V, Dabbas-Tyan M, Taupin P, et al. Long-term outcome of children receiving home parenteral nutrition: a 20-year single-center experience in 302 patients. J Pediatr Gastroenterol Nutr 2007; 44:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/22\">",
"      Wessel JJ, Kocoshis SA. Nutritional management of infants with short bowel syndrome. Semin Perinatol 2007; 31:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/23\">",
"      Severijnen R, Bayat N, Bakker H, et al. Enteral drug absorption in patients with short small bowel : a review. Clin Pharmacokinet 2004; 43:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/24\">",
"      Safioleas M, Stamatakos M, Safioleas P, et al. Short bowel syndrome: amelioration of diarrhea after vagotomy and pyloroplasty for peptic hemorrhage. Tohoku J Exp Med 2008; 214:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/25\">",
"      Kato J, Sakamoto J, Teramukai S, et al. A prospective within-patient comparison clinical trial on the effect of parenteral cimetidine for improvement of fluid secretion and electrolyte balance in patients with short bowel syndrome. Hepatogastroenterology 2004; 51:1742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/26\">",
"      Nightingale JM, Walker ER, Farthing MJ, Lennard-Jones JE. Effect of omeprazole on intestinal output in the short bowel syndrome. Aliment Pharmacol Ther 1991; 5:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/27\">",
"      Jeppesen PB, Staun M, Tjellesen L, Mortensen PB. Effect of intravenous ranitidine and omeprazole on intestinal absorption of water, sodium, and macronutrients in patients with intestinal resection. Gut 1998; 43:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/28\">",
"      Jaksic T, Shew SB, Keshen TH, et al. Do critically ill surgical neonates have increased energy expenditure? J Pediatr Surg 2001; 36:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/29\">",
"      Woolf GM, Miller C, Kurian R, Jeejeebhoy KN. Nutritional absorption in short bowel syndrome. Evaluation of fluid, calorie, and divalent cation requirements. Dig Dis Sci 1987; 32:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/30\">",
"      Olieman JF, Penning C, Spoel M, et al. Long-term impact of infantile short bowel syndrome on nutritional status and growth. Br J Nutr 2012; 107:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/31\">",
"      Andorsky DJ, Lund DP, Lillehei CW, et al. Nutritional and other postoperative management of neonates with short bowel syndrome correlates with clinical outcomes. J Pediatr 2001; 139:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/32\">",
"      Mazon A, Solera E, Alentado N, et al. Frequent IgE sensitization to latex, cow's milk, and egg in children with short bowel syndrome. Pediatr Allergy Immunol 2008; 19:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/33\">",
"      Ventura A, Pineschi A, Tasso M. Cow's milk intolerance and abdominal surgery: a puzzling connection. Helv Paediatr Acta 1986; 41:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/34\">",
"      Vanderhoof JA, Young RJ. Hydrolyzed versus nonhydrolyzed protein diet in short bowel syndrome in children. J Pediatr Gastroenterol Nutr 2004; 38:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/35\">",
"      Ksiazyk J, Piena M, Kierkus J, Lyszkowska M. Hydrolyzed versus nonhydrolyzed protein diet in short bowel syndrome in children. J Pediatr Gastroenterol Nutr 2002; 35:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/36\">",
"      Cummins AG, Thompson FM. Effect of breast milk and weaning on epithelial growth of the small intestine in humans. Gut 2002; 51:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/37\">",
"      Yang Q, Kock ND. Effects of dietary fish oil on intestinal adaptation in 20-day-old weanling rats after massive ileocecal resection. Pediatr Res 2010; 68:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/38\">",
"      Thompson JS, Weseman R, Rochling FA, Mercer DF. Current management of the short bowel syndrome. Surg Clin North Am 2011; 91:493.",
"     </a>",
"    </li>",
"    <li>",
"     Harvard School of Public Health files on oxalate content of foods. Available at: https://regepi.bwh.harvard.edu/health/Oxalate/files (Accessed on March 08, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/40\">",
"      Joly F, Dray X, Corcos O, et al. Tube feeding improves intestinal absorption in short bowel syndrome patients. Gastroenterology 2009; 136:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/41\">",
"      Lennard-Jones JE. Indications and need for long-term parenteral nutrition: implications for intestinal transplantation. Transplant Proc 1990; 22:2427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/42\">",
"      Olieman JF, Penning C, Ijsselstijn H, et al. Enteral nutrition in children with short-bowel syndrome: current evidence and recommendations for the clinician. J Am Diet Assoc 2010; 110:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/43\">",
"      Youssef NN, Mezoff AG, Carter BA, Cole CR. Medical update and potential advances in the treatment of pediatric intestinal failure. Curr Gastroenterol Rep 2012; 14:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/44\">",
"      Est&iacute;variz CF, Luo M, Umeakunne K, et al. Nutrient intake from habitual oral diet in patients with severe short bowel syndrome living in the southeastern United States. Nutrition 2008; 24:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/45\">",
"      Duro D, Jaksic T, Duggan C. Multiple micronutrient deficiencies in a child with short bowel syndrome and normal somatic growth. J Pediatr Gastroenterol Nutr 2008; 46:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/46\">",
"      Luo M, Est&iacute;variz CF, Schleicher RL, et al. Prospective analysis of serum carotenoids, vitamin A, and tocopherols in adults with short bowel syndrome undergoing intestinal rehabilitation. Nutrition 2009; 25:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/47\">",
"      Pakarinen MP, Kurvinen A, Gylling H, et al. Cholesterol metabolism in pediatric short bowel syndrome after weaning off parenteral nutrition. Dig Liver Dis 2010; 42:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/48\">",
"      Yang CF, Duro D, Zurakowski D, et al. High prevalence of multiple micronutrient deficiencies in children with intestinal failure: a longitudinal study. J Pediatr 2011; 159:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/49\">",
"      Fried M. Octreotide in the treatment of refractory diarrhea. Digestion 1999; 60 Suppl 2:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/50\">",
"      Davies BW, Abel G, Puntis JW, et al. Limited ileal resection in infancy: the long-term consequences. J Pediatr Surg 1999; 34:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/51\">",
"      Byrne TA, Morrissey TB, Nattakom TV, et al. Growth hormone, glutamine, and a modified diet enhance nutrient absorption in patients with severe short bowel syndrome. JPEN J Parenter Enteral Nutr 1995; 19:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/52\">",
"      Byrne TA, Persinger RL, Young LS, et al. A new treatment for patients with short-bowel syndrome. Growth hormone, glutamine, and a modified diet. Ann Surg 1995; 222:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/53\">",
"      Ladd AP, Grosfeld JL, Pescovitz OH, Johnson NB. The effect of growth hormone supplementation on late nutritional independence in pediatric patients with short bowel syndrome. J Pediatr Surg 2005; 40:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/54\">",
"      Seguy D, Vahedi K, Kapel N, et al. Low-dose growth hormone in adult home parenteral nutrition-dependent short bowel syndrome patients: a positive study. Gastroenterology 2003; 124:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/55\">",
"      Weiming Z, Ning L, Jieshou L. Effect of recombinant human growth hormone and enteral nutrition on short bowel syndrome. JPEN J Parenter Enteral Nutr 2004; 28:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/56\">",
"      Szkudlarek J, Jeppesen PB, Mortensen PB. Effect of high dose growth hormone with glutamine and no change in diet on intestinal absorption in short bowel patients: a randomised, double blind, crossover, placebo controlled study. Gut 2000; 47:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/57\">",
"      Peretti N, Loras-Duclaux I, Kassai B, et al. Growth hormone to improve short bowel syndrome intestinal autonomy: a pediatric randomized open-label clinical trial. JPEN J Parenter Enteral Nutr 2011; 35:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/58\">",
"      Van Gossum A, Cabre E, H&eacute;buterne X, et al. ESPEN Guidelines on Parenteral Nutrition: gastroenterology. Clin Nutr 2009; 28:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/59\">",
"      da Costa MA, Campos AC, Coelho JC, et al. Oral glutamine and the healing of colonic anastomoses in rats. JPEN J Parenter Enteral Nutr 2003; 27:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/60\">",
"      Tian J, Hao L, Chandra P, et al. Dietary glutamine and oral antibiotics each improve indexes of gut barrier function in rat short bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2009; 296:G348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/61\">",
"      Duggan C, Stark AR, Auestad N, et al. Glutamine supplementation in infants with gastrointestinal disease: a randomized, placebo-controlled pilot trial. Nutrition 2004; 20:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/62\">",
"      Albers MJ, Steyerberg EW, Hazebroek FW, et al. Glutamine supplementation of parenteral nutrition does not improve intestinal permeability, nitrogen balance, or outcome in newborns and infants undergoing digestive-tract surgery: results from a double-blind, randomized, controlled trial. Ann Surg 2005; 241:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/63\">",
"      Ong EG, Eaton S, Wade AM, et al. Randomized clinical trial of glutamine-supplemented versus standard parenteral nutrition in infants with surgical gastrointestinal disease. Br J Surg 2012; 99:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/64\">",
"      Wagner JV, Moe-Byrne T, Grover Z, McGuire W. Glutamine supplementation for young infants with severe gastrointestinal disease. Cochrane Database Syst Rev 2012; 7:CD005947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/65\">",
"      Nucci AM, Finegold DN, Yaworski JA, et al. Results of growth trophic therapy in children with short bowel syndrome. J Pediatr Surg 2004; 39:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/66\">",
"      Vanderhoof JA, Kollman KA, Griffin S, Adrian TE. Growth hormone and glutamine do not stimulate intestinal adaptation following massive small bowel resection in the rat. J Pediatr Gastroenterol Nutr 1997; 25:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/67\">",
"      Scolapio JS, Camilleri M, Fleming CR, et al. Effect of growth hormone, glutamine, and diet on adaptation in short-bowel syndrome: a randomized, controlled study. Gastroenterology 1997; 113:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/68\">",
"      Wales PW, Nasr A, de Silva N, Yamada J. Human growth hormone and glutamine for patients with short bowel syndrome. Cochrane Database Syst Rev 2010; :CD006321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/69\">",
"      Goulet O, Dabbas-Tyan M, Talbotec C, et al. Effect of recombinant human growth hormone on intestinal absorption and body composition in children with short bowel syndrome. JPEN J Parenter Enteral Nutr 2010; 34:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/70\">",
"      Guo M, Li Y, Li J. Role of growth hormone, glutamine and enteral nutrition in pediatric short bowel syndrome: a pilot follow-up study. Eur J Pediatr Surg 2012; 22:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/71\">",
"      Martin GR, Wallace LE, Hartmann B, et al. Nutrient-stimulated GLP-2 release and crypt cell proliferation in experimental short bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2005; 288:G431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/72\">",
"      Jeppesen PB, Gilroy R, Pertkiewicz M, et al. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Gut 2011; 60:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/73\">",
"      Kato Y, Yu D, Schwartz MZ. Enhancement of intestinal adaptation by hepatocyte growth factor. J Pediatr Surg 1998; 33:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/74\">",
"      Fiore NF, Ledniczky G, Liu Q, et al. Comparison of interleukin-11 and epidermal growth factor on residual small intestine after massive small bowel resection. J Pediatr Surg 1998; 33:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/75\">",
"      Alavi K, Prasad R, Lundgren K, Schwartz MZ. Interleukin-11 enhances small intestine absorptive function and mucosal mass after intestinal adaptation. J Pediatr Surg 2000; 35:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/76\">",
"      Sigalet DL, Martin GR, Butzner JD, et al. A pilot study of the use of epidermal growth factor in pediatric short bowel syndrome. J Pediatr Surg 2005; 40:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/77\">",
"      Yoshida A, Noda T, Tani M, et al. The role of basic fibroblast growth factor to enhance fetal intestinal mucosal cell regeneration in vivo. Pediatr Surg Int 2009; 25:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/78\">",
"      Modi BP, Langer M, Ching YA, et al. Improved survival in a multidisciplinary short bowel syndrome program. J Pediatr Surg 2008; 43:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/79\">",
"      Sigalet D, Boctor D, Robertson M, et al. Improved outcomes in paediatric intestinal failure with aggressive prevention of liver disease. Eur J Pediatr Surg 2009; 19:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/80\">",
"      Khalil BA, Ba'ath ME, Aziz A, et al. Intestinal rehabilitation and bowel reconstructive surgery: improved outcomes in children with short bowel syndrome. J Pediatr Gastroenterol Nutr 2012; 54:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/81\">",
"      Sigalet D, Boctor D, Brindle M, et al. Elements of successful intestinal rehabilitation. J Pediatr Surg 2011; 46:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/82\">",
"      Bonnard A, Staub G, Segura JF, et al. Evaluation of intestinal absorption after longitudinal intestinal lengthening for short bowel syndrome. J Pediatr Surg 2005; 40:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/83\">",
"      Kim HB, Lee PW, Garza J, et al. Serial transverse enteroplasty for short bowel syndrome: a case report. J Pediatr Surg 2003; 38:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/84\">",
"      Javid PJ, Kim HB, Duggan CP, Jaksic T. Serial transverse enteroplasty is associated with successful short-term outcomes in infants with short bowel syndrome. J Pediatr Surg 2005; 40:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/85\">",
"      Modi BP, Langer M, Duggan C, et al. Serial transverse enteroplasty for management of refractory D-lactic acidosis in short-bowel syndrome. J Pediatr Gastroenterol Nutr 2006; 43:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/86\">",
"      Reinshagen K, Kabs C, Wirth H, et al. Long-term outcome in patients with short bowel syndrome after longitudinal intestinal lengthening and tailoring. J Pediatr Gastroenterol Nutr 2008; 47:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/87\">",
"      Duggan C, Piper H, Javid PJ, et al. Growth and nutritional status in infants with short-bowel syndrome after the serial transverse enteroplasty procedure. Clin Gastroenterol Hepatol 2006; 4:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/88\">",
"      Modi BP, Javid PJ, Jaksic T, et al. First report of the international serial transverse enteroplasty data registry: indications, efficacy, and complications. J Am Coll Surg 2007; 204:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/89\">",
"      Ching YA, Fitzgibbons S, Valim C, et al. Long-term nutritional and clinical outcomes after serial transverse enteroplasty at a single institution. J Pediatr Surg 2009; 44:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/90\">",
"      Morikawa N, Kuroda T, Kitano Y, et al. Repeat STEP procedure to establish enteral nutrition in an infant with short bowel syndrome. Pediatr Surg Int 2009; 25:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/91\">",
"      Miyasaka EA, Brown PI, Teitelbaum DH. Redilation of bowel after intestinal lengthening procedures--an indicator for poor outcome. J Pediatr Surg 2011; 46:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/92\">",
"      Sudan D. Advances in the nontransplant medical and surgical management of intestinal failure. Curr Opin Organ Transplant 2009; 14:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/93\">",
"      Thompson JS, Langnas AN. Surgical approaches to improving intestinal function in the short-bowel syndrome. Arch Surg 1999; 134:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/94\">",
"      Moon J, Iyer K. Intestinal rehabilitation and transplantation for intestinal failure. Mt Sinai J Med 2012; 79:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/95\">",
"      Pomfret EA, Fryer JP, Sima CS, et al. Liver and intestine transplantation in the United States, 1996-2005. Am J Transplant 2007; 7:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/96\">",
"      Fryer JP. Intestinal transplantation: current status. Gastroenterol Clin North Am 2007; 36:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/97\">",
"      Gruessner RW, Sharp HL. Living-related intestinal transplantation: first report of a standardized surgical technique. Transplantation 1997; 64:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/98\">",
"      Ji G, Chu D, Wang W, Dong G. The safety of donor in living donor small bowel transplantation--an analysis of four cases. Clin Transplant 2009; 23:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/99\">",
"      Gangemi A, Tzvetanov IG, Beatty E, et al. Lessons learned in pediatric small bowel and liver transplantation from living-related donors. Transplantation 2009; 87:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/100\">",
"      Abu-Elmagd KM, Mazariegos G, Costa G, et al. Lymphoproliferative disorders and de novo malignancies in intestinal and multivisceral recipients: improved outcomes with new outlooks. Transplantation 2009; 88:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/101\">",
"      Mazariegos GV. Intestinal transplantation: current outcomes and opportunities. Curr Opin Organ Transplant 2009; 14:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/102\">",
"      Vianna RM, Mangus RS. Present prospects and future perspectives of intestinal and multivisceral transplantation. Curr Opin Clin Nutr Metab Care 2009; 12:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/103\">",
"      Sudan D, Horslen S, Botha J, et al. Quality of life after pediatric intestinal transplantation: the perception of pediatric recipients and their parents. Am J Transplant 2004; 4:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/104\">",
"      Iyer K, Horslen S, Iverson A, et al. Nutritional outcome and growth of children after intestinal transplantation. J Pediatr Surg 2002; 37:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/105\">",
"      Venick RS, Farmer DG, Saikali D, et al. Nutritional outcomes following pediatric intestinal transplantation. Transplant Proc 2006; 38:1718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/106\">",
"      Mangus RS, Subbarao GC. Intestinal transplantation in infants with intestinal failure. Clin Perinatol 2013; 40:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/107\">",
"      Quintini C, Kato T, Gaynor JJ, et al. Analysis of risk factors for the development of posttransplant lymphoprolipherative disorder among 119 children who received primary intestinal transplants at a single center. Transplant Proc 2006; 38:1755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/108\">",
"      Bueno J, Green M, Kocoshis S, et al. Cytomegalovirus infection after intestinal transplantation in children. Clin Infect Dis 1997; 25:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/9/26778/abstract/109\">",
"      Sigurdsson L, Reyes J, Putnam PE, et al. Endoscopies in pediatric small intestinal transplant recipients: five years experience. Am J Gastroenterol 1998; 93:207.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5894 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-200.215.4.194-785DB895A1-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_9_26778=[""].join("\n");
var outline_f26_9_26778=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1885633\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      LIKELIHOOD OF RESUMING AN ORAL DIET",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Length of remaining small intestine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Segments of remaining intestine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Intestinal adaptation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      EARLY MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32888166\">",
"      GROWTH GOALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ENTERAL FEEDING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Composition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18643821\">",
"      - Protein",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18643835\">",
"      - Fats",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18643842\">",
"      - Carbohydrates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H841098\">",
"      - Fiber",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17780577\">",
"      - Oxalate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Frequency of feeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Tapering of parenteral nutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11453706\">",
"      Oral feeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11453713\">",
"      Malabsorption of fat and vitamins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H841297\">",
"      - Extensive small bowel resection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11453814\">",
"      - Loss of the distal ileum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19815126\">",
"      Laboratory monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PHARMACOLOGIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1887329\">",
"      Antisecretory agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17779220\">",
"      Antimotility agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1887170\">",
"      Growth factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Glutamine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Growth hormone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Glucagon-like peptide-2 (GLP-2)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10774151\">",
"      - Other growth factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H841534\">",
"      BOWEL TAILORING AND LENGTHENING PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15788461\">",
"      INTESTINAL REHABILITATION PROGRAMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SMALL BOWEL TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H859556\">",
"      Donors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5894\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5894|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/61/34775\" title=\"figure 1\">",
"      Intestinal sites of nutrient absorption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/3/21557\" title=\"figure 2\">",
"      Bianchi procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/18/3363\" title=\"figure 3\">",
"      STEP procedure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5894|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/58/10157\" title=\"table 1\">",
"      Management of short bowel syndrome in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/45/29400?source=related_link\">",
"      Chronic complications of the short bowel syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/16/11529?source=related_link\">",
"      Enteral nutrition in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=related_link\">",
"      Food protein-induced proctitis/colitis and enteropathy of infancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/6/44136?source=related_link\">",
"      Management of the short bowel syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/29/1497?source=related_link\">",
"      Overview of intestinal and multivisceral transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18730?source=related_link\">",
"      Parenteral nutrition-associated liver disease in infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/56/30601?source=related_link\">",
"      Pathophysiology of the short bowel syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_9_26779="Secondary prophylaxis for rheumatic fever - Duration of therapy";
var content_f26_9_26779=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F55223&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F55223&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Secondary prophylaxis for rheumatic fever - Duration of therapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Category",
"      </td>",
"      <td class=\"subtitle1\">",
"       Duration after last attack",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        Rheumatic fever with carditis and residual heart disease",
"       </p>",
"       <p>",
"        (persistent valvular disease*)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        10 years or until 40 years of age (whichever is longer);",
"       </p>",
"       <p>",
"        sometimes lifelong prophylaxis (see text)",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        Rheumatic fever with carditis but no residual heart disease",
"       </p>",
"       <p>",
"        (no valvular disease*)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        10 years or until 21 years of age",
"       </p>",
"       <p>",
"        (whichever is longer)",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Rheumatic fever without carditis",
"      </td>",
"      <td>",
"       <p>",
"        5 years or until 21 years of age",
"       </p>",
"       <p>",
"        (whichever is longer)",
"       </p>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Clinical or echocardiographic evidence.",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Gerber MA, Baltimore RS, Eaton CB, et al. Prevention of Rheumatic Fever and Diagnosis and Treatment of Acute Streptococcal Pharyngitis: A Scientific Statement From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research. Circulation 2009; 119(11):1541-51. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_9_26779=[""].join("\n");
var outline_f26_9_26779=null;
var title_f26_9_26780="Clinical features tyrosine disorders";
var content_f26_9_26780=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60732&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60732&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical manifestations of enzyme deficiencies in tyrosine catabolism",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Defective enzyme",
"      </td>",
"      <td>",
"       Tyrosine aminotransferase",
"      </td>",
"      <td>",
"       4-OH-phenylpyruvate dioxygenase",
"      </td>",
"      <td>",
"       Homogentisate dioxygenase",
"      </td>",
"      <td>",
"       Maleylaceto-acetate isomerase",
"      </td>",
"      <td>",
"       Fumarylaceto-acetate hydrolase",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Disease name(s)",
"      </td>",
"      <td>",
"       <p>",
"        Tyrosinemia type II",
"       </p>",
"       <p>",
"        Oculocutaneous tyrosinemia",
"       </p>",
"       <p>",
"        Richner-Hanhardt syndrome",
"       </p>",
"      </td>",
"      <td>",
"       Tyrosinemia type III",
"      </td>",
"      <td>",
"       Alkaptonuria",
"      </td>",
"      <td>",
"       No human patients described",
"      </td>",
"      <td>",
"       <p>",
"        Tyrosinemia type I",
"       </p>",
"       <p>",
"        Hepatorenal tyrosinemia",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Elevated blood tyrosine",
"      </td>",
"      <td>",
"       +++",
"      </td>",
"      <td>",
"       ++",
"      </td>",
"      <td>",
"       &empty;",
"      </td>",
"      <td>",
"       ?",
"      </td>",
"      <td>",
"       ++",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Corneal ulcers",
"      </td>",
"      <td>",
"       +++",
"      </td>",
"      <td>",
"       +/-",
"      </td>",
"      <td>",
"       &empty;",
"      </td>",
"      <td>",
"       ?",
"      </td>",
"      <td>",
"       &empty;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Hyper-keratosis",
"      </td>",
"      <td>",
"       ++",
"      </td>",
"      <td>",
"       +/-",
"      </td>",
"      <td>",
"       &empty;",
"      </td>",
"      <td>",
"       ?",
"      </td>",
"      <td>",
"       &empty;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Mental retardation",
"      </td>",
"      <td>",
"       +/-",
"      </td>",
"      <td>",
"       +/-",
"      </td>",
"      <td>",
"       &empty;",
"      </td>",
"      <td>",
"       ?",
"      </td>",
"      <td>",
"       &empty;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Arthritis",
"      </td>",
"      <td>",
"       &empty;",
"      </td>",
"      <td>",
"       &empty;",
"      </td>",
"      <td>",
"       +++",
"      </td>",
"      <td>",
"       ?",
"      </td>",
"      <td>",
"       &empty;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Liver failure",
"      </td>",
"      <td>",
"       &empty;",
"      </td>",
"      <td>",
"       &empty;",
"      </td>",
"      <td>",
"       &empty;",
"      </td>",
"      <td>",
"       ?",
"      </td>",
"      <td>",
"       +++",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Renal Fanconi syndrome",
"      </td>",
"      <td>",
"       &empty;",
"      </td>",
"      <td>",
"       &empty;",
"      </td>",
"      <td>",
"       &empty;",
"      </td>",
"      <td>",
"       ?",
"      </td>",
"      <td>",
"       ++",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Markus Grompe, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_9_26780=[""].join("\n");
var outline_f26_9_26780=null;
var title_f26_9_26781="Pacemaker vs drug treatment for syncope";
var content_f26_9_26781=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F69675&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F69675&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 494px\">",
"   <div class=\"ttl\">",
"    Pacing is more effective than atenolol for preventing recurrent neurocardigenic syncope",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 474px; height: 316px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a study of 93 patients with neurocardiogenic sysncope occurring in association with relative bradycardia, as determined by tilt table study, a DDD pacemaker was more effective than atenolol for preventing recurrent syncope (4 versus 26 percent, p = 0.003).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Ammirati F, Colivicchi F, Santini M. Circulation 2001; 104:52.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_9_26781=[""].join("\n");
var outline_f26_9_26781=null;
var title_f26_9_26782="Contents: Pediatric urology";
var content_f26_9_26782=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Pediatric urology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Pediatric urology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Circumcision",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/18/11559\">",
"           Care of the uncircumcised penis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Congenital anomalies",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/24/24966\">",
"           Clinical manifestations and initial management of infants with bladder exstrophy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/0/11271\">",
"           Clinical presentation and diagnosis of posterior urethral valves",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/3/26680\">",
"           Congenital ureteropelvic junction obstruction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/3/39989\">",
"           Ectopic ureter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/30/32231\">",
"           Evaluation of congenital anomalies of the kidney and urinary tract (CAKUT)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/59/24506\">",
"           Evaluation of the infant with ambiguous genitalia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/42/26280\">",
"           Hypospadias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/41/36502\">",
"           Management of posterior urethral valves",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/47/35577\">",
"           Management of the infant with ambiguous genitalia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/52/42824\">",
"           Overview of antenatal hydronephrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/60/22472\">",
"           Overview of congenital anomalies of the kidney and urinary tract (CAKUT)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/58/16296\">",
"           Prenatal diagnosis of renal agenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/28/1479\">",
"           Primary megaureter in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/52/28487\">",
"           Renal ectopic and fusion anomalies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/36/11849\">",
"           Surgical management and postoperative outcome of children with bladder exstrophy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/44/17098\">",
"           Undescended testes (cryptorchidism) in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/8/41093\">",
"           Ureterocele",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/59/15288\">",
"           Urinary tract complications of myelomeningocele (spina bifida)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Male urologic disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/23/24953\">",
"           Balanoposthitis in children: Clinical manifestations, diagnosis, and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/55/33654\">",
"           Balanoposthitis in children: Epidemiology and pathogenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/47/43766\">",
"           Causes of painless scrotal swelling in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/39/32376\">",
"           Causes of scrotal pain in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/50/4903\">",
"           Complications of circumcision",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/38/2663\">",
"           Evaluation of scrotal pain or swelling in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/44/712\">",
"           Neonatal testicular torsion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/48/33543\">",
"           Paraphimosis reduction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/39/29302\">",
"           Paraphimosis: Definition, pathophysiology, and clinical features",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Nephrolithiasis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/41/38552\">",
"           Acute management of nephrolithiasis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/19/13623\">",
"           Clinical features and diagnosis of nephrolithiasis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/60/6090\">",
"           Epidemiology of and risk factors for nephrolithiasis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/62/19432\">",
"           Prevention of recurrent nephrolithiasis in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Ureteral disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/62/41961\">",
"           Management of vesicoureteral reflux",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/10/3242\">",
"           Presentation, diagnosis, and clinical course of vesicoureteral reflux",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Urinary incontinence",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/7/28793\">",
"           Etiology and clinical features of bladder dysfunction in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/21/40281\">",
"           Etiology and evaluation of nocturnal enuresis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/50/25384\">",
"           Evaluation and diagnosis of bladder dysfunction in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/51/41785\">",
"           Management of bladder dysfunction in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/0/7178\">",
"           Management of nocturnal enuresis in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Urine abnormalities",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/6/1127\">",
"           Evaluation of gross hematuria in children",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-7CD061D018-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f26_9_26782=[""].join("\n");
var outline_f26_9_26782=null;
var title_f26_9_26783="Contents: Gynecologic surgery";
var content_f26_9_26783=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Gynecologic surgery",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Gynecologic surgery",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Cervical surgery",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/19/44343\">",
"           Cervical intraepithelial neoplasia: Ablative therapies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/17/33048\">",
"           Cervical intraepithelial neoplasia: Procedures for cervical conization",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/51/11062\">",
"           Cervical pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/3/27701\">",
"           Trachelectomy following supracervical hysterectomy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cliinical anatomy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/27/41400\">",
"           Surgical female pelvic anatomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/41/16026\">",
"           Surgical female urogenital anatomy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Clinical anatomy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/18/17703\">",
"           Anatomy of the abdominal wall",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Fistula repair",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/11/32951\">",
"           Rectovaginal, anovaginal, and colovesical fistulas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/47/44792\">",
"           Urogenital tract fistulas in women",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         General issues",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/39/21113\">",
"           Abdominal surgical incisions: Prevention and treatment of complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/25/32151\">",
"           Basic principles of medical lasers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/37/31321\">",
"           Classification, clinical features and diagnosis of inguinal and femoral hernias in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/3/24631\">",
"           Complications of gynecologic surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/57/29592\">",
"           Diagnostic cystourethroscopy for gynecologic conditions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/60/31689\">",
"           Exenteration for gynecologic cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/18/43305\">",
"           Management of hemorrhage in gynecologic surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/57/27546\">",
"           Management of postoperative pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/7/15482\">",
"           Management of pregnant women undergoing nonobstetric surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/3/3129\">",
"           Nerve injury associated with pelvic surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/59/17334\">",
"           Overview of conventional gynecologic laparoscopic surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/54/37737\">",
"           Overview of electrosurgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/55/39800\">",
"           Overview of preoperative evaluation and preparation for gynecologic surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/1/20499\">",
"           Pelvic examination under anesthesia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/33/2586\">",
"           Postoperative ileus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/47/26359\">",
"           Preventing postoperative peritoneal adhesions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/24/10633\">",
"           Principles of abdominal wall closure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/35/30265\">",
"           Principles of abdominal wall incisions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/34/38440\">",
"           Surgical instruments for gynecologic surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/27/7609\">",
"           Urinary tract injury in gynecologic surgery: Evaluation and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/46/14056\">",
"           Urinary tract injury in gynecologic surgery: Prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/19/4408\">",
"           Uterine perforation during gynecologic procedures",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Laparoscopic surgery",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/15/7415\">",
"           Complications of gynecologic laparoscopic surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/56/12168\">",
"           Gynecologic laparoscopy: Non-umbilical entry sites",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/52/9029\">",
"           Laparoendoscopic single-site (single port) surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/22/14698\">",
"           Laparoscopic approach to hysterectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/0/24583\">",
"           Laparoscopic surgery for ovulation induction in polycystic ovary syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/59/17334\">",
"           Overview of conventional gynecologic laparoscopic surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/63/21495\">",
"           Overview of laparoscopy in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/17/24858\">",
"           Rectovaginal or bowel endometriosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/18/9513\">",
"           Reproductive surgery for female infertility",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/34/27176\">",
"           Robot-assisted laparoscopy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/60/1993\">",
"           Urinary tract endometriosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Ovarian surgery",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/46/5863\">",
"           Diagnosis and management of ovarian endometriomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/48/36618\">",
"           Epithelial ovarian cancer: Initial surgical management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/15/25847\">",
"           Epithelial ovarian cancer: Second look surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/40/9863\">",
"           Evaluation and management of ruptured ovarian cyst",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/6/12393\">",
"           Oophorectomy and ovarian cystectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/8/23690\">",
"           Ovarian and fallopian tube torsion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/47/6902\">",
"           Ovarian transposition before pelvic radiation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/26/28070\">",
"           Surgery for recurrent epithelial ovarian cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/24/33162\">",
"           Treatment of malignant germ cell tumors of the ovary",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pregnancy termination",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/45/1750\">",
"           Induced fetal demise",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/38/33386\">",
"           Mifepristone for the medical termination of pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/42/28330\">",
"           Misoprostol as a single agent for medical termination of pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/9/39065\">",
"           Multifetal pregnancy reduction and selective termination",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/2/19498\">",
"           Overview of pregnancy termination",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/47/6905\">",
"           Psychological aspects of pregnancy termination",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/29/39384\">",
"           Retained products of conception",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/22/4453\">",
"           Surgical termination of pregnancy: First trimester",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/47/28409\">",
"           Termination of pregnancy: Second trimester",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/14/41191\">",
"           Unsafe abortion",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Rectovaginal surgery",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/29/34263\">",
"           Delayed surgical management of the disrupted anal sphincter",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/11/32951\">",
"           Rectovaginal, anovaginal, and colovesical fistulas",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sterilization",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/23/12665\">",
"           Hysteroscopic sterilization",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/42/15018\">",
"           Surgical sterilization of women",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Tubal surgery",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/47/26359\">",
"           Preventing postoperative peritoneal adhesions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/18/9513\">",
"           Reproductive surgery for female infertility",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/53/5976\">",
"           Surgical treatment of ectopic pregnancy and prognosis for subsequent fertility",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Uterine surgery",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/46/32490\">",
"           Abdominal hysterectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/3/12346\">",
"           Abdominal myomectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/7/31866\">",
"           An overview of endometrial ablation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/41/35480\">",
"           Dilation and curettage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/21/15706\">",
"           Elective oophorectomy or ovarian conservation at the time of hysterectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/42/44708\">",
"           Endometrial ablation or resection: Resectoscopic techniques",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/24/393\">",
"           Endometrial ablation: Non-resectoscopic techniques",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/8/131\">",
"           Endometrial sampling procedures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/41/8858\">",
"           Hyponatremia following transurethral resection or hysteroscopy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/53/32601\">",
"           Hysteroscopic myomectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/26/22951\">",
"           Hysteroscopy: Managing fluid and gas distending media",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/31/26101\">",
"           Intrauterine adhesions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/22/14698\">",
"           Laparoscopic approach to hysterectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/48/8970\">",
"           Laparoscopic myomectomy and other laparoscopic treatments for uterine leiomyomas (fibroids)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/19/12602\">",
"           Overview of hysterectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/17/9498\">",
"           Overview of hysteroscopy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/24/16775\">",
"           Prolapsed uterine leiomyoma (fibroid)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/24/14730\">",
"           Radical hysterectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/21/29014\">",
"           Surgical management of congenital uterine anomalies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/54/10088\">",
"           Techniques to reduce blood loss during abdominal or laparoscopic myomectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/60/22473\">",
"           Uterine leiomyoma (fibroid) embolization",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/0/41990\">",
"           Vaginal cuff dehiscence after hysterectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/36/35401\">",
"           Vaginal hysterectomy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Vulvovaginal surgery",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/21/34133\">",
"           Female genital cutting (circumcision)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/10/37028\">",
"           Labia minora hypertrophy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/52/4936\">",
"           Radical vulvectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/46/6885\">",
"           Vaginectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/40/22147\">",
"           Vaginoscopy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/46/31464\">",
"           Vulvar abscess",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/12/14535\">",
"           Vulvar wide local excision, simple vulvectomy, and skinning vulvectomy",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-70AC5F1CB6-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f26_9_26783=[""].join("\n");
var outline_f26_9_26783=null;
